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Abstract 
Despite significant advances in anti-emetic therapy, chemotherapy-induced 
nausea and vomiting (CINV) remains a significant burden to cancer patients. Ginger 
(Zingiber officinale) has shown promise as an adjuvant to standard anti-emetic therapy 
to allay CINV. It contains several bioactive compounds that could interact beneficially 
with the multiple pathways involved in this adverse outcome of treatment. However, 
the results of previous clinical trials testing ginger are equivocal and the extant 
literature has multiple limitations that require further investigation.  
The primary purpose of this Thesis by Publication is to determine the efficacy, 
safety, and feasibility of ginger in clinical practice through a systematic program of 
literature reviews, and clinical, survey, and laboratory studies that account for the 
limitations of the extant literature, and current gaps in the knowledge.  
The aim of the first study undertaken in this thesis was to investigate the 
potential mechanisms of action exerted by ginger on CINV. Certain active compounds 
in ginger act via antagonism of the 5-HT3 receptors within the gastrointestinal tract 
leading to a possible reduction in CINV. Whether these compounds act directly at the 
serotonin binding site or act allosterically to modulate receptor activity has not been 
fully elucidated. Interactions between the principle compounds of ginger on the 
recently solved crystal structure of the murine 5-HT3 receptor were investigated using 
in silico techniques, in order to characterise the sites and determine if a preference in 
binding affinity is evident within the two distinct binding sites (Chapter 6). The results 
of this study demonstrated the investigated ginger compounds exhibited high binding 
affinity at both sites. We postulated that these compounds may potentially act at both 
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sites – as seen with other serotonin modulators. The observed binding promiscuity of 
these compounds is likely due to their high degree of non-covalent interaction 
potential  
The second study included in this thesis investigated the concentration of the 
primary bioactive compounds within 20 widely-available ginger products (including 
dietary supplements, beverages, and confectionary) using Reverse-Phase High-
Performance Liquid Chromatography analysis (Chapter 7). This study addressed the 
efficacy and safety component of the projects aims by providing the following results. 
First, of the six dietary supplements analysed, standardized ginger extracts provided 
the most potent and consistent concentration of analysed ginger compounds, 
providing support for the use of standardized extracts in clinical trials. Second, when 
the concentration of compounds was presented by the approximate concentration that 
would be consumed in one serving, there were products from each product category 
that contained concentrations of the analysed compounds equal to, or exceeding, 
dietary supplements. This demonstrates that cancer patients could consume 
therapeutic concentrations of the active compounds within ginger through dietary 
intake alone. This has important implications for future clinical trials that aim to 
investigate the use of ginger supplementation. Furthermore, due to the potential effect 
ginger supplementation might exert on platelet aggregation, these results suggest that 
a high dietary intake of ginger products during chemotherapy could have safety 
implications. By analysing the concentration of primary compounds in a wide-range 
of commercially available ginger products, the information provided by this study will 
be able to inform Australian clinicians interested in these products for their adjuvant 
medicinal properties. 
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In the third and main study (Chapter 9), the efficacy and safety of ginger 
supplementation in humans was investigated in a clinical setting by way of a double-
blind, randomized, placebo-controlled trial (N=51). This trial addressed the 
methodological limitations of the extant literature through the introduction of multiple 
robust features to the study design. These include following patients over an extended 
number of chemotherapy cycles, controlling for CINV-specific prognostic factors by 
recruiting only chemotherapy-naïve patients, implementing a dosing schedule 
consistent with the pharmacokinetics of oral ginger supplements, and independently 
analysing ginger supplements before and after the recruitment phase in order to ensure 
potency. The primary outcome was chemotherapy-induced nausea-related quality of 
life. Secondary outcomes included the severity, prevalence, and frequency of nausea, 
vomiting, and retching. This was also the first trial to assess the effect of ginger 
supplementation on cancer-related fatigue and nutritional status. The results of this 
study demonstrated a significant association between CINV- and nausea-related 
quality of life (p=0.043 and 0.029, respectively), global cancer-related quality of life 
(p=0.015), and cancer-related fatigue (p=0.007) in patients receiving the ginger 
intervention during the first cycle of chemotherapy. However, ginger supplementation 
did not reduce the prevalence or severity of CINV overall. There was no significant 
difference in reported adverse effects in the intervention group compared to the 
placebo group. By cycle 3 of chemotherapy, there was also significant attrition (33%). 
This suggests that the trial protocol could have been overly burdensome for 
participants and that the trial might not have been sufficiently powered to detect 
difference in CINV prevalence and severity. These results support previous studies, 
which indicate that ginger is well-tolerated; however, despite significant associations 
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between ginger supplementation and CINV-related quality of life (QoL), cancer-
related QoL, and cancer-related fatigue, the use of ginger supplementation as an 
effective treatment for CINV is not supported by this trial. 
The final study provided information regarding the feasibility of introducing 
dietary supplements such as ginger as a complement to routine clinical practice 
(Chapter 10). Healthcare professionals (N=370) responded to this survey, which 
assessed their current level of confidence, usage, and barriers with respect to 
recommending dietary supplements. The findings indicate mixed levels of confidence 
in recommending dietary supplements for their patients; nonetheless, there is strong 
interest in further training in this area despite the multiple barriers articulated, 
including concerns regarding drug-nutrient interactions. 
In summary, the results of this thesis demonstrate that ginger supplementation 
is generally safe and feasible, and has several viable mechanisms of action related to 
CINV. While no reduction in the severity or prevalence of CINV were reported in our 
trial, ginger supplementation could be an effective and well-tolerated adjuvant 
intervention to enhance CINV-related QoL and reduce fatigue. Currently, healthcare 
professionals are interested in dietary supplements; however, further professional 
training in this area would improve the integration of dietary supplements into 
standard clinical practice. Future studies that explore the efficacy and the safety-
profile of ginger are warranted in larger clinical trials.  
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“[The nausea] was just so consuming at times that I really 
couldn’t think about anything else, and I just certainly couldn’t, I 
just couldn’t function. The only thing I could do was just 
curl up in bed.” - One patient’s description of their experience with 
chemotherapy-induced nausea and vomiting1 
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1 
Introduction 
Two-thirds of chemotherapy patients report significant nausea,2 which they 
often rate as the most disabling side-effect of their treatment.3 Research consistently 
demonstrates that CINV deleteriously affects patient quality of life (QoL) and 
function, most significantly impairing their ability to undertake normal family and 
employment roles.4 Persistent CINV can also result in malnutrition, cancer treatment 
delays and dose reductions, culminating in poorer treatment outcomes.5,6 When 
nausea and vomiting are measured separately, nausea is reported to affect QoL to a 
greater extent than vomiting.4,7 Hence, while interventions to reduce vomiting clearly 
benefit the patient, due to the high prevalence and severe impact of nausea on QoL, 
interventions that aim to treat chemotherapy-induced nausea should be prioritised. 
Empirical data demonstrate that ginger root (Zingiber officinale) could be an 
effective anti-CINV agent, particularly with respect to nausea.8 The bioactive 
compounds within ginger interact with several pathways that are implicated both 
directly and indirectly in CINV. These properties include 5-HT3, substance P and 
acetylcholine receptor antagonism; as well as the modulation of cellular redox 
signalling, gastrointestinal motility, and gastric emptying rate.9 Clinical trials also 
provide preliminary support, with several randomised-controlled trials reporting 
efficacy in the chemotherapy setting as well as in the context of gestational nausea, 
motion sickness, and post-operative nausea and vomiting.8,10,11 However, due to the 
equivocal results and acknowledged limitations of these studies, further research is 
required before ginger can be recommended as a complement  to standard antiemetic 
therapy for cancer patients.  
2 
There is also significant clinician and patient interest in evidence-based 
complementary therapies to prevent or relieve CINV. Cancer patients with persistent 
nausea often seek additional treatments to manage their symptoms, with up to 40% of 
cancer patients requesting additional information on supplements to help with side 
effects.12 Studies indicate that ginger use by patients, and the recommendation of 
ginger as a supplement by clinicians, is also common in western countries. For 
example, a recent survey of UK oncologists found that 38% of respondents 
recommended ginger as a nausea treatment to their patients.13 An additional concern 
is that patients do not consistently discuss their use of CAM with their physician, 
resulting in potential contraindications and safety concerns.14 
Due to the need to improve current control of CINV, coupled with the rising 
use and interest in ginger as a therapeutic agent, the need to systematically evaluate 
its efficacy, safety, and feasibility in this setting is paramount. Therefore, the overall 
aim of this thesis was to answer the following research question:  
What is the efficacy, safety, and feasibility of ginger as an adjuvant treatment 
for chemotherapy-induced nausea and vomiting in chemotherapy-naïve patients 
undergoing highly- and moderately- emetogenic chemotherapy? 
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 Aims and Objectives 
In order to address the research question, the following aims and outcomes 
were devised, with hypotheses generated for certain outcomes.  
Aim: To determine the efficacy of ginger as an adjuvant treatment for CINV 
Outcomes: 
 To describe the mechanisms of action by which ginger could improve 
chemotherapy-induced nausea and vomiting. 
 To determine the optimal form of ginger to be used as an adjuvant therapy in 
clinical trials. 
 To determine the effect of ginger on i) CINV-related QoL and ii) the incidence, 
frequency and severity of chemotherapy-induced nausea and vomiting in 
chemotherapy-naïve patients receiving moderately or highly emetogenic 
chemotherapy regimens. The hypotheses associated with this aim are that, in 
chemotherapy-naïve cancer patients prescribed moderately or highly 
emetogenic therapy, compared to placebo:  
o H1: The standardized ginger extract will provide a significant reduction 
in measures of CINV-related QoL in patients receiving moderately or 
highly emetogenic chemotherapy regimens compared to placebo.   
o H2: The standardized ginger extract will provide a significant reduction 
in measures of acute chemotherapy-induced nausea in patients 
receiving moderately or highly emetogenic chemotherapy regimens 
compared to placebo. 
 
4 
Aim: To determine the safety of ginger as an adjuvant treatment for CINV 
Outcomes: 
 To determine the dosage of bioactive ginger compounds within a variety of 
ginger products. 
 To assess the safety profile of ginger in a clinical setting, including adverse 
effects and contraindications. 
Aim: To determine the feasibility of ginger as an adjuvant treatment for CINV 
Outcomes:  
 To determine the perceived confidence, reported use, and barriers for the use 
of dietary supplements such as ginger in clinical practice. 
 To assess patient adherence to a standardized ginger regimen in a clinical 
setting. 
 Thesis Orientation  
This Doctor of Philosophy research program is presented as a thesis by 
publication. Ten chapters of this thesis are manuscripts that have either been published 
in peer-reviewed journals (n=5) or are in various stages of the submission process 
(n=5). The thesis is separated into three parts. Part One comprises a series of published 
systematic and narrative literature reviews that detail the extant evidence regarding 
the role of dietetic management in CINV and the evidence regarding the clinical 
efficacy and safety of ginger supplementation during chemotherapy, as well as its 
suspected mechanisms of action. This includes the following chapters. 
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Chapter 1 is a narrative review accepted for publication in the Journal of 
Academy of Nutrition and Dietetics (2014 Impact Factor: 3.467). This chapter 
introduces the concept of chemotherapy-induced nausea and vomiting and discusses 
issues that relate to the dietetic management of these symptoms.  
Chapter 2 is a systematic literature review of clinical data that assessed the 
evidence base for adjuvant ginger supplementation targeting chemotherapy-induced 
nausea and vomiting. This manuscript was published in Nutrition Reviews (2014 
Impact Factor: 5.541; Scopus Citations: 14).  
Chapter 3 complements Chapter 2 by reviewing the clinical trials conducted 
since the publication of the original systematic literature review. This was the result 
of an invitation by the editors of Current Opinion in Supportive and Palliative Care 
(2014 Impact Factor: 1.656) to provide an update on recent clinical data regarding the 
use of ginger for nausea from any stimuli (e.g. CINV as well as morning sickness, 
motion sickness).  
Chapter 4 discusses the suggested mechanisms of action of ginger in relation 
to CINV and provides recommendations for future research. This manuscript was 
published in Critical Reviews in Food Science and Nutrition (2014 Impact Factor: 
5.176; Scopus Citations: 2).  
In Chapter 5, the potential effect of ginger on platelet aggregation, a widely-
cited safety concern, was reviewed using existing clinical and observational data. This 
was recently published in PLOS One (2014 Impact Factor: 3.2). 
Part Two comprises the four laboratory, clinical and survey studies undertaken 
during this PhD program. The first study aimed to investigate one of the mechanisms 
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of actions of ginger. While there are multiple potential pathways through which the 
bioactive compounds of ginger could ameliorate CINV, the exact mechanism is 
currently unknown (see Chapters 3 and 4). One promising hypothesis is that the 
primary compounds within ginger could interact with the 5-HT3 receptors within the 
gastrointestinal tract, through a currently unknown binding site, in order to reduce 
CINV. In Chapter 7, through the use of in silico modelling techniques, this potential 
binding site was elucidated through investigation of the binding characteristics of the 
principle ginger compounds on two distinct areas of the murine 5-HT3 receptor. This 
manuscript, currently in the advanced stages of preparation, will be submitted to 
European Journal of Medicinal Chemistry (Impact factor: 3.447) 
In Chapter 8, the concentration of bioactive compounds within several 
commercial ginger products, including various dietary supplements, beverages, 
spices, and confectionery, was analysed in order to 1) determine the suitability of 
various types of ginger supplements as an adjuvant to standard pharmacological 
practice; 2) determine the amount of bioactive compound that can be consumed 
through dietary intake of ginger-containing food products; and 3) inform healthcare 
professionals interested in the medicinal use of ginger from an evidence-based 
perspective. This manuscript, also in the advanced stages of preparation, will be 
submitted to Journal of Chromatography A (Impact factor: 4.169). 
The main study of this thesis is presented in Chapters 9 and 10. A double-
blind, randomised, placebo-controlled trial was designed and implemented to 
rigorously investigate the efficacy, safety, and feasibility of a standardised form of 
adjuvant ginger supplementation for CINV. The protocol for this study was published 
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in BioMed Central Complementary and Alternative Medicine  (Impact factor: 
2.02; Scopus Citations: 2). The results of this study, which addressed the significant 
limitations apparent in the literature, has the potential to advance understanding 
regarding the viability of ginger in the oncology setting and will be submitted to 
BioMed Central Cancer (Impact factor: 3.36). 
In order to ensure that dietary supplements can be utilised effectively during 
clinical practice, it is important to determine the current barriers, needs and behaviours 
of healthcare professionals regarding the use and recommendation of dietary 
supplements. In Chapter 11, a survey of 370 healthcare professionals determined their 
attitudes, beliefs and behaviours regarding dietary supplements. This manuscript will 
be submitted to BioMed Central Complementary and Alternative Medicine  
(Impact factor: 2.02) by the end of 2015. 
Part Three is the final section of this thesis. In providing an overall discussion 
of the results obtained in Parts One and Two, it answers the research question driving 
this thesis; that is, how effective, safe and feasible is ginger supplementation in the 
clinical setting. This includes a discussion regarding the strengths and limitations of 
the studies undertaken in the course of my PhD candidature (Chapter 13), the overall 
implications of these studies, recommendations for clinical practice, and future 
research questions (Chapter 14). 
 
8 
 
 
9 
Part One: Literature review  
In order to determine the current state of the science and the knowledge gaps 
within the literature, a series of narrative and systematic literature reviews were 
undertaken. The aim of these reviews was to 1) provide an overview of the effect of CINV 
in the current oncology setting; 2) to determine the clinical efficacy and safety profile of 
ginger during chemotherapy; and 3) review relevant mechanisms of action. Please note 
the referencing styles included in the following chapters are in accordance with the 
respective journal guidelines.  
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 Chemotherapy-induced nausea and vomiting: a 
narrative review to inform dietetic practice. 
This chapter introduces the concept of chemotherapy-induced nausea and 
vomiting and discusses issues that relate to the dietetic management of these symptoms. 
This chapter also briefly introduces the evidence-base for ginger supplementation for 
CINV; however, more detailed reviews of the literature are included in Chapter 2 and 3. 
Themes from this manuscript were presented at the following conference: 
Wolfgang M Marx, Alexandra L McCarthy, Luis Vitetta, Dan McKavanagh, 
Damien Thomson, Avni Sali, Karin Ried, Elisabeth Isenring. Chemotherapy-induced 
nausea and vomiting: a guide for dietetic practice. Dietitians Association of Australia 
30th National Conference (23– 25 May 2013, Sydney). Oral presentation. 
Submission status: Accepted for publication in the Journal of the Academy of Nutrition 
and Dietetics (Impact factor: 3.467; Accepted 23/10/15) 
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 Abstract 
Chemotherapy-induced nausea and vomiting (CINV) are common nutrition-
impact symptoms experienced by cancer patients. They exert a detrimental effect on 
dietary intake, risk of malnutrition and quality of life. While CINV are primarily managed 
with medication, dietitians play an important role in the management of CINV-related 
complications such as reduced dietary intake. This review discusses the burden of nausea 
and vomiting which cancer patients can experience, including its effect on quality of life, 
nutrition status, and treatment outcomes. Implications for dietetic practice include the 
need to explore the nature of reported symptoms, identify predisposing risk factors, and 
to consider the use of a variety of interventions that are individualised to the patient’s 
symptoms. There are little clinical data regarding effective dietetic interventions for 
nausea and vomiting. In summary, this review discusses dietetic-related issues 
surrounding CINV including the pathophysiology, risk factors, prevalence, and both 
pharmacological and dietetic treatment options. 
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 Introduction 
There are multiple chemotherapy agents that can induce nausea and vomiting. 
However, with the advent of modern anti-emetics, there has been a significant reduction 
in the prevalence of vomiting, with a current estimated incidence of less than 20%.1, 2 
Efforts to control nausea in this setting have been less effective, with up to 60% of patients 
reporting nausea despite the use of anti-emetic medication.1 Consequently, nausea 
remains one of the most distressing side effects experienced by cancer patients, while 
vomiting is now of less concern.3-5 In addition, research has consistently associated 
chemotherapy-induced nausea and vomiting (CINV) with adverse effects on dietary 
intake, risk of malnutrition and quality of life (QoL).6, 7 
Dietitians routinely consult with cancer patients experiencing CINV and related 
symptoms. The aim of this manuscript is to inform dietetic practice by providing a general 
overview of CINV, as well as CINV-specific issues related to clinical nutrition. These 
include the pathophysiology, and management options for CINV, including current 
medications and potential dietetic treatment options. 
 Methods 
A literature search was undertaken between January and July 2015 using the 
following databases: Medline, Cumulative Index to Nursing and Allied Health Literature, 
and the Cochrane Library. Search terms were not limited by timeframe; instead, all 
searches were from the date of each database’s inception until July 2015.The 
bibliographies of relevant articles were scanned to identify additional articles of interest. 
The evidence-based guidelines of the Academy of Nutrition and Dietetics, Dietetics 
14 
Association of Australia and the Practice-based Evidence in Nutrition Knowledge 
Pathway were reviewed for additional references. The following search terms were used: 
(Chemotherapy AND (nausea OR vomiting OR CINV)) AND ((Risk factors OR 
prognostic OR predictor) OR (Mechanism OR pathophysiology OR physiopathology) 
OR (Nutrition OR malnutrition OR weight) OR “Quality of life” OR guidelines OR 
ginger OR protein OR (CAM OR Complementary OR Alternative)). Only studies 
published in English with human subjects were included. The results of this search 
strategy are detailed in Figure 1 and include the following citations:1-67. The results of the 
literature search were sorted based on the headings included in this review and were used 
to inform the discussion of each topic.  
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Figure 1-1 Flow diagram of literature search process conducted between January 
and July 2015 
 
 Defining chemotherapy-induced nausea and vomiting 
CINV is a collective term used to describe the presentation of nausea, vomiting 
or a combination of both symptoms associated with the administration of cytotoxic 
chemotherapy. While nausea and vomiting are related concepts, they involve distinct 
physiological mechanisms and are therefore defined separately in Table 1-1.68 
Nausea is a subjective sensation of discomfort, typically associated with the 
epigastrium, which might result in vomiting. Due to this subjective nature, the sensation, 
location, duration and intensity of nausea reported by patients can vary.30 In addition, 
multiple nutrition impact symptoms interlink with nausea such as appetite loss, lack of 
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energy, taste changes and pain.31 Hence, if a patient experiences nausea, it is prudent to 
investigate the individual’s sensations in order to effectively target treatment towards 
those symptoms. 
Table 1-1 Definitions of chemotherapy-induced nausea, vomiting and retching. 
Symptom Definition  
Vomiting Reflexive, rapid, and forceful oral expulsion of upper 
gastrointestinal tract contents due to powerful and sustained 
contractions in the abdominal and thoracic musculature.70 
Nausea  
 
Unpleasant, subjective feeling of discomfort, typically 
associated with the epigastrium that can result in vomiting. 
While nausea can cause pain and/or stress, it is considered as 
a distinct concept.69 
 
CINV is further classified as acute, delayed, anticipatory, breakthrough, and 
refractory. Exact definitions of acute CINV vary but it is generally considered to be 
nausea and/or vomiting that occurs within 24 hours of chemotherapy administration.32 
Delayed CINV is defined as nausea and/or vomiting that occurs after the first 24 hours 
post-chemotherapy.68 While this distinction might appear arbitrary, research suggests that 
differing physiological processes are involved in the acute phase when compared to the 
delayed phase.69  
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Anticipatory CINV is a conditioned response that occurs after previous cycles of 
chemotherapy in which nausea and/or vomiting were not adequately controlled. The 
current understanding of anticipatory CINV is explained in Pavlovian terms. According 
to this framework, a neutral stimulus (e.g. the smell of the hospital, the sight of treating 
staff) is coupled with an unconditioned response (CINV), caused by the unconditioned 
stimuli (chemotherapy). Once this occurs, a conditioned response develops wherein the 
formerly neutral stimulus elicits the same response as the unconditioned stimulus.33 
While a conditioning period is required for this coupling to occur, the length of this period 
varies according to the individual and can occur as soon as the second cycle of 
chemotherapy. Anticipatory CINV may also cause of certain food aversions, as food eaten 
during the days surrounding chemotherapy can be mentally paired with the sensation of 
nausea.  
Breakthrough CINV is nausea and/or vomiting that occurs despite adherence to 
optimal anti-emetic protocols and is treated by administering additional “rescue” anti-
emetic medication.34 Refractory CINV comprises symptoms that occur in subsequent 
cycles despite delivery of optimal anti-emetic control in previous cycles.34 If this occurs, 
additional medication is likely to be required.  
 Risk factors 
An individual’s risk of developing CINV is influenced by numerous factors 
(Table 2), which can be categorised into four broad categories: previous experience with 
nauseating stimuli (e.g. previous history of motion or morning sickness); genetic and trait 
factors (e.g. age and gender); psychosocial factors (e.g. anxiety); and finally, medical and 
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treatment-related factors (e.g. dose, type of chemotherapy). The primary determinant of 
a patient’s risk of experiencing CINV is the emetogenic potential of the chemotherapy 
regimen. In order to guide anti-emetic therapy, chemotherapy regimens are stratified into 
the following classifications based on their emetogenic potential: minimally, fewer than 
10% at risk; low , 10% to 30% of patients at risk; moderately, 30% to 90% of patients at 
risk; and highly emetogenic chemotherapy regimens, nearly all patients (> 90%) at risk.34, 
71  
Individual risk factors are associated with different levels of risk. For example, 
Molassiotis et al.35 reported that patients with a history of nausea and vomiting (e.g. 
morning or motion sickness) were three times more likely to experience CINV (OR 3.2 , 
95% CI: 1.29–7.95), while the odds of experiencing CINV increased by 69% for each 
incremental increase in reported pain (OR 1.69, 95% CI: 1.03–2.77). Patients with a 
greater number of these risk factors are more likely to experience CINV compared to 
patients with fewer traits. This has led to the development of multiple tools designed to 
predict the risk of CINV by assessing the cumulative effect of risk factors. For example, 
Bouganim et al.’s36 tool to predict CINV risk demonstrated that patients categorized as at 
high-risk of CINV were three times more likely to experience symptoms than patients 
who were considered to be low risk. Predictive tools such as this are currently being 
refined and validated in larger populations, but with further studies these tools could 
improve symptom control by helping to identify high-risk patients before chemotherapy 
begins.   
Table 1-2 Individual risk factors of CINV 
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Medical or treatment-related factors 
 Dose and emetogenicity of chemotherapy regimen37 
 History of inner ear infections38 
 Feeling of 'warm or hot all over' or sweating during previous treatment 
cycles39 
 Feeling of generalised weakness during previous treatment cycles39 
 Lack of food consumption before chemotherapy session40 
Psycho-social factors 
 Anxiety (both trait and state) 41 
 Negative expectations of chemotherapy41 
Previous experience with nauseating stimuli 
 History of poorly controlled chemotherapy42 
 History of motion sickness or morning sickness25,26 
 History of low alcohol intake72 
Genetic and trait factors 
 Female gender3,25 
 Younger age (< 40-65 years old) 2, 43 
 Genetic polymorphisms related to 5-HT3 metabolism73, 74 
 Pathophysiology 
The development of CINV is complex; this section briefly describes the 
pathophysiology in CINV development. 
The trigger site for CINV is thought to be within the gastrointestinal tract. 
Chemotherapy agents can directly interact with enterochromaffin cells located within the 
gastric epithelium, resulting in the release of the neurotransmitters serotonin and 
substance P.75 The released neurotransmitters then interact with receptors located upon 
the vagus nerve, which subsequently transmits afferent signals to the chemoreceptor 
receptor zone (CTZ), a section of the brain within the area postrema, via the nucleus 
tractus solitarius. It is thought that modern 5-HT3 antagonist medications (e.g. 
ondansetron) interact with the 5-HT3 receptors involved in this process, which then 
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mitigates the degree of afferent vagal signalling. Another neurotransmitter, substance P, 
is also implicated in the generation of CINV primarily by binding to NK1 receptors 
located centrally within the brain. Stimuli transmitted using these two neuropeptides, as 
well as stimuli from other neurotransmitters (e.g. dopamine, histamine) and other regions 
of the brain (e.g. the amygdala), are processed by the CTZ and vomiting centre, which 
then coordinate the relevant musculature to induce a nausea and/or vomiting response.76 
An additional source of afferent signalling is suggested to be via direct interaction 
with the area postrema, as this part of the brain has a semi-permeable membrane that 
enables direct interaction with emetic stimuli within the blood or cerebrospinal fluid. 
 Impact on patient 
 Nutrition status 
Malnutrition is both a serious and prevalent concern within the oncology setting.44 
Estimates vary but between 30-50% of the general oncology population experience 
malnutrition and has been reported to be as high as 88% in certain populations (i.e. head 
and neck cancer patients).45-47 Malnutrition is considered an independent risk factor for 
mortality, increased length of stay, secondary infections, and healthcare costs.44, 48, 49 
Patients who experience CINV are particularly susceptible to malnutrition due to the 
direct effect of nausea and vomiting (e.g. the expulsion of food) or through behavioural 
factors (such as avoiding certain foods in an effort to prevent future bouts of CINV). 
Furthermore, vomiting can impede accurate nutrition diagnoses as it can reduce the 
validity of recorded dietary intake. Both nausea and vomiting are considered nutrition 
impact symptoms that can result in malnutrition.50-53 Cross-sectional and prospective 
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studies investigating the effect of CINV on a patient’s risk of malnutrition have reported 
a significant link.7, 54  
For example, in a cross-sectional study of cancer patients undergoing 
chemotherapy (N=121), CINV was associated with malnutrition, as assessed using the 
Patient Generated-Subjective Global Assessment, demonstrating that the majority of 
patients with severe CINV were malnourished.7 Similarly, in a prospective study 
including 104 chemotherapy patients, patients that experienced severe acute (mean: 5 vs 
8; p=0.003) and delayed nausea (mean: 5.1 vs 8; p=0.017) were associated with higher 
PG-SGA scores compared to patients who experienced less severe or no nausea. .54 
However, the authors of this study noted that the anti-emetic regimens prescribed to 
patients within this study were not congruent with current guidelines. Therefore, while 
the observed prevalence might reflect typical clinical practice, the incidence and severity 
of CINV within this cohort could be higher than what might be observed if current anti-
emetic recommendations were implemented.  
When weight loss was measured instead of malnutrition, similar associations were 
identified. In a retrospective analysis of cachectic patients with pancreatic cancer 
(N=107), the absence of nausea and vomiting was an independent determinant of weight 
stabilisation (OR 6.5, 95% CI: 1.6-27.2; p=0.010).29 Another study in a mixed oncology 
population (N=254) found that the prevalence of vomiting was higher in patients that 
experienced significant weight loss (>5% usual body weight) compared to patients that 
experienced minimal weight loss(32% vs 14%, respectively; p=0.005).55  
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In summary, while few studies have purposely investigated the association 
between CINV and malnutrition, the existing literature is consistent in its support of this 
association. In particular, these studies suggest that in patients who experience CINV, 
nutritional status should be actively monitored and managed in order to reduce the risk of 
malnutrition.  
 Quality of life (QoL) 
QoL is poorer amongst patients who experience CINV, either during the acute or 
delayed phase, compared to patients without these symptoms.27, 28 Highly emetogenic 
chemotherapy regimens are more likely to reduce QoL than moderately- or low 
emetogenic regimens. This detrimental effect on QoL is exacerbated with each additional 
day of CINV and is often compounded as treatment progresses, because patients who 
experience CINV in their initial cycle of chemotherapy are more likely to report poorer 
CINV-related QoL in subsequent cycles.27, 56  This indicates that the burden of CINV 
might be cumulative and affects future chemotherapy cycles if not adequately controlled 
during the first cycle.25, 77  When nausea and vomiting are measured separately, the 
adverse effect of nausea on QoL has been reported to be greater than the effect of 
vomiting, which is particularly pertinent as the prevalence of nausea is higher when 
compared to vomiting.57 This difference in effect on QoL is likely due to current 
antiemetic therapy being predominantly effective for controlling vomiting as compared 
to nausea.  
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 Physical function 
Uncontrolled CINV can lead to a number of potentially serious physical 
conditions and CINV-related hospital admissions. Due to the loss of potassium, sodium, 
chloride and water resulting from frequent or severe vomiting, CINV might result in 
dehydration, electrolyte disturbances, and acid-base imbalances.24 Another concern is the 
risk of aspiration pneumonia, a condition where vomitus enters the bronchial tree, 
resulting in pneumonitis. This can lead to further complications and in some cases is 
fatal.24 In severe cases of vomiting, oesophageal tearing and related bleeding and pain 
can occur. Nutritional deficiencies are also a potential issue due to inadequate dietary 
intake of nutrients secondary to nausea and the inability to digest consumed food due to 
vomiting. These conditions can be further exacerbated by additional comorbidities.58 
Finally, during the 1980s, CINV-related treatment termination was reported to occur in 
patients;23 however, it is likely that the prevalence of CINV-related treatment termination 
has been significantly reduced due to the improvement in anti-emetic medications.22, 59 
 Pharmacotherapy of CINV 
Multiple medications prevent and relieve the distressing symptoms of CINV. 
International evidence-based guidelines, such as those developed by the Multinational 
Association for Supportive Care in Cancer and the National Comprehensive Cancer 
Network, suggest the ideal combination and timing of the available anti-emetics, 
according to the emetogenicity of the chemotherapy treatment.34, 71 It is now common 
practice to include this standardised, combination approach to provide optimal control of 
CINV. While these medications are effective in reducing CINV, there is no single 
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medication that offers complete protection during highly or moderately emetogenic 
regimens and therefore, the medications discussed below are administered in 
combination.34 
5-HT3 antagonists such as ondansetron, granisetron and palonosetron are 
important components of modern anti-emetic therapy. 5-HT3 antagonists work by binding 
to the 5-HT3 receptors within the gastrointestinal tract, which consequentially blocks 
afferent emetic signalling to the CTZ within the brain. Corticosteroids such as 
dexamethasone are used for their incidental anti-emetic attributes and are commonly 
prescribed in combination with other anti-emetics.34 The mechanism of action for this 
class of drug is poorly understood but suggested mechanisms include the modulation of 
the capillary permeability of the CTZ, anti-inflammatory effects within the 
gastrointestinal tract, and the release of endorphins.21 A relatively new class of anti-
emetic medication is NK1 antagonists such as aprepitant and fosaprepitant. These 
medications are believed to act centrally within the CTZ by inhibiting the actions of the 
neuropeptide, substance P.60 NK1 antagonists are used in combination, usually with 
dexamethasone and a 5-HT3 antagonist. They are most effective for moderate to highly 
emetogenic chemotherapy, especially where delayed CINV occurs. Until the introduction 
of 5-HT3 antagonists, metoclopramide was one of the primary anti-emetic medications 
used to treat CINV. It has been suggested that metoclopramide, as with other dopamine 
antagonists such as phenothiazine and butyrophenone, primarily interacts with dopamine 
D2 receptors within the central nervous system, eliciting a prokinetic effect on the gut 
and therefore regulating gut mobility. However, due to the superiority of the new 
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generation of anti-emetic therapy and the incidence of extrapyramidal reactions with 
high-dose metoclopramide, anti-emetic guidelines only recommend metoclopramide for 
low emetogenic regimens and as a rescue anti-emetic in breakthrough emesis.34, 71 
 Dietetic and lifestyle interventions 
 Dietetic-related interventions 
Dietitians regularly recommend a number of strategies to help patients manage 
their nausea and vomiting during chemotherapy. Broadly, these are categorised as 
strategies that involve modification to meal types and/or composition, behavioural 
strategies that target the way food is consumed, and lifestyle or environmental strategies 
(Table 3).78-80 While many of these strategies appear intuitive, there are currently no 
clinical trials that have specifically investigated the efficacy of these strategies in reducing 
measures of CINV. Furthermore, while there are guidelines for the dietetic management 
of CINV,80, 81 the lack of clinical trials means that these guidelines largely rely on expert 
opinion. However, medical nutrition therapy (MNT) is an intervention delivered by a 
dietitian that is tailored to the individual’s need and circumstances and utilises the 
strategies outlined in table 3. Therefore, despite the lack of studies specifically 
investigating dietary interventions for CINV, studies investigating MNT as an 
intervention may provide some evidence for the use of these strategies in the management 
of CINV.44, 82 
The oncology guidelines of the Academy of Nutrition and Dietetics state that there 
is currently strong evidence that MNT improves multiple treatment outcomes in patients 
undergoing chemotherapy, radiation or chemoradiotherapy in ambulatory or outpatient 
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and inpatient oncology settings.82 However, when studies that have investigated the use 
of MNT in chemotherapy have been analysed separately from studies that have 
investigated MNT during radiotherapy, the evidence remains strong  to suggest that MNT 
improves clinical and patient-centred outcomes (e.g. quality of life) in patients receiving 
radiotherapy but less so in patients receiving chemotherapy. Updated evidence-based 
practice guidelines  endorsed by the Dietetic Association of Australia, state that evidence 
that MNT during chemotherapy results in similar improvements in clinical or patient-
centred outcomes is currently insufficient.44 The authors of these guidelines found that 
while dietary supplements or simple dietary interventions (e.g. provision of handouts 
detailing food high protein and energy or basic nutrition counselling) were able to 
improve nutritional outcomes such as dietary intake and weight status, they did not find 
an improvement in quality of life or survival.  
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Table 1-3 Common dietetic-related interventions 
Meal modification strategies 
 Avoiding overly spicy, fatty, and sweet foods 
 Flavouring cold or warm drinks and foods 
 Drink cold clear fluids between meals such as cordial, lemonade, dry ginger ale or 
fruit juice 
 Using well-tolerated foods with neutral odors 
 Avoid unpleasant food textures 
 Preference for dry foods such as toasts, crackers, and cereals 
Behavioural strategies 
 Eating slowly 
 Small and frequent meals 
 Avoid skipping meals 
 Eating before feeling hungry, since hunger can increase nausea 
 Avoid overeating  
Lifestyle or environmental strategies 
 Staying away from the kitchen during food preparation. 
 Eating in a pleasant, cool environment with fresh air 
 Avoid strong odours such as perfumes and cleaning products 
 Undertake activities that might distract from ones nausea (e.g. exercise, hobbies) 
Interventions obtained from the following sources78-80 
There is preliminary support for the use of MNT as part of CINV management. 
In a small study (N=35) of ambulatory cancer patients, nausea modestly improved after 
a two month multidisciplinary intervention involving a dietitian as well as a physical 
therapist, social worker, nurse, and a physician (no p value reported).20 Furthermore, two 
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randomized controlled trials that investigated the use of dietary counselling or nutrition 
supplements in colorectal and head and neck cancer patients undergoing radiotherapy 
found that the severity and incidence of CINV was reduced within participants who 
received dietary counselling.19, 61 While this was in a population undergoing radiotherapy, 
the pathways involved in the generation of nausea and vomiting are thought to be similar 
to CINV. These studies therefore provide preliminary support for the use of dietary 
counselling for these symptoms. Further studies are required to investigate the use of 
MNT during chemotherapy to manage CINV and assess the effect on clinical outcomes 
such as survival, length of stay and QoL.  
There is limited evidence that CINV is associated with taste changes. One study 
found that patients who reported experiencing CINV also reported greater levels of taste 
changes and metallic taste.18 The nature of this relationship has not been elucidated, so it 
is unclear if the use of MNT to manage taste changes may also provide relief to nausea 
and vomiting symptoms. 
 Protein-rich meal consumption 
Preliminary clinical data suggest the consumption of a mixed meal, and in 
particular, a protein-rich meal, might improve nausea and vomiting symptoms from a 
variety of nauseating stimuli, including chemotherapy. For example, a prospective study 
(N=143) reported that patients who did not consume food before chemotherapy were 6.8 
times more likely to experience CINV compared to patients who reported eating meals 
prior to chemotherapy.57 Jednak et al.62 examined this effect further in a clinical trial that 
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investigated the effect of different macronutrients on nausea during pregnancy. The 
results indicated that a protein-rich meal significantly reduced nausea symptoms 
compared to both equicaloric carbohydrate and fat meals, and non-caloric meals. 
Subsequently, Levine et al.17 explored this in 28 cancer patients undergoing 
chemotherapy and reported that a combination of ginger and protein supplementation 
resulted in a significant reduction in CINV. This effect was more pronounced in the group 
receiving the highest dose of protein, which indicates that protein supplementation might 
have been primarily responsible for the reduction in CINV.  
The exact mechanism for this is unclear but it has been observed that during 
exposure to nauseating stimuli, the electrical rhythm of the stomach becomes 
dysregulated.17 The ingestion of a meal maintains the normal physiological rhythm of the 
stomach, which might in turn reduce symptoms of nausea and vomiting. The observed 
superiority of protein in reducing nausea symptoms is attributed to its effect on gastrin 
secretion, which is believed to normalise gastric activity.16 However, while the current 
evidence is supportive, further studies that include larger sample sizes are required, 
particularly in the chemotherapy setting. 
 Ginger supplementation 
In vitro and animal research indicate that compounds within ginger might exert 
several effects on pathways relevant to CINV. These include 5-HT3 receptor antagonism 
and the modulation of gastrointestinal motility and gastric emptying rate.14 _ In a recent 
systematic literature review, seven clinical trials were included that tested doses between 
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0.5-2g of ginger capsules.15 The results provide equivocal evidence, with two studies 
reporting no effect,13, 63_ three finding some effect,12, 64, 83 and two studies in favour but 
with caveats that reduce the real world application of these results.10, 65 Our review also 
identified multiple limitations within the literature such as a lack of control for 
anticipatory nausea and prognostic factors that might influence individual CINV 
response, inconsistent use of standardized ginger formulations and validated 
questionnaires, and the use of potentially suboptimal dosing regimens. Hence, while some 
evidence supports ginger as an adjuvant anti-CINV therapy, existing limitations must be 
addressed before firm recommendations for its use can be made.  
 Additional complementary therapies 
Several additional complementary therapies have demonstrated varying degrees 
of efficacy. These include yoga, progressive muscle relaxation, massage, aromatherapy, 
hypnosis, exercise, education programs, and acupuncture-point stimulation.8, 9, 66, 67 
However, while many of these therapies are likely to be low-cost and have minimal side 
effects, further trials are required to address limitations within the literature such as small 
sample sizes and inconsistent results.  
 Conclusion 
In summary, CINV poses a significant burden to patients undergoing 
chemotherapy with the potential to result in further medical complications, reduce QoL, 
and  increase the risk of malnutrition. While some evidence of a benefit from dietary 
intervention using MNT or protein rich meals exists further research is required.   
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 Abstract 
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of 
cytotoxic treatment. It continues to affect a significant proportion of patients despite the 
widespread use of anti-emetic medication. In traditional medicine, ginger (Zingiber 
officinale) has been used to prevent and treat nausea in many cultures for thousands of 
years. However, its use has not been confirmed in the chemotherapy context.  To 
determine the potential use of ginger as a prophylactic or treatment of CINV, a systematic 
literature review was conducted. Reviewed studies comprised randomised controlled 
trials or cross-over trials that investigated the anti-CINV effect of ginger as the sole 
independent variable in chemotherapy patients. Seven studies met the inclusion criteria. 
All studies were assessed on methodological quality and their limitations were identified.  
Studies were mixed in their support of ginger as an anti-CINV treatment in patients 
receiving chemotherapy, with three demonstrating a positive effect, two in favour but 
with caveats and two showing no effect on measures of CINV. Future studies are required 
to address the limitations identified before clinical use can be recommended.  
Key words: nausea, ginger, chemotherapy, CINV  
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 Introduction 
Chemotherapy is one of medicine’s key interventions in the treatment of cancer. 
While cytotoxic interventions for cancer are efficacious, they are often accompanied by 
a variety of adverse effects. Chemotherapy-induced nausea and vomiting (CINV) is a 
relatively common side effect of this treatment.  A combination of different classes of 
anti-emetic medications such as 5-HT3 antagonists, neurokinin 1 (NK1) receptor 
antagonists, corticosteroids and anti-anxiolytics have been shown to have additive effects 
and are commonly prescribed for patients having chemotherapy.  Vomiting has now been 
largely controlled but efforts to control nausea have been less successful; affecting 
upwards of 60% of patients.1 Persistent nausea is also considered the most distressing 
symptom for patients in this setting.2,3 This is of particular concern in oncology patients 
as nausea and vomiting can adversely affect food intake, increasing the risk of 
malnutrition during treatment. Previous studies report one in two patients in this setting 
as malnourished.4 The cumulative effect of pre-treatment and treatment-related 
malnutrition can be one of compromised immune function, decreased performance status, 
poor response to treatment, and sometimes, treatment discontinuation.5-7  
The use of integrative or complementary therapies has been steadily increasing in 
western countries.8 This wide-spread use of integrative therapies has resulted in an 
increased interest in the investigation of these therapies as either stand-alone or adjuvant 
treatments for treating clinical conditions. Ginger (Zingiber officinale) has a long history 
in many cultures as a folk-remedy for nausea and gastrointestinal discomfort. Empirical 
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research has demonstrated that ginger could be effective as an anti-nausea agent and in 
particular, it has been proposed as a possible candidate for anti-CINV therapy.  
While the exact mechanism of action is unknown, multiple active constituents 
within ginger (i.e. gingerols, shogoals, zingiberene, zingerone, and paradol) have been 
identified as potentially exerting beneficial effects on multiple areas implicated in the 
pathophysiology of CINV. Cell culture and animal studies suggest that these constituents 
stimulate oral and gastric secretions, regulate gastrointestinal motility,9,10 interact with 
the 5-HT3 receptors implicated in the CINV reflex,
11  and assists in rescuing intracellular 
redox.12,13 Furthermore, animal studies provide preliminary support for the role of ginger 
supplementation in the prevention of cisplatin-induced emesis.14,15  
Few adverse effects from the ingestion of ginger are reported in the literature.16 
Oral ginger is generally well tolerated, with mild gastrointestinal adverse effects 
including abdominal discomfort, heartburn, and diarrhoea being the most commonly 
reported. Theoretically, ginger inhibits platelet aggregation which could result in 
excessive bleeding, however this has not been reported in practice.17 When added to 
conventional anti-emetics used in the prophylaxis and treatment of CINV, ginger does 
not appear to increase adverse effects.18 Indeed, conventional anti-emetics appear to have 
a more varied adverse effect profile (including more severe adverse effects) compared to 
ginger. For example, steroids such as dexamethasone used for short durations commonly 
cause gastrointestinal adverse effects such as dyspepsia and psychological effects such as 
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insomnia, while 5-HT3 receptor antagonists such as ondansetron commonly cause 
constipation and headache.19,20  
Whilst direct cost comparison between ginger and standard anti-emetic therapies 
is difficult due to lack of dose equivalency, it is likely that ginger would compare well, 
given its low ingredient cost and accessibility. Ginger is already readily available in 
several commercial non-prescription formulations, and requires little technical innovation 
in terms of cultivation and preparation.21 
Ernst et al.16 published a review on the effect of ginger on nausea and vomiting in 
a variety of settings, including only one paper that specifically investigated its effects on 
CINV. The review found that ginger was generally beneficial; however, firm conclusions 
could not be made due to the low number of studies in each setting. Multiple papers have 
since been published in this area and therefore, our review aims to detail the current 
published research from randomised, controlled trials (RCTs) and evaluate the efficacy 
of ginger in the prevention of CINV, highlighting areas for future investigation.  
 Method 
A systematic search of the literature was conducted using PubMed, the Cochrane 
Library, and CINAHL, as well as bibliographies of past research on the subject (see 
Figure 2-1). Search terms were not limited by timeframe and therefore all searches were 
between April 2012 and the date of the databases inception. Articles were identified using 
the search terms “(“Zingiber officinale” OR “ginger”) AND (”cancer” or 
“chemotherapy”) AND (“nausea” OR “emesis” OR “vomit” OR “CINV”)”. Inclusion 
criteria for this review were: 1) RCT and/or cross-over trials that used either placebo or 
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current anti-CINV treatment as a control; 2) In human participants, undergoing 
chemotherapy; 3) The use of ginger as the main intervention and specifically investigating 
its effects on nausea and vomiting; and 4) Published in English.  
All studies included in this review were analysed for common characteristics and 
methodologies, major findings, and potential limitations. Additionally, all studies were 
individually rated for evidence level using the National Health and Medical Research 
Council (NHMRC) Hierarchy of Evidence guidelines (IV-I, with I being the strongest 
level of evidence) as well as assessed in terms of quality (positive, neutral, negative) using 
the American Dietetic Association’s quality criteria checklist. 22,23  
The overall body of evidence (based on a summary of the individual studies) 
evaluated within this review was assessed using a separate tool, the NHMRC’s body of 
clinical evidence assessment matrix, an assessment tool that assigns a letter grade (A: 
strongest to D: weakest) based on the strength of the literature included in a review. 22 
 Results 
The search strategy identified seven studies (Table 2-1) that provided Level II 
evidence and all had a positive quality rating. Hence, all studies included in this review 
possessed attributes consistent with rigorous scientific method, such as randomised group 
allocation and clear inclusion and/or exclusion criteria. Of note, two studies did not meet 
the inclusion criteria as they were unpublished literature (Pecoraro et al.24, Pace et al.25) 
and two studies (Levine et al.26, Meyer at al.27) were excluded as they utilised an ineligible 
study design.  
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 Study characteristics  
All seven studies included in this review were RCTs, three of which were cross-
over trials. Two cross-over trials used current anti-CINV treatment as the control group 
rather than placebo.28,29 Five of the seven studies had relatively small sample sizes 
(approximately 30-70 participants in total). Zick et al.18 and Ryan et al.30 were the 
exceptions, with 129 and 576 participants completing each trial respectively. The length 
and timeframe of symptom assessment varied between studies, with assessment of CINV 
symptoms conducted anytime from three days prior to chemotherapy treatment and up to 
10 days post-treatment. The outcomes measured in the majority of studies (5/7) were 
acute nausea and vomiting (24 hours post-chemotherapy) and delayed nausea and 
vomiting (between two and ten days post-chemotherapy); however, Ryan et al.30 did not 
measure vomiting symptoms and Sontakke et al.28 measured acute nausea and emetic 
events only.  
Typical dosing regimens were 1g to 2g of ginger, divided into four to eight 
capsules and consumed over a period of one to ten days. The majority of studies used 
powdered ginger preparations, while two studies used extracts that were standardised to 
either their gingerol content or to a combination of active compounds (shogoals, gingerols 
and zingerone). Zick et al.18 independently verified the preparations using high-
performance liquid chromatography to ensure the potency of the intervention and found 
their extract contained “5.38 mg (2.15%) 6-gingerol, 1.80 mg (0.72%) 8-gingerol, 4.19 
mg (1.78%) 10-gingerol, and 0.92 mg (0.37%) 6-shogaol”. Ryan et al.30 reported that the 
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ginger preparation used within their study contained 8.5mg of active constituents per 
capsule; however, it was unclear whether this was independently analysed or from the 
manufacturers’ analysis. None of the studies that used a powdered formulation reported 
an analysis of active constituents. The timing of doses did not vary greatly between 
studies, with the initial dose generally given +/-1 hour of the first chemotherapy session. 
Ryan et al.30 was the exception to this in providing ginger supplementation for the three 
days prior to chemotherapy. 
Five of the seven studies used standard anti-CINV medication in conjunction with 
ginger. In the two studies that did not use ginger as an adjuvant to standard therapy, ginger 
was compared to ondansetron and metoclopramide as a stand-alone treatment in a cross-
over trial28 or combined with standard anti-CINV treatment in the acute phase, but 
compared as a stand-alone treatment in the delayed phase of the study.29 Participants in 
four of the seven of studies were adults of mixed gender, with the exceptions of Panahi 
et al.31 and Manusirivithaya et al.29 who studied females and Pillai et al.32 who studied 
children.  
 Study results 
The results of the included studies were mixed. Two of the seven studies reported 
no benefit,18,33 three determined some benefit on measures of CINV (measures of either 
acute nausea30,31 or both acute and delayed nausea and vomiting32) and two reported that 
ginger performed equally as well as metoclopramide (Table 2-2).28,29 Zick et al.18 found 
that  higher doses (2g) of ginger had a negative effect on delayed-CINV in participants 
prescribed aprepitant (p=0.01).16  
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Figure 2-1 Flow of information for systematic review. 
 
Sontakke et al.28 found 2g of ginger effective in reducing acute CINV equal to 
metoclopramide; Pillai et al.32 determined that 1-2g of ginger was effective in reducing 
the severity of both acute and delayed CINV by 37-47%; while Ryan et al.30 reported that 
all doses used in the intervention successfully reduced symptoms of acute nausea by 0.16-
0.44 on a 1-7 Likert scale in patients experiencing mild baseline-CINV (p=0.003), with 
0.5g and 1g (p=0.017 and p=0.036, respectively) being the most effective doses; 
however, delayed nausea and quality of life were not affected by ginger supplementation. 
A 16% reduction in acute nausea during the first 6-24 hours post-chemotherapy was also 
found by Panahi et al.31 using 1.5g of ginger (p=0.04). 
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Manusirivithaya et al.29 reported that during the acute phase of chemotherapy, 1g 
of ginger did not further reduce CINV when combined with metoclopramide therapy. It 
did, however, perform equally to metoclopramide during the delayed phase (2-5 days 
post-chemotherapy). Zick et al.18 and Fahimi et al.33 found no additional benefit when 
ginger was used as an adjuvant therapy to standard nausea and emetic control.  
A variety of tools were used to assess nausea and vomiting in the studies reviewed. 
Two studies measured symptoms using a modified version of the Morrow Assessment of 
Nausea and Emesis (MANE),18,33 a validated instrument for assessing nausea in cancer 
patients34; Pillai et al.32 employed the Edmonton Symptom Assessment Scale and the 
National Cancer Institute Guidelines for Nausea and Vomiting, respectively; two studies 
used an unspecified tool28,29;  Panahi et al. 31 employed the Rhodes Index of Nausea, 
Vomiting, and Retching; and Ryan et al.30 utilized a tool developed by Burish and 
Carey.35  
Five of the seven studies specifically included patients receiving highly 
emetogenic chemotherapy regimens; however, while all being highly emetogenic 
regimens, there was little consistency in the agent and protocol used. The remaining two 
studies included patients undergoing combination chemotherapy containing agents with 
different degrees of emetogenicity.18,30 
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Table 2-1 Studies reviewed 
Author 
 
Study Design Population Type of cancer Chemotherapy Protocol Country Level of 
evidence 
Quality 
Ryan et al. 
(2012)30 
 
Randomized, double-
blind, placebo-
controlled, dose-finding 
trial 
576 adult cancer 
patients. Mean age of 
53 years. 93% women. 
72% Breast, 28% 
Alimentary Genitourinary, 
Gynaecologic, 
Hematologic, Lung. 
Not specified. USA II Positive 
Panahi et al. 
(2012)31 
 
Randomized, open-label, 
pilot clinical trial 
78 women. Mean age: 
51.83 years.  
Advanced breast cancer Predominately, the TEC regimen 
(docetaxel, epirubicin, and 
Cyclophosphamide).  
Iran II Positive 
Pillai et al. 
(2011)32 
 
Prospective, double-
blind, randomized 
controlled trial 
58 children, cancer 
patients. Mean age: 15 
years. 40 men, 20 
women.  
Bone sarcoma. Combination of cisplatin (40 mg/m2/day) 
and doxorubicin (25 mg/m2/day). 
India II Positive 
Fahimi et al. 
(2010)33 
 
Randomized, cross-over, 
double-blinded, placebo-
controlled trial 
36 adult cancer 
patients. Mean age of 
50.23 years. 10 women, 
26 men. 
50% Lung cancer, 50% 
Unspecified. 
Cisplatin with at least one of the 
following agents: Etoposide, Docetaxel, 
Gemcitabine, Docetaxel, Vinorelbine 
Cyclophosphamide, Paclitaxel, 
Doxorubicin, 5-FU, Pemetrexed. 
Iran II Positive 
Zick et al. 
(2009)18 
 
Randomized, double-
blind, placebo-controlled 
trial 
129 adult cancer 
patients. Mean age of 
55.5-58 years. 
Approximately 75% 
female. 
Unspecified. Multiple regimens of varying 
emetogenicity. 
USA II Positive 
Manusirivit
haya et al. 
(2004)29 
 
Randomized, double-
blind crossover trial 
43 female cancer 
patients. Mean age of 
43 years. 
76% Ovary, 23% Cervix. Cisplatin with one of the following 
agents: cyclophosphamide, ifosfamide, 
etoposide & bleomycin, 5-fluorouracil. 
Thailand II Positive 
Sontakke et 
al. (2003)28 
 
Randomized, 
prospective, cross-over, 
double-blind trial 
50 cancer patients. 
Median age of 46 years. 
39 female, 11 male. 
Unspecified. Cyclophosphamide (500-1000mg) with at 
least one of the following agents: 
vincristine, methotrexate, 5-fluorouracil, 
actinomycin D. 
India II Positive 
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Table 2-2 Study results 
Author 
 
Ginger regimen Duration of 
intervention 
Endpoint measured Results and adherence Comments 
Ryan et al. 
(2012)30 
 
Placebo, 0.5g 
ginger, 1g ginger 
or 1.5g ginger (6 
capsules, 
combination of 
ginger and 
placebo). 
Received regimen 
for 2 X 6 day 
periods. Measured 
for 3 X 4 day 
periods. 
Primary objective: acute 
nausea. Secondary 
objectives: delayed nausea, 
anticipatory nausea, 
and quality of life. 
All doses reduced acute nausea (p=0.003) but not 
delayed, using an assessment tool developed by Burish 
and Carey.35 77.4% of participants completed the trial 
(N=576/744), 83-93% adherence rate depending on 
treatment arm. 
0.5 and 1g doses were 
most effective in 
reducing acute CINV. 
Largest study to date. 
Panahi et al. 
(2012)31 
 
1.5g (3 X 500mg) 4 days post-
chemotherapy 
Prevalence, score, and 
severity of 
nausea, vomiting, and 
retching 
Reduction in nausea 6 to 24 hours post-chemotherapy (p 
= 0.04) using a simplified version of the Rhodes Index of 
Nausea, Vomiting, and Retching. All other measures 
were non-significant. 78% of participants completed the 
trial (N=78/100), 18 participants were withdrawn due to 
lack of adherence or were lost to follow-up. 
 
Non-blinded. Sample 
group relatively 
homogenous compared to 
other studies in this 
review.  
Pillai et al. 
(2011)32 
 
1g ginger (6 X 
167mg) or 2g (5 
X 400mg) 
determined by 
participants 
weight, or 
placebo. 
Received regimen 
for 3 days post-
chemotherapy, 
measured 
symptoms for 10 
days post-
chemotherapy. 
Incidence and severity of 
acute and delayed nausea 
and emetic events.  
Reduction in moderate and severe acute nausea and 
emesis (p=0.003, p=0.002, respectively) and reduction in 
moderate and severe delayed nausea and emesis 
(p<0.001, p=0.022, respectively), using Edmonton’s 
Symptom Assessment Scale and National Cancer Institute 
guidelines.  95% of participants completed the trial 
(N=57/60), 2 participants were withdrawn due to non-
adherence with data collection protocol.   
Experimental group 
contained a larger 
proportion of males, 
almost reaching statistical 
significance. Gender 
could influence 
susceptibility to nausea 
and vomiting. 
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Fahimi et al. 
(2010)33 
 
1g (4 X 250mg) 
or placebo then 
crossed over. 
2 X 3 day periods 
with a 3 week 
washout period in 
between. 
Prevalence, severity and 
duration of acute and 
delayed nausea and emetic 
events.  
No benefit in any measure of acute or delayed CINV, 
using MANE assessment tool. Prevalence: Day 1 
(p=0.14). Day 2 (p=0.31). Day 3 (p=0.73). 72% of 
participants completed the trial (N=36/50), 13 
participants were withdrawn due to non-adherence. 
  
Zick et al. 
(2009)18 
 
1g (4 X 250mg, 
4x placebo) or 2g 
(8 X 250mg) per 
day or placebo. 
3 days post-
chemotherapy 
Primary objective: Severity 
and prevalence of delayed 
nausea and emetic events. 
Secondary objectives: 
Severity and prevalence of 
acute nausea and emetic 
events as well determine 
safety and blinding of study. 
No benefit in any measure of acute or delayed CINV, 
using MANE assessment tool. Prevalence:  Acute: 
p=0.86 Delayed: 0.16 Severity: Non-Appretiant group: 
Acute: p=0.47, Delayed: p=0.69. 80% of participants 
completed the trial (N=129/162). Authors reported 79% 
of participants reported consuming 80% of all study 
medication. 
Delayed nausea was 
more severe in 
participants receiving 2g 
ginger with aprepitant. 
Blinding assessment 
found that participants 
were more likely to 
correctly determine 
which treatment group 
they were assigned to. 
Manusirivith
aya et al. 
(2004)29 
 
1g ginger (4 X 
250mg) or 
placebo then 
crossed over. 
2 X 5 day periods 
with 3-4 week 
washout period in-
between 
Acute and delayed nausea 
and emetic events.  
No benefit in acute nausea. Reduction in delayed CINV 
equal to standard treatment. 90% of participants 
completed the trial (N=43/48). No data on adherence rate 
specified. 
The name of assessment 
tool in this study was not 
identified.   
In delayed phase, ginger 
was compared as a stand-
alone treatment to 
metoclopramide, not 
placebo.  
Sontakke et 
al. (2003)28 
2g (4 X 500mg) 
ginger, crossed 
over with two 
control groups 
3 X 24 hour 
periods with 21 
days between 
sessions 
Control of acute nausea and 
emesis. 
Complete control of vomiting was achieved in 68% of 
patients with ginger, 64% with metoclopramide and 86% 
with ondansetron. Complete control of nausea was 
achieved in 62% of patients with ginger, 58% with 
metoclopramide and 86% with ondansetron. No data on 
withdrawals or adherence was specified. 
Compared ginger to 
standard emetics as a 
standalone therapy.  
The name of assessment 
tool in this study was not 
identified.   
Abbreviations: MANE, Morrow Assessment of Nausea and Emesis; CINV, Chemotherapy-induced Nausea and Vomiting. 
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 Adverse events and adherence 
Despite previous research indicating that ginger supplementation could 
theoretically cause excessive bleeding in susceptible patients due to the inhibition of 
platelet aggregation,36 all adverse events that were attributed to the intervention were non-
serious in nature. The most common reactions reported included heartburn, bruising or 
flushing, rash, and gastrointestinal discomfort. Adverse events were generally not 
significantly higher in the ginger group compared to the control group in any study. 
Most studies (5/7) reported some degree of non-adherence during their 
investigations. Studies that included information regarding adherence found a rate 
between 75-90%.18,30,31,33 The exact method for determining adherence was not stated in 
five of the seven studies, however, Ryan et al.30reported that adherence was measured by 
counting the amount of remaining pills at the end of each study cycle while Panahi et al.31 
measured self-reported adherence.  
 Discussion 
The evidence is mixed in its support of ginger as an adjuvant or stand-alone 
treatment for CINV. Of the seven RCTs published to date; five reported favourable results 
while two were unfavourable. Of the five favourable studies, three studies reported ginger 
as improving some measure of CINV when combined with standard anti-CINV treatment, 
with Ryan et al.30 and Panahi et al.31 reporting a reduction in acute nausea and Pillai et 
al.32 reporting a reduction in acute and delayed nausea and vomiting. The two other 
favourable studies found ginger reduced some measure of CINV equal to metoclopramide 
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but due to the lack of a placebo group in both studies, it is difficult to determine the 
clinical significance of these results28,29. This is due to the fact that in both of these trials, 
the percentage of individuals that reported symptoms in the ginger group was still within 
the predicted emetic risk for the chemotherapy regimen used and therefore, without a 
placebo group, it is difficult to determine the intervention’s true impact. Results from 
positive trials have found ginger to reduce measures of CINV by 16-47% and while these 
findings need to be reconciled with the negative findings from other studies in this review, 
this magnitude of reduction could provide meaningful relief to patients experiencing 
CINV. 
Using the NHMRC body of evidence assessment matrix, our review indicates that 
there is C level evidence for the use of ginger as an anti-nausea agent in this context. 
Therefore while there is some supporting evidence for its use, the considerable 
inconsistency in study methods and outcomes reported here reflect genuine uncertainty 
about its use in the chemotherapy setting. Until this uncertainty is resolved, professional 
opinion will continue to guide the healthcare team when choosing ginger as a treatment 
option.  
 Confounding factors within current literature  
There are multiple factors that explain the mixed results reported in the literature. 
One possible explanation is that some ginger preparations have higher levels of certain 
active compounds when compared to the preparations used in other studies. Research 
investigating the concentration of active compounds in commercial ginger products 
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indicates that the levels of these compounds can vary greatly between products, 
demonstrating a need to analyse ginger interventions for their active compounds and to 
utilise standardised extracts rather than powdered formulations.37,38 In order to improve 
the significance of future trials in this area, dose-finding studies using varied standardised 
extracts are required to determine the effective dose and preparation of ginger. 
Recent studies have also determined that once a patient undergoing chemotherapy 
develops any form of nausea or vomiting (i.e. anticipatory, acute, delayed), regardless of 
the emetogenicity of that treatment, the likelihood of that patient experiencing nausea for 
the remainder of their treatment regimen is significantly higher and more difficult to treat 
with standard anti-CINV medication. 39 This is due to the complex aetiology of CINV, a 
response that is initiated by varying stimuli within the central and peripheral nervous 
systems. These include the effects of chemotherapy on both the central nervous system 
and gastrointestinal tract as well as the effect of sensory input (e.g. smell, sight) and the 
psychological conditions of the individual (e.g. fear, anxiety).40 These stimuli activate 
peripheral and central nerve signals which are then received by the chemoreceptor trigger 
zone an area within the brain, which coordinates the body’s emetic response base. 
Anticipatory nausea and vomiting is thought to be a conditioned response to previous 
chemotherapy exposure. Anticipatory CINV  is mediated by the central nervous system 
and is caused by the coupling of neutral stimuli (such as the smell or sight of the hospital 
environment) with the undesirable effects of chemotherapy, which then results in the 
initially neutral stimuli eliciting a similar response to the cytotoxic treatment.41  Since 
many studies in this review included patients who had previously experienced CINV, the 
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participants within these studies might have had an increased resistance to the 
intervention due to conditioning. This is of particular concern in the studies that used a 
cross-over design, as patients who were initially in the control group could have had 
established resistance to the intervention when subsequently crossed-over. Conducting 
statistical analysis to ensure that the sequence of intervention does not influence the 
results, as undertaken by Manusirivithaya et al.29 and Zick et al.18, will help monitor this 
effect. Alternatively, Roscoe and colleagues30,42 were able to determine that a self-
assessed susceptibility to nausea and vomiting by chemotherapy patients was a predictor 
of CINV and might be a viable method of screening in future trials.  
Research has found that female patients are significantly more likely to experience 
CINV than their male counterparts.43 The majority of studies (5/7) included a sample that 
was predominantly female, of which four studies reported benefits from ginger treatment. 
This suggests that gender could have influenced the patients’ response to ginger 
treatment, possibly by decreasing the threshold at which CINV is experienced and thereby 
increasing the efficacy of anti-CINV treatments. In light of this, the null results reported 
by Fahimi et al.33 could be partially explained by the male-dominant sample. In this study, 
the severity of nausea in both the intervention and control group was rated as low at all 
time points which indicates that the patients within this study could not have been 
experiencing CINV at a sufficiently high level of severity to have responded to anti-CINV 
intervention. This could also explain the results found by Pillai et al.32 When the gender 
distributions between the control and treatment group were compared, there was a greater 
proportion of men within the experimental group compared to the control, which almost 
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reached statistical significance (p=0.055). This could have also resulted in the 
experimental group being more resistant to CINV compared to the control group 
regardless of ginger treatment. Therefore, similarly to anticipatory nausea, future trials 
should either include screening protocols or conduct statistical analyses to account for 
gender variations within the study sample.   
Additionally, because of the subjective nature of nausea, direct comparison of 
findings can be difficult and therefore investigators should aim to use validated tools such 
as the MANE, which would ensure that results are both validated and easily comparable 
to other studies. It should be noted that the two studies that failed to find any benefit from 
ginger supplementation both used the MANE as the assessment tool, which suggests that 
the use of different assessment tools used within each study might have been a factor 
contributing to the mixed results of the reviewed literature.18,33  
Another concern is that due to the distinctive aroma of ginger, it is important to 
ensure that studies are properly blinded. For example, Zick et al.18 tested the effectiveness 
of the blinding in their investigation. While they had taken steps to ensure adequate 
blinding, the participants were able to discern the intervention group from the placebo at 
a statistically significant rate (p=0.01). To overcome this problem, Ryan et al.30 utilised 
a combination of double encapsulation with a nitrogen cap to mask the odour and colour 
of the ginger. While this is an example of a potentially effective blinding technique, they 
did not test its effectiveness. Interestingly, Ryan et al’s.30 was one of the two studies that 
reported positive results when ginger was used as an adjuvant therapy; effective blinding 
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could, at least in part, help explain the disparity of results between studies within this 
review. Future clinical trials should incorporate more stringent blinding procedures to 
avoid a potential placebo or nocebo effect from occurring.  
 Possible drug-interactions at high doses 
An interesting result reported within two studies in this review is that when 
subjects were given higher doses (1.5-2g) of ginger, there was a statistically significant 
decline in CINV control when compared to the participants that either received lower 
doses or the placebo. Zick et al.18 reported that when subjects received a combination of 
2g ginger plus aprepitant (an NK1 inhibitor), the severity of delayed nausea increased 
when compared to control (p=0.01). Similarly, Ryan et al.30 concluded that while all 
doses of ginger were effective in reducing acute CINV, 1.5g of ginger was less effective 
when compared to the 0.5g and 1g of ginger preparations. These findings corroborate 
previous studies in this field, which reported that higher doses of ginger were less 
effective when treating nausea from causes other than chemotherapy.44,45 This led Zick et 
al.18 to hypothesise that ginger reduces absorption of medication by increasing gastric 
emptying and intestinal motility, which has been demonstrated in animal models. 
However, research in human trials has not determined that ginger affects gastric emptying 
rates.46,47 Another hypothesis is that ginger competitively interacts with the same 
receptors that standard anti-CINV medication acts upon; thereby reducing the binding 
rate of medications when used in combination.30  Animal studies support this hypothesis, 
indicating that gingerols and shoagoals are able to bind to both 5-HT3 and substance P 
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receptors, which are the receptors that medications such as aprepitant and ondansetron 
interact with.48,49 It should also be noted that these studies showed that different ginger 
compounds bound to these receptors with varying strengths and therefore, different 
preparations of ginger could exert differing effects on nausea. This highlights further 
limitations in our current understanding in this area, as there are multiple active 
compounds in ginger that appear to be responsible for these interactions. This poses a 
significant limitation to the current research as the majority of studies, excluding Zick et 
al.18 and Ryan et al.30, used ginger preparations with unknown levels of these active 
constituents.  
 Clinical Implications 
The feasibility of ginger supplementation has not been extensively or rigorously 
studied in chemotherapy populations. Fatigue, mouth sores and taste sensitivities are all 
common symptoms that chemotherapy patients experience while undergoing treatment. 
Given that some studies included in this review have used up to 8 capsules, consumed at 
multiple times throughout the day, this could place a significant burden on a population 
group who might already be compromised. Future research is required to investigate areas 
of practice such as participant tolerability and adherence to the intervention, in addition 
to its effect on quality of life and patient satisfaction with the intervention, in order to 
determine its real-world efficacy.   
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 Review limitations 
The exclusion of unpublished literature could have affected this review by 
introducing a publication bias; however, the two unpublished studies that were identified 
and excluded from this review both reported positive results and therefore this seems 
unlikely.24,25   
 Conclusion 
Despite the widespread use of ginger in the treatment of nausea in other contexts 
such as gestational nausea, the current literature provides mixed support for the use of 
ginger as a standard part of anti-CINV control for patients undergoing chemotherapy. 
Hence standard recommendations for such use are premature. This review has discussed 
some of the limitations in our current understanding of the area and highlights the need 
for further investigation. In particular, issues regarding rigorous blinding procedures, 
patient screening, timing of the intervention to encompass the range of CINV, and ginger 
preparation should be considered in future research in this area. Our analysis of the 
evidence using NHMRC grading indicates that ginger could be useful for some patients 
but also that care needs to be taken in its application until further studies are conducted.  
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 Is ginger beneficial for nausea and vomiting? An 
update of the literature. 
The manuscript included in Chapter 3 was the result of an invitation by the editors 
of Current Opinion in Supportive & Palliative Care (2014 Impact Factor: 1.656; 47 of 
89 Health Care Science & Service) to provide an update on the clinical data regarding the 
use of ginger for nausea from any stimuli (e.g. CINV as well as morning sickness and 
motion sickness). This chapter provides an update to the systematic literature review 
included in Chapter 2 by discussing clinical trials that were conducted since the literature 
search date and provides a broader overview of the recent evidence for the use of ginger 
for nausea.   
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 Abstract 
Purpose of review: Nausea and vomiting can pose a significant burden to patients 
in a variety of clinical settings. Previous evidence suggests ginger could be an effective 
treatment for these symptoms; however, current evidence has been mixed. This review 
discusses recent clinical trials that have investigated ginger as a treatment for multiple 
types of nausea and vomiting. In addition, the potential mechanisms of action of ginger 
will be discussed.  
Recent findings: This review identified nine studies and seven reviews that 
investigated ginger for morning sickness, post-operative nausea and vomiting, 
chemotherapy and anti-retroviral induced nausea and vomiting.  All studies reported 
ginger to provide a significant reduction in nausea and vomiting; however, the clinical 
relevance of some studies is less certain. Common limitations within the literature include 
the lack of standardised extracts, poorly controlled or blinded studies, and limited sample 
size. In addition, recent evidence has provided further support for 5-HT3 receptor 
antagonism as a mechanism by which ginger could exert its potentially beneficial effect 
on nausea and vomiting. 
Summary: The results of studies in this review suggest that ginger is a promising 
treatment for nausea and vomiting in a variety of clinical settings and possesses a 
clinically relevant mechanism. However, further studies are required to address the 
limitations in the current clinical literature before firm recommendations for its use can 
be made. 
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 Key Points 
 The active constituents within ginger have been reported to exert 5-HT3 receptor 
antagonism, a clinically relevant mechanism for treating nausea and vomiting. 
 Ginger has demonstrated preliminary efficacy in reducing nausea and/or vomiting 
in response to a variety of stimuli including surgery, pregnancy, chemotherapy, 
and more recently, antiretroviral therapy. 
 While the included studies generally reported statistically significant reductions 
in nausea and vomiting measures, the clinical significance of these results were 
mixed.  
 Current limitations in clinical studies include lack of standardised extracts, poorly 
controlled or blinded studies, and limited sample size. 
 To date, studies have reported few adverse events associated with ginger 
supplementation; however, further studies are required to assess its safety profile. 
 Introduction 
Nausea and vomiting can pose a significant burden to the patient, resulting in 
reduced quality of life, further medical complications, malnutrition, and in some settings, 
could potentially result in treatment disruption and stoppage.[1] Due to the high 
prevalence of nausea and/or vomiting in settings such as during chemotherapy and 
pregnancy, there has been considerable research interest in a variety of adjuvant therapies 
aimed at improving symptom control. 
Ginger has had a long history of use in traditional systems of medicine for 
gastrointestinal complaints and continues to be commonly used as an anti-nausea 
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agent.[2] Ginger contains a wide-array of bioactive compounds which have been 
investigated for their effects on nausea and vomiting. Multiple potential mechanisms of 
action have been identified including 5-HT3 receptor antagonism, anti-inflammatory 
properties and the modulation of gastrointestinal motility.[3] Clinical studies have also 
reported promising results and ginger has now been investigated as a treatment for a 
several types of nausea including motion sickness, post-operative nausea and vomiting, 
morning sickness, and chemotherapy-induced nausea and vomiting.[4]  
Due to the continued investigation in this area, the aim of this review is to discuss 
recently published clinical studies that have investigated the use of ginger as a treatment 
for nausea and vomiting in any setting. Secondly, this review will provide an update 
regarding results of recent research on the mechanisms by which ginger could exert its 
potentially beneficial effect.  
 Methodology 
A systematic search of the literature was conducted using the following databases: 
Medline, CINAHL, and the Cochrane Library. Search queries were limited to 
manuscripts published from 2013 until December 2014. Due to the limited time frame, 
the search query, (“ginger” AND “nausea”), was left broad so as to capture all relevant 
articles. Reference lists of retrieved manuscripts were also examined for additional 
publications.  
Inclusion criteria for this review were as follows: 1) manuscripts published in 
English 2) study examined ginger as the primary intervention, and 3) investigated the 
effect of the intervention on nausea and/or vomiting outcomes or on mechanisms involved 
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in the generation of nausea and/or vomiting. Clinical studies that investigated ginger for 
nausea and/or vomiting in response to any stimuli were included.  
 Clinical efficacy 
The search retrieved 16 articles related to the clinical efficacy of ginger in relation 
to nausea and vomiting. These include seven reviews,[1, 4-9] three of which also 
conducted a meta-analyses,[6-8] and nine original studies that investigated either the 
safety or efficacy of ginger as a treatment of nausea and/or vomiting.[10-18] For the 
clarity of this manuscript, the following discussion has been categorised by the type of 
nausea and/vomiting that was investigated. Clinical trials are also included in an 
extraction table (Table 3-1). 
 Morning sickness 
Four systematic reviews were retrieved, two of which also performed a meta-
analysis of included studies.[5-7, 9] Although the inclusion criteria varied between 
reviews, all four reviews reported ginger to be effective in reducing symptoms of nausea 
and/or vomiting.  
Viljoen et al.[6] conducted a systematic review which included 12 studies, 
comprising 1278 participants. A particular strength of this study is that instead of 
restricting the inclusion criteria to increase the homogeneity, it categorised studies 
according to the comparison intervention (i.e placebo, metoclopramide, vitamin B6 and 
dimenhydrinate) which was then discussed separately. The majority of studies review 
reported either a beneficial effect when compared to placebo or either an equivalent or 
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superior effect when compared to metoclopramide, vitamin B6 and dimenhydrinate.[6]  
When possible, a meta-analysis was conducted but due to the significant heterogeneity in 
study designs and reporting of outcomes, generally only two studies per analysis was 
included and so the significance of these results is limited. 
This study also analysed the adverse events and risk of spontaneous abortion and 
while the number of studies analysed for each adverse effect was small, the analysis found 
no significant difference in any adverse effect or risk of spontaneous abortion between 
ginger and placebo.[6] Heitmann et al.[13] also explored the relationship between ginger 
usage during pregnancy and risk of congenital malformations in a cohort study. From the 
1020 women that reported consuming ginger during pregnancy, no statistically significant 
increase in multiple adverse outcomes (including stillbirth or perinatal death, preterm 
birth, low birth weight, low apgar score) was detected. Although an increased risk of non-
severe vaginal bleeding was reported (7.8 % vs. 5.8 %, p=0.007).  
The two clinical trials that were identified in our literature search both reported 
ginger to be effective in improving measures of nausea and vomiting. The first study was 
conducted by Javadi et al.[18] who conducted an open-label study that compared the 
efficacy of 1g ginger and vitamin B6 in 95 women. Saberi et al.[15] conducted a 
randomised controlled trial which compared the efficacy of ginger or acupressure to a 
control group. Both studies found ginger to be effective in significantly reducing the 
severity of nausea and vomiting from moderate severity to mild severity. However, 
neither study was blinded which presents a significant study limitation.  
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 Post-operative nausea and vomiting 
Four clinical studies were included in this review that investigated the effect of 
ginger for post-operative nausea and vomiting. All studies had relatively large sample 
sizes (N=100-303), making these the largest studies to date that have investigated post-
operative nausea and vomiting.  
Mandal et al.[17] investigated the effect of ginger on 100 participants undergoing 
a range of surgeries in the ambulatory setting and reported significantly reduced severity 
of nausea and vomiting symptoms four and six hours post-surgery as well as significant 
reductions in the incidence of post-operative nausea and vomiting at multiple time points 
within the 18 hours post-surgery.. Montezzari et al.[11] also investigated ginger as a 
treatment for post-operative nausea and vomiting at two, four and six hours post-surgery 
in patients undergoing diverse surgeries and reported a modest benefit in nausea reduction 
at two hours. As previous studies have been primarily in patients receiving 
gynaecological surgeries, these results add to the literature by demonstrating potential 
efficacy in a broader range of surgeries. However, the mean severity of post-operative 
nausea and vomiting reported in these studies was low for both the intervention and 
placebo groups and so the reported difference in severity could not be clinically 
significant.  
In addition to post-operative nausea and vomiting, Kalava et al.[14] investigated 
the use of 1g ginger supplementation for intraoperative nausea and vomiting in 239 
participants receiving elective caesarean section. The results showed a statistically 
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significant reduction in the frequency of intraoperative nausea but not intraoperative 
vomiting or post-operative nausea or vomiting. However, the mean difference in nausea 
between groups (0.396 on a 10 point visual analogue scale) is unlikely to translate into a 
meaningful difference to the patient. Despite this, this is the first study to investigate the 
effect of ginger on intra-operative nausea and vomiting and as this is a significant issue 
during particular surgeries, the results of this study suggest that this is an area worth 
further investigation.
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Table 3-1. Extraction table of included clinical trials investigating ginger for nausea and vomiting. 
Name Type of nausea 
and/or 
vomiting 
Study design Intervention Dosage Outcomes Assessment form Results Comments 
Javadi et al. 
(2013) 
Morning 
Sickness 
N=95 women 
Duration: 4 days 
Design: open-label 
clinical trial 
Ginger or 
vitamin B6 
1g 
(4x250mg) 
Occurrenc
e and 
frequency 
of nausea  
Occurrenc
e of 
retches and 
vomiting 
MPUQE scoring 
system 
Both ginger and vitamin B6 
significantly reduced all outcomes 
compared to pre-treatment 
Treatment effect of interventions 
was equal 
No placebo 
group  
Not blinded 
Saberi et al. 
(2013) 
Morning 
Sickness 
N=159 
Duration: 7 days 
Design: 
Randomised 
controlled trial 
Ginger or P6 
acupressure 
750mg 
(3x250mg) 
Nausea 
score 
Vomiting 
score 
Retching 
score 
Total score 
Rhodes Index of 
Nausea, Vomiting 
and Retching 
Nausea score was reduced by 
48% 
Vomiting score was reduced by 
52% 
Total score was reduced by 49% 
in ginger group 
Ginger group has greater 
reductions in all scores compared 
to control and acupressure group 
Acupressure 
scores not 
included in 
this table 
Not blinded 
Kalava et al. 
(2013) 
Post- and intra- 
operative 
nausea and 
vomiting 
N=239 women 
Duration: During 
and 24 hours post-
surgery 
Design: Double-
blind randomized 
placebo controlled 
trial 
Ginger 2g (2x1g) Intraoperat
ive 
incidence 
and 
frequency 
of nausea 
and 
vomiting 
Postoperati
ve 
incidence 
and 
severity of 
nausea and 
vomiting 
Three Item visual 
analogue scale 
Intra-operative symptoms: 
Reduced nausea frequency (p= 
0.023) but not incidence. No 
significant effect on vomiting.  
Post-operative symptoms: No 
statistically significant difference 
in any outcome 
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Mandal et al. 
(2014) 
Post-operative 
nausea and 
vomiting 
N=100 
Duration: 18 hours 
post operation 
Design: Double-
blind randomized 
placebo controlled 
trial 
Ginger 1g 
(2x500mg) 
Frequency 
and 
severity of 
nausea, 
vomiting 
and 
retching 
Frequency of 
symptoms and 
medications used 
was recorded using 
tool developed by 
Bellville et al.15 
Severity of 
symptoms measured 
using a one item 
visual analogue scale 
Reduce frequency of nausea, 
vomiting and retching at  2, 4, 6, 
8 and 12 hours post-surgery 
(p<0.05) 
Reduced severity of nausea and 
vomiting at four and six hours 
post operation (p<0.05) 
Use of rescue medications was 
significantly lower in the ginger 
group (P<0.05) 
  
Montazeri et 
al. (2013) 
Post-operative 
nausea and 
vomiting 
N=160 
Duration: 
Design: Double-
blind randomized 
placebo controlled 
trial 
Ginger 1g 
(4x250mg) 
Frequency 
of retching 
and 
vomiting 
Severity of 
nausea 
Visual analogue scale Reduced severity and frequency 
of nausea at 2 hours post-surgery 
but not at 4 and 6 hours (p=0.04, 
0.05, respectively). 
No significant difference in 
frequency of vomiting or retching 
  
Hunt et al 
(2013) 
Post-operative 
nausea and 
vomiting 
N=301 
Duration:  
Design: 
Randomised, 
placebo-controlled 
trial 
Ginger 
essential oil 
Essential oil 
blend (ginger, 
cardamom, 
spearmint, 
peppermint) 
Isopropyl 
alcohol 
N/A Severity of 
nausea 
Anti-
emetic 
medication 
request 
Visual analogue scale Reduced number of requests for 
anti-emetic medication (p=0.001) 
Reduced severity of nausea 
(p=0.002) 
Essential oil 
blend also 
significantly 
improved 
outcomes 
Montazeri et 
al. (2013) 
Chemotherapy
-induced 
nausea and 
vomiting 
N=44 
Duration: Two 
chemotherapy 
cycles 
Design: 
randomized cross-
over trial 
Ginger 1g 
(4x250mg) 
Frequency 
and 
severity of 
acute 
nausea and 
vomiting 
Retching 
frequency 
Rescue 
medication 
usage 
Two item visual 
analogue scale 
Reduced severity and frequency 
of nausea and vomiting (p=0.001) 
Delayed 
nausea not 
assessed 
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Dabaghzadeh 
et al. (2014) 
Antiretroviral-
induced nausea 
and vomiting 
N=102 
Duration: 14 days 
Design: Double-
blind randomized 
placebo controlled 
trial 
Ginger 1g 
(4x250mg) 
Incidence 
of any 
severity of 
nausea and 
vomiting 
Incidence 
of mild, 
moderate, 
and severe 
nausea and 
vomiting 
Visual analogue scale Reduced incidence of total nausea 
and vomiting in ginger group 
(p<0.001) 
Reduced incidence of mild, 
moderate, and severe  nausea and 
vomiting in ginger group (p = 
0.02, 0.04 and 0.001, 
respectively) 
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Hunt et al.[10] reported ginger as an aromatherapy, either stand-alone or when 
combined with other essential oils, significantly reduced postoperative-nausea when 
compared to a saline control. Data regarding the baseline severity of nausea in patients 
was not reported and so the effect of ginger on different severities of nausea is unclear. 
In addition, as the method of delivery was via inhalation, it is likely that the mechanism 
of action could differ from ingested ginger and so the results of this study could not be 
able to be directly compared to studies that used ginger in supplement form.  
 Chemotherapy-induced nausea and vomiting 
Two systematic literature reviews were identified which examined the use of 
ginger for chemotherapy-induced nausea and vomiting (CINV), predominately in patients 
receiving moderately and highly emetogenic chemotherapy regimens.[1, 8] Both reviews 
concluded that the current evidence for the use of ginger during chemotherapy is mixed 
and that further trials are needed to address existing limitations.  
Limitations that were specific to CINV include the use of anti-emetic regimens 
that are not in line with current anti-emetic guidelines, and the lack of control or 
consideration for prognostic factors that could have influenced risk of nausea and 
vomiting (e.g. history of alcohol intake and motion sickness). 
Lee et al.[8] performed a meta-analysis of included studies and while no effect on 
incidence of acute nausea and vomiting, and severity of acute nausea was reported, only 
two to three studies were included per analyses which limits the strength of these 
conclusions.  
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One clinical study was also identified which reported significant reductions in the 
frequency and incidence of acute nausea and vomiting in patients receiving 1g of ginger 
when compared to placebo.[12] While this trial adds to the promising literature regarding 
the clinical application of ginger in the chemotherapy setting, the limitations identified in 
the aforementioned reviews are still present in this study.  
 Antiretroviral-induced nausea and vomiting 
Dabaghzadeh et al.[16] conducted a randomised controlled trial on the effect of 
ginger on nausea and vomiting induced by antiretroviral medication in 102 HIV positive 
participants. The investigators reported that 1g of ginger over 2 weeks significantly 
reduced the frequency and severity of nausea and the frequency of vomiting (p=0.001). 
Furthermore, the magnitude of effect was considerable with large difference in reported 
outcomes between the intervention and placebo group. To our knowledge, this is the first 
report of ginger being used as an anti-nausea and vomiting agent during antiretroviral 
therapy and therefore, demonstrates another setting where ginger could be of benefit and 
due to the promising results, warrants further study.  
 Mechanisms of action 
Our search retrieved two original studies and two review articles that had 
investigated the mechanisms of action of ginger and its bioactive compounds in relation 
to pathways involved in nausea and vomiting.[19-22]  
There are several mechanisms by which ginger could reduce nausea and vomiting 
symptoms; however, 5-HT3 receptor antagonism is arguably one of the strongest 
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candidates for its primary mechanism. Previous work has demonstrated that bioactive 
compounds exhibit 5-HT3 antagonism in murine cell lines but while these studies have 
provided strong support for ginger interacting with these receptors, Walstab et al.[21] has 
advanced this area by investigating this effect in human 5-HT3 receptors and confirmed 
the following findings. First, this study has demonstrated that both ginger extracts and the 
compounds, 6-gingerol and 6-shogaol, non-competitively inhibited 5-HT3 receptor 
activation. This provides both support for ginger interacting with the 5-HT3 receptors in 
humans but also provides additional evidence that these compounds bind to a currently 
unknown binding site, distinct from other types of 5-HT3 receptor antagonists. As 
Walstab et al.[21] noted, this could allow for potentially synergistic inhibition of 5-HT3 
signalling when combined with standard 5-HT3 antagonists (e.g ondansetron, a common 
anti-emetic during chemotherapy and surgery). In addition, it was also noted that a CO2 
extract had a greater inhibition potency than what would be expected from 6-gingerol and 
6-shogaol alone which suggests other compounds could also play a role.  
Jin et al.[22] also investigated the effect of 6-gingerol and 6-shogaol as well as an 
additional compound, zingerone, on 5-HT3 signalling and while the methodology differed 
to the studies conducted by Walstab et al.[21], the study also demonstrated an inhibition 
of 5-HT3 signalling by these compounds. The finding that zingerone also exerted an effect 
on 5-HT3 signalling confirms the results of Walstab et al.[21] by demonstrating an 
additional bioactive compound. 
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 Discussion and future directions 
Despite the limitations that have been discussed in the included reviews, the 
current literature regarding the use of ginger as a treatment for nausea and vomiting is 
promising as all studies in this review reported some degree of improvement in 
symptoms.  
However, before recommendations can be made regarding its use in clinical 
practice, the existing limitations need to be addressed. These include the lack of use of 
validated assessment tools for nausea and vomiting, the significant heterogeneity of study 
designs and the use of unstandardized ginger supplements, which could account for the 
sometimes conflicting results and makes comparison between studies difficult. The 
continued use of unstandardized supplements, in particular, poses a significant issue when 
comparing studies with conflicting results due to the significant variation in bioactive 
compounds that can occur between different ginger products. The implementation of 
standardised extracts and/or quantification of bioactive compounds within ginger 
products are steps that would address this issue and that should be considered in future 
studies in this area.  
In addition to the need for continued research into the efficacy of ginger for 
nausea, larger studies are required to assess the potential contraindications of ginger 
supplementation. These include general concerns such as the potential effect of ginger on 
platelet aggregation which could affect multiple patient populations as well as more 
population-specific concerns such as the potential risk of aspiration from oral ginger 
supplementation prior to surgery.  
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One important factor to be considered when appraising an intervention is the 
clinical significance of the results. If results are found to be statistically significant, two 
questions need to be considered: 1) can these results be generalised to a real world setting? 
And 2) are these results likely to significantly influence clinical outcomes? 
This review has commented on both the statistical and clinical significance of the 
included studies and has found that the results of these studies provide mixed responses 
to these questions. The identified clinical studies that have investigated post-operative 
nausea and vomiting and CINV, for example, have generally reported statistically 
significant reductions in measures of nausea and vomiting; however, the magnitude of 
this reduction was generally small and so less likely to result in a substantial benefit to 
the patient.[11, 14, 17] The study conducted by Dabaghzadeh et al,[16] in contrast, 
demonstrated a considerable difference between the intervention and placebo group and 
if further studies report similar findings, this is likely to provide a clinically significant 
benefit to the patient.  
In order to improve the interpretation of clinical significance, the inclusion of 
quality of life measures, for example the Functional Living Index Emesis – 5 day recall 
tool, in future studies would provide insight into the effect that the patients symptoms 
have on their day-to-day experience.  
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 Conclusion  
In summary, despite existing limitations, the clinical evidence included in this 
review suggests ginger could be an effective treatment for nausea and vomiting in 
multiple settings. However, further studies are required to address these limitations and 
to investigate the safety profile in each population. In addition, recent research has 
provided further evidence that the compounds within ginger exert 5-HT3 receptor 
antagonism which suggests a clinically relevant mechanism for the treatment of nausea 
and vomiting, particularly for symptoms experienced during chemotherapy and surgery. 
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 Abstract 
Despite advances in anti-emetic therapy, chemotherapy-induced nausea and 
vomiting (CINV) still poses a significant burden to patients undergoing chemotherapy. 
Nausea, in particular, is still highly prevalent in this population. Ginger has been 
traditionally used as a folk remedy for gastrointestinal complaints and has been suggested 
as a viable adjuvant treatment for nausea and vomiting in the cancer context. Substantial 
research has revealed ginger to possess properties that could exert multiple beneficial 
effects on chemotherapy patients who experience nausea and vomiting. Bioactive 
compounds within the rhizome of ginger, particularly the gingerol and shogaol class of 
compounds, interact with several pathways that are directly implicated in CINV in 
addition to pathways that could play secondary roles by exacerbating symptoms. These 
properties include 5-HT3, substance P and acetylcholine receptor antagonism; anti-
inflammatory properties; and modulation of cellular redox signalling, vasopressin release, 
gastrointestinal motility, and gastric emptying rate. This review outlines these proposed 
mechanisms by discussing the results of clinical, in vitro and animal studies both within 
the chemotherapy context and in other relevant fields. The evidence presented in this 
review indicates that ginger possesses multiple properties that could be beneficial in 
reducing chemotherapy-induced nausea and vomiting. 
 Introduction 
Chemotherapy-induced nausea and vomiting (CINV) is a significant burden for 
patients undergoing anticancer chemotherapy. Nausea and vomiting are rated as two of 
the most distressing symptoms by chemotherapy patients and have been shown to 
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significantly and adversely affect quality of life and physical function during 
treatment.(Carelle et al., 2002; Sun et al., 2005) Ratings of quality of life can be reduced 
by as much as 20% in patients who experience CINV compared to symptom-free 
patients.(Lindley et al., 1992) Additionally, CINV is associated with malnutrition and 
further physical complications such as acid-base imbalance and electrolyte 
disturbances.(Davidson et al., 2012; Lindley and Hirsch, 1992; Osoba, 2005) All of these 
issues affect the patients’ ability to adhere to, or complete chemotherapy, resulting in a 
potential concomitant impact on survival outcomes.  
Despite significant improvement in the control of CINV through the use of 
modern anti-emetics such as 5-HT3 antagonists, corticosteroids and NK1 antagonists, 
nausea and vomiting still affects up to 60% and 37% of patients undergoing 
chemotherapy, respectively.(Bloechl-Daum et al., 2006)   
Ginger has traditionally been used for centuries as a treatment for gastrointestinal 
complaints and more recently has been investigated for its use in treating motion sickness, 
post-operative nausea and vomiting, and morning sickness in clinical studies.(Ernst and 
Pittler, 2000) A recent systematic review of randomised-controlled trials that investigated 
the effect of ginger as an adjuvant treatment for CINV found that the literature was 
equivocal with significant limitations.(Marx et al., 2013)  
An array of compounds are bioactive within the rhizome of ginger, such as 
shogaols, gingerols, zingerone, and paradols.(Baliga et al., 2011) These compounds are 
typically categorised into two classes: volatile oils and non-volatile pungent compounds. 
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Both of these classes of compounds are contained within the oleoresin, the collective term 
for the oil and resin fraction of the rhizome. While the concentration of these compounds 
varies greatly depending on the country of origin, storage, and preparation of the ginger 
product, the gingerol and shogaol compounds are likely to be the primary components 
responsible for ginger’s pharmacological effects. These compounds are believed to 
interact with multiple areas implicated in the development of CINV. Specific properties 
of these compounds that could be relevant to CINV include 5-HT3, substance P and 
acetylcholine receptor antagonism; anti-inflammatory properties; and modulation of 
cellular redox signalling, vasopressin release, gastrointestinal motility, and gastric 
emptying rate.(Abdel-Aziz et al., 2006; Prakash and Srinivasan, 2010; Wu et al., 2008; 
Zick et al., 2011) Whereas recent reviews have focused upon the clinical efficacy of 
ginger, this paper will focus on the potential mechanisms by which ginger could exert 
anti-CINV effects.  
 Physiology of CINV 
The physiology of CINV is a complex neural interaction involving central and 
peripheral stimuli and reactions. While multiple pathways are involved in CINV, this 
discussion will focus on the primary pathway of CINV (i.e 5-HT3 and NK1 antagonism) 
and pathways that could potentially be modulated by ginger (Figure 4-1). The site of the 
initial trigger of CINV is thought to be within the gastrointestinal tract. Chemotherapy 
agents interact with enterochromaffin cells, possibly via oxidative stress, resulting in a 
release of the neurotransmitters serotonin and substance P.(Torii et al., 1994a) The 
released neurotransmitters then interact with receptors located upon the vagus nerve, 
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which subsequently transmits afferent signals to the chemotherapy receptor zone within 
the brain via the nucleus tractus solitarius. It is thought that modern 5-HT3 antagonist 
medications (e.g. ondansetron) interact with the 5-HT3 receptors involved in this process, 
which then mitigates the degree of afferent signalling. Another neurotransmitter, 
substance P, has also been implicated in the generation of CINV by binding to NK1 
receptors located centrally within the brain. Stimuli transmitted using these two 
neuropeptides, as well as stimuli from other regions of the brain, are processed by the 
chemoreceptor trigger zone and vomiting centre, which then coordinates the relevant 
musculature to induce a nausea and/or vomiting response.(Rudd, 2005)  
While not directly involved in the generation of CINV, other secondary pathways 
could exacerbate the experience of nausea and vomiting in this setting. These include the 
modulation of gastric emptying, increased inflammation, and vestibular and vasopressin-
related mechanisms.(Cawley and Benson, 2005; Rudd, 2005; Sharma and Gupta, 1998)   
Chemotherapy agents such as cisplatin and methotrexate are known to delay 
gastric emptying, potentially resulting in gastrointestinal distress due to antral 
distension.(Sharma and Gupta, 1998) Research related to chemotherapy-induced 
mucositis has demonstrated that pro-inflammatory signalling pathways, particularly 
nuclear factor kappa-B (NF-κB), are increased within the gastrointestinal mucosa as a 
result of chemotherapy-induced cell injury. It has been suggested that this increase in gut 
inflammation might contribute to the development of CINV, particularly during the 
delayed phase (≥24 hours after chemotherapy)(Rudd, 2005) which is supported by the 
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increase in inflammatory cytokines largely occurring between 2-10 days post-
chemotherapy.(Cawley and Benson, 2005)    
The vestibular system, which is located within the inner ear, is involved in 
providing a sense of balance. While the vestibular system might not be a primary pathway 
in the development of CINV, vestibular disturbances are implicated in the exacerbation 
of CINV. In support of this, the vestibular system is involved in the development of 
motion sickness, which is a known risk factor for CINV.(Leventhal et al., 1988) 
Furthermore, scopolamine, a pharmacological treatment for motion sickness, has 
demonstrated efficacy in reducing CINV when used in conjunction with other anti-emetic 
medications, but not when used as a stand-alone treatment.(Longo et al., 1982; Meyer et 
al., 1987) This suggests that the vestibular system plays a secondary role in the 
development of CINV.   
Lastly, it has been suggested that vasopressin (also known as antidiuretic 
hormone) contributes to the sensation of nausea in chemotherapy patients. Studies have 
demonstrated that vasopressin is significantly increased in patients experiencing 
CINV(Fisher et al., 1982; Rudd, 2005) and that the  administration of supraphysiological 
doses of endogenous vasopressin is sufficient to induce nausea in healthy human 
participants.(Caras et al., 1997) However, other studies do not support this hypothesis. 
For example, when vasopressin was administered at physiological doses, nausea was not 
experienced.(Kim et al., 1997) This has lead researchers to suggest that vasopressin could 
play a modulatory role in the generation of CINV instead.(Rudd, 2005)  
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 Proposed mechanisms of action 
 Interaction with neurotransmitters and vagal afferent signalling 
Results from in vitro and animal studies demonstrate that ginger is likely to exert 
5-HT3 antagonistic effects. Yamahara et al.(Yamahara et al., 1989) were the first to 
demonstrate that whole ginger, as well as 6-, 8- and 10-gingerols, could inhibit 5-HT3-
induced contractions in an isolated guinea pig ileum. Huang et al.(Huang et al., 1991) 
demonstrated inhibition of 5-HT3-induced contractions using the ginger compound, 
galanolactone. However, these two studies have significant limitations.(Abdel-Aziz et al., 
2006) Both studies used serotonin to induce contractions, not an agonist that is selective 
for 5-HT3 receptors. This allows for the possibility that ginger inhibited the action of 
serotonin on another receptor, making the exact mechanism of action unclear.(Abdel-
Aziz et al., 2006) 
 Additionally, Huang et al.(Huang et al., 1991) studied galanolactone, a 
compound only found in Japanese ginger and which therefore cannot be extrapolated to 
other types of ginger.(Abdel-Aziz et al., 2006; Ravindran and Babu, 2004)  
To address these limitations, Abdel-Aziz et al.(Abdel-Aziz et al., 2006) 
investigated the effect of four major compounds found in ginger, namely 6-, 8- and 10-
gingerol and 6-shogaol, on 5-HT3-mediated contractions in an isolated rat ileum using a 
selective 5-HT3 agonist. The results indicated that these compounds significantly 
inhibited contractions induced by this agonist; however, all four compounds failed to 
displace the 5-HT3 receptor antagonist, [
3H]GR65630, from binding to the 5-HT3 
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receptor. It was therefore concluded that the mechanism of action of ginger, at least in 
relation to 5-HT3 pathways, is most likely due to indirect modulation of 5-HT3 signalling 
through the binding of an alternative, unidentified site.(Abdel-Aziz et al., 2006) 
Additionally, the authors reported that these compounds weakly inhibited acetyl-choline 
and substance P-induced contractions, suggesting additional mechanisms for the anti-
CINV effects of ginger. 
 Modulation of gastrointestinal motility and gastric emptying 
Metoclopramide has been used for decades as an anti-emetic in chemotherapy, 
partly due to its prokinetic effect on the gastrointestinal system.(Schapira et al., 1990) 
Research, particularly from in vitro studies, suggest that ginger is also likely to affect 
gastrointestinal motility and gastric emptying.(Hashimoto et al., 2002; Hu et al., 2011; 
Wu et al., 2008) While gastrointestinal dysmotility could not play a direct role in the 
generation of CINV, it could play a secondary role by contributing to other 
gastrointestinal symptoms such as bloating, early satiety, and abdominal pain.   
Multiple animal and in vitro studies indicate that whole ginger as well as specific 
compounds within ginger affect gastric emptying rates and gastrointestinal contractions. 
For example, Hashimoto et al.(Hashimoto et al., 2002) demonstrated that 6-shogaol 
improved muscle contractions and charcoal-induced transit time in porcine small 
intestines. Similarly, acetone ginger extract as well as the ginger components, 6-shogoal, 
6-. 8-, and 10-gingerol, all enhanced the transport of a charcoal meal in mice.(Yamahara 
et al., 1990) Furthermore, both an ethanolic and acetone extract of ginger as well as ginger 
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juice all reversed cisplatin-induced delayed gastric emptying in rats.(Sharma and Gupta, 
1998)  In contrast, the ginger compounds zingerone and zingerol as well as whole ginger 
were reported to inhibit colonic motility in rats.(Iwami et al., 2011a; Iwami et al., 2011b) 
These diverse results indicate that ginger’s effects could be a result of the particular 
concentration of different bioactive compounds, or the synergy between them.  
The effect of ginger on gastrointestinal motility in human participants has been 
investigated in multiple studies; however, the degree to which the results of these studies 
can be extrapolated to the CINV setting is limited as no study has been conducted with 
patients undergoing chemotherapy to date. This is likely due to CINV-related anti-emetic 
research focusing on other pathways (i.e 5-HT3-mediated CINV) and the burden that such 
a study could place on patients undergoing chemotherapy; however, relief from 
symptoms related to gastrointestinal dysmotility could prove to be effective as a 
secondary measure of CINV management and therefore, future research in the CINV 
setting is recommended.  
To date, six studies have examined the effect of ginger on gastrointestinal motility 
in varied patient populations, including healthy participants and participants with 
dyspepsia or admitted to an intensive care unit.(Hu et al., 2011; Micklefield et al., 1999; 
Phillips et al., 1993; Shariatpanahi et al., 2010; Stewart et al., 1991; Wu et al., 2008) 
However, the significant differences in methodology employed in these studies makes 
comparison difficult. Differences included the dosage of ginger, the composition of the 
test meal used, and the instrument used to measure gastric emptying and motility. 
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Scintography is the recommended method to evaluate gastric empting.(Abell et al., 2008) 
However, due to the use of radioactive materials in this technique and the risk attendant 
on this, alternative methods are preferred.(Wu et al., 2008) While the use of alternative 
methods might reduce the equipment costs and expertise required, they are not as 
sensitive and could introduce confounders.  For example, in one study of intensive care 
patients, when gastric emptying was measured by the amount of feeding tolerated over a 
48 hour period by participants, ginger improved gastric motility.(Shariatpanahi et al., 
2010) However, in an another study that evaluated gastric emptying by a similarly indirect 
method (the measurement of paracetamol absorption), Phillips et al.(Phillips et al., 1993) 
found 1g of ginger had no effect on gastric emptying. The indirect measures used in these 
two studies provided a lower level of precision. The results could also be influenced by 
other factors, such as the nutrient density of the test meal, its fluid and macronutrient 
content and its total volume. All of these factors can influence the rate of gastric 
emptying; hence, a nutrient-dense test meal is critical when measuring rates of gastric 
emptying.(Wu et al., 2008) Because no test meal was used in this study, significant delays 
in gastric emptying would not be expected.  A similarly non-nutrient-dense test meal was 
used in a study of the effect of 500mg of ginger on gastric emptying rates.(Stewart et al., 
1991)  The failure of this study to demonstrate efficacy in relation to ginger could be a 
result of the 75kcal solution used as the test meal, which could have been insufficient to 
induce an effect.(Stewart et al., 1991) 
 Wu et al.(Wu et al., 2008) and Hu et al.(Hu et al., 2011) addressed many of these 
limitations by using a dose of 1.2g of ginger and a test meal with a relatively high caloric 
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content (118kcal in both studies). The two studies found that ginger was effective at 
reducing gastric emptying rates in both healthy and dyspeptic participants. A smaller dose 
of ginger (200mg) has also demonstrated effectiveness in increasing gastrointestinal 
motility in healthy volunteers.(Micklefield et al., 1999)  
In summary, animal studies as well as most human studies conducted to date 
(66%) suggest ginger modulates the rate of gastric emptying and gastrointestinal motility. 
However, no studies so far have investigated the effect in participants undergoing 
chemotherapy and therefore, the applicability of these results to the chemotherapy setting 
is currently unclear.  
 Anti-oxidant properties 
Oxidative stress, defined as an over production of reactive oxygen species, has 
been reported to be linked to the etiology of the emetic reflex. One of the initial steps in 
the generation of CINV is believed to be the generation of free radicals by chemotherapy 
agents within the gastrointestinal tract which in turn leads to the release  
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of neurotransmitters from enterochromaffin cells.(Torii et al., 1994b)  This notion has led 
to investigations of the antioxidant activity of ginger. In vitro experiments have 
demonstrated the antioxidant kinetic behaviour of isolated compounds extracted from the 
Figure 4-1. Proposed anti-CINV mechanisms of action of ginger 
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dried rhizomes of ginger, subjected to a 1,1-diphenyl-2-picrylhydrazyl radical scavenging 
reaction.(Masuda et al., 2004) 
However, there are no clear human clinical trials or animal experiments that 
demonstrate that ginger extracts might modulate CINV via an antioxidant effect. Given 
that the oxidative stress/antioxidant theory of cellular metabolism has been 
challenged,(Linnane et al., 2007) an alternative plausible biochemical explanation for 
ginger’s effect on CINV is the rebalancing of the disrupted cellular oxido-reductase 
mechanism that often accompanies chemotherapy treatments.(Linnane et al., 2007) 
 Anti-inflammatory properties 
During chemotherapy, cell injury caused within the gastrointestinal tract (GIT) 
results in the release of multiple inflammatory factors including cyclooxygenase-2 (COX-
2), interleukin-6 (IL-6), and nuclear factor kappa-B (NF-kB). The end result of this 
pathway is continued tissue damage and potentially mucositis along the length of the 
GIT.(Sultani et al., 2012) It has been suggested that inflammation and cell injury could 
be particularly involved in the delayed phase of CINV.(Hesketh, 2005)  
In vitro research has found that multiple ginger compounds are able to elicit an 
anti-inflammatory effect through a number of pathways including the inhibition of NF-
kB, COX enzymes, and 5-lipoxogenase.(van Breemen et al., 2011) Ginger compounds 
have also demonstrated an anti-inflammatory effect in murine and rat models, with these 
effects replicated in human clinical trials.(Ojewole, 2006; Zick et al., 2011)  For example, 
28 days of ginger supplementation (2g) in humans modulated eicosanoid synthesis in the 
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colonic mucosa by lowering prostaglandin-2 levels in healthy participants(Zick et al., 
2011) and COX-1 in participants who were at risk of colon cancer.(Jiang et al., 2012) 
Additionally, a review that included 8 clinical trials in this field concluded that while 
there is a paucity of well-designed trials, there is tentative evidence that ginger possesses 
anti-inflammatory properties in the treatment of pain related to osteoarthritis, 
dysmenorrhea, and exercise.(Terry et al., 2011)  
In summary, while these studies did not directly measure the effect of ginger on 
inflammation during chemotherapy, the current literature indicates that ginger is likely to 
modulate inflammation in the gut and this could contribute to ginger’s anti-CINV effects.   
 Vestibular interactions 
Acetylcholine and histamine are two neurotransmitters involved in the 
development of motion sickness. In vitro studies demonstrate that ginger compounds 
have antagonistic properties to both muscarinic and histaminergic receptors and therefore, 
represent a potential pathway by which ginger could interact with the vestibular 
system.(Abdel-Aziz et al., 2006) Clinical trials have largely confirmed this effect in 
clinical or experimentally-induced motion sickness. Eight trials were identified in our 
review, of which five reported ginger to be either superior to placebo or equal to standard 
anti-motion sickness medications. (Grontved et al., 1988; Grontved and Hentzer, 1986; 
Holtmann et al., 1989; Lien et al., 2003; Mowrey and Clayson, 1982; Schmid et al., 1994; 
Stewart et al., 1991; Wood et al., 1988) Therefore, it is likely that ginger is able to interact 
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with signalling involved in the vestibular system and could potentially modulate CINV 
symptoms. 
 Modulation of vasopressin 
Ginger is known to reduce plasma vasopressin in adults exposed to 
experimentally-induced motion sickness; however, when endogenous vasopressin was 
injected, ginger was ineffective in preventing nausea.(Lien et al., 2003) This suggests that 
ginger exerts an indirect action on vasopressin release. However, to date there is only one 
study measuring ginger’s effect on vasopressin. Future studies are required to confirm 
these effects in the chemotherapy setting. Furthermore, the exact role of vasopressin in 
CINV needs to be elucidated before this can be considered a clinically-relevant 
mechanism.  
 Conclusion 
CINV is a significant burden experienced by many oncology patients. While the 
control of overt vomiting has advanced, it is still prevalent and nausea remains stubbornly 
problematic for numerous chemotherapy patients. Ginger contains a wide array of 
bioactive compounds that can potentially act on multiple pathways involved in the 
physiology of CINV (Figure 4-1). These pathways include the modulation of relevant 
neuropeptides, vasopressin release and gastrointestinal motility as well as redox and anti-
inflammatory signalling. The clinical evidence for its use in the treatment in CINV is 
currently equivocal;(Marx et al., 2013) however, the data presented in this paper 
demonstrate an array of viable mechanisms of action and provide a sound foundation for 
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continued research in this area. Of primary importance is the need for future trials to 
investigate these beneficial properties in the chemotherapy setting.  
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 The effect of ginger (Zingiber officinale) on platelet 
aggregation: a systematic literature review. 
The potential effect of ginger on platelet aggregation is a widely-cited concern 
both within the published literature and by clinicians; however, there had been no 
systematic appraisal of the evidence prior to this manuscript. In this systematic review of 
the literature, all existing clinical and observational data regarding the potential effect of 
ginger on platelet aggregation were evaluated. This abstract was presented at the 
following conference: 
Marx W, McKavanagh D, McCarthy AL, Bird R, Chan A, Ried K, Isenring E. 
The effect of ginger (Zingiber officinale) on platelet aggregation: a systematic literature 
review. MASCC/ISOO Symposium (25 – 27 June 2015, Copenhagen, Denmark). 
Citation:  
Marx W, McKavanagh D, McCarthy AL, et al. The Effect of Ginger (Zingiber 
officinale) on Platelet Aggregation: A Systematic Literature Review. PLoS ONE. 
2015;10:e0141119. (Impact factor: Impact Factor: 3.2).  
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 Abstract 
Background: The potential effect of ginger on platelet aggregation is a widely-
cited concern both within the published literature and to clinicians; however, there has 
been no systematic appraisal of the evidence to date. 
Methods: Using the PRISMA guidelines, we systematically reviewed the results 
of clinical and observational trials regarding the effect of ginger on platelet aggregation 
in adults compared to either placebo or baseline data. Studies included in this review 
stipulated the independent variable was a ginger preparation or isolated ginger compound, 
and used measures of platelet aggregation as the primary outcome.  
Results: Ten studies were included, comprising eight clinical trials and two 
observational studies. Of the eight clinical trials, four reported that ginger reduced platelet 
aggregation, while the remaining four reported no effect. The two observational studies 
also reported mixed findings.  
Discussion: Many of the studies appraised for this review had moderate risks of 
bias. Methodology varied considerably between studies, notably the timeframe studied, 
dose of ginger used, and the characteristics of subjects recruited (e.g. healthy vs. patients 
with chronic diseases). 
Conclusion: The evidence that ginger affects platelet aggregation and coagulation 
is equivocal and further study is needed to definitively address this question.   
Key words: ginger, platelet, coagulation, thrombocytopenia 
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 Introduction 
There is increasing evidence that ginger and its constituents might exert 
meaningful anti-nausea effects during cancer chemotherapy. Our recent systematic 
review of the literature found preliminary evidence that supported its use as an adjuvant 
anti-nausea drug to standard anti-emetics in the chemotherapy setting.[1] Concerns over 
potential “off target” antiplatelet effects, however, could limit the application of ginger 
in oncology patients, who frequently experience thrombocytopenia due to 
myelosuppression.  
The ginger rhizome has been used in traditional systems of medicine for centuries 
and more recently, its potentially medicinal properties have been empirically studied.[2] 
Current research suggests that the active constituents of ginger, namely the gingerol and 
shogaol classes of compounds, might exert several beneficial effects including anti-
inflammatory, antioxidant, and cholesterol lowering properties.[2] In addition, ginger is 
a promising treatment for nausea associated with a variety of stimuli including post-
operative nausea and vomiting, motion sickness, morning sickness, and chemotherapy-
induced nausea and vomiting.[1, 3-5]  
While the safety profile of ginger supplementation requires further investigation, 
previous clinical trials report few side-effects, mostly minor in nature (e.g. mild nausea, 
heartburn).[1] Of these reported side effects, potentially the most significant is an 
antiplatelet effect. Two published case-studies reported adverse symptoms and abnormal 
platelet aggregation that was temporally related to recent ingestion of ginger products.[6, 
7] In addition, several animal and in vitro studies have reported ginger as well as 
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individual ginger compounds to have an effect on platelet aggregation.[8-10] While this 
action could be beneficial in vascular diseases, it could potentiate bleeding risk in 
conditions such as thrombocytopenia or pre-existing platelet dysfunction. This is 
particularly relevant in the chemotherapy setting, where therapy-induced 
thrombocytopenia is associated with treatment delays, dose reductions, and bleeding 
events.[11]   
To the authors knowledge, Srivastava et al.[8] were the first group to investigate 
the effect of ginger on platelet aggregation by using four ginger extracts, produced using 
different solvents (aqueous, n-hexane, chloroform, and ethyl acetate). They reported that 
ginger inhibited platelet aggregation using arachidonic acid (AA), epinephrine, adenosine 
diphosphate (ADP), and collagen as agonists. Others have corroborated this, reporting 
that certain ginger compounds inhibit in vitro platelet aggregation when using a variety 
of agonists (AA, collagen, platelet activating factor, and thrombin).[12, 13] This 
reduction in platelet aggregation was most potent when AA was used as the agonist, 
requiring lower concentrations to cause inhibition when compared to the other 
agonists.[9, 12]  
While few studies investigating the effect of ginger and its compounds on the 
clotting cascade have been undertaken, a considerable amount of in vitro research 
suggests that ginger compounds interact with AA-derived eicosanoid and thromboxane 
synthesis.[14-18] The AA cascade can produce the eicosanoids involved in inflammation 
(i.e. prostaglandin E2) as well as thromboxane, which is amongst the many agonists of 
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platelet aggregation. Numerous studies indicate that ginger extract and particular ginger 
compounds inhibit products specific to the cyclooxygenase pathway, including a 
reduction in thromboxane B2 (TxB2) production,[19] prostaglandin formation (PGF2a, 
PGE2, and PGD2),[8, 15] and cyclooxygenase enzyme activity.[16, 18] These same 
compounds also interact with the lipoxygenase pathway, including reductions in 5-
lipoxygenase enzyme activity.[14] Finally, ginger compounds might also inhibit the 
activity of phospholipase A2, which suggests that ginger exerts its anti-platelet 
aggregating as well as its potential anti-inflammatory actions through interaction with 
one of the initial steps in this pathway.[20] 
Due to the observed in vitro effects of ginger on the AA cascade, excessive 
bleeding and interactions with platelet therapy during cancer chemotherapy are of clinical 
concern. While the results of in vitro studies are consistent, these results are not always 
translatable to the complex human system. Clinical and observational data, however, 
provide a reasonable indication of the potential human response. There is a growing body 
of clinical and epidemiological literature in this area, although no systematic appraisal of 
the relevant literature has been undertaken to date. In this paper, we summarise and 
discuss the findings of clinical and observational studies regarding the effect of ginger, 
compared to placebo or baseline, on platelet aggregation in multiple participant 
populations.  
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  Methodology 
 Data Sources and Searches 
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines,[21] a systematic search of the literature was conducted using the 
following databases: MEDLINE, CiNAHL, Embase, and Cochrane Library. The 
reference lists of retrieved papers were also searched for additional manuscripts. Search 
terms were not limited by a specific timeframe; rather, all search queries were from the 
date of the journal’s inception to May 2014. Search terms were broad so as to ensure all 
relevant manuscripts were captured. 
 Study Selection 
The search terms used were “ginger AND (platelet OR thrombo* OR clot* OR 
bleed OR “adverse effects” OR “side effects” OR haemorrhage)”. Studies included in this 
review 1) were written in English 2) stipulated the independent variable was a ginger 
preparation or isolated ginger compound, and 3) used measures of platelet aggregation as 
the primary outcome.  
 Data Extraction and Quality Assessment 
Extracted data included: participant demographic (e.g age, gender, reported 
comorbidities), type of ginger intervention (e.g dosage, timing, form of ginger), study 
design characteristics (e.g. sample size, risk of bias, type of study, study length), and 
reported outcomes (e.g measures of platelet aggregation, adverse events, dropout rates). 
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All clinical studies were individually rated for evidence level by author WM using 
the National Health and Medical Research Council Hierarchy of Evidence guidelines (IV-
I, with I being the strongest level of evidence).[22] They were also independently 
assessed for bias, by two authors (WM and DM) using the Cochrane Handbook for 
Systematic Reviews of Interventions checklist.[23] Where insufficient information was 
included in the manuscript to assess particular forms of bias, further information was 
sought via correspondence with the study authors. Blinding is unlikely to affect the results 
of the clinical biomarkers measured in these studies, hence trials that were not blinded 
were rated in the review as low-risk for detection and performance included bias. In 
addition, due to the small number of trials in this area, no study was excluded based on 
its risk of bias. 
 Data Synthesis and Analysis 
A statistically significant (P≤0.05) result was considered evidence of an effect. 
Relevant study details were retrieved from their respective manuscript using a 
standardised form. Forest plot and meta-analysis was intended; however, due to the 
heterogeneity of the studies included in this review, these analyses were found to be 
unfeasible.  
 Results  
A total of 367 papers were identified (Figure 5-1). After assessment of study 
abstracts and the removal of duplicates 26 abstracts were retrieved for further 
examination.  Seventeen were subsequently excluded, resulting in 9 manuscripts included 
in the final review.  
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 Clinical trials 
Seven manuscripts reporting the effect of ginger on platelet aggregation in human 
participants using a clinical trial design were retrieved (Table 5-1). Of the seven 
manuscripts, one described two separate trials, resulting in a total of eight clinical trials 
included in this review.[24]  
Figure 5-1 PRISMA Study flow diagram 
 
The methodology varied considerably between trials. Half of the studies used a 
cross-over design[25-28]  while three used a parallel design[19, 24] and one was a single 
arm study.[19] Most of the studies (7/8) had elements of robust study design such as 
placebo controls, randomisation and double-blinding. However, few studies incorporated 
all of these elements, with only two studies featuring both randomisation and double-
blinding procedures. For example, Jiang et al.[26] used a randomised cross-over design 
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that was also open-label (Table 5-1). Despite this, the assessment of bias determined the 
majority of studies were relatively low-risk in terms of performance, detection, and 
attrition bias while a high risk of random sequence generation and allocation concealment 
bias was detected (Figure 5-2 Risk of bias graph: review authors' judgements about each 
risk of bias item presented as percentages across all included studies.).  
Figure 5-2 Risk of bias graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies. 
 
The average sample size was small. Seven of the eight studies ranged from 7-36 
participants[19, 25-29] with one study comprising  60 participants.[24] The duration of 
each study varied considerably, ranging from one day to three months. Six of the eight 
studies included healthy participants,[19, 25-27, 29] two studies included patients with 
confirmed myocardial infarction and one study included hypertensive patients as well as 
healthy participants.[24, 28] Most studies required participants to consume only ginger, 
either as a supplement or as a food preparation, while three studies measured the effect 
of ginger in combination with various medications and food products including 
nifedipine,[28] warfarin,[26] custard,[30] and a high-calorie diet.[29]
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Table 5-1 Extraction table of reviewed clinical trials. 
Author/Date Study design Time points  Population Intervention  Outcome Results Country Level of 
evidence 
Comment 
Bordia et al. 
1997 
Placebo-
controlled trial 
Total study 
period: 3 months. 
Outcomes 
measured at: 
baseline, 1.5 
months and 3 
months.  
Patients with 
confirmed 
myocardial 
infarction  
N=60 
Dose: 4g per day 
Unstandardized 
capsules 
Platelet aggregation  
- Agonist(s): ADP and 
Epi 
- Method (Device, if 
reported): Turbidimetric   
Fibrinogen 
Fibrinolytic activity 
Ginger had no 
significant effect on 
both measures of 
aggregation 
India III-1* Ginger had 
no significant 
effect on 
blood lipids 
or blood 
sugar. 
Results 
relating to 
fenugreek 
excluded 
from table. 
No mention 
of 
randomisatio
n  
P value not 
reported 
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Bordia et al. 
1997 
Placebo-
controlled trial 
Total study 
period: One day 
Outcomes 
measured at: 
baseline, 4 hours 
post-consumption 
Patients with 
confirmed 
myocardial 
infarction  
N= 20 
Dose: 10g single 
dose 
Unstandardized 
capsules 
Platelet aggregation  
- Agonist(s): ADP and 
Epi 
- Method (Device, if 
reported): Turbidimetric   
Reduction of both 
measures of platelet 
aggregation when 
compared to placebo 
(p<0.05). 
India III-1 This study 
was detailed 
in same 
manuscript as 
above. 
Janssen et al. 
1996 
Randomised, 
placebo-
controlled 
cross-over trial 
Total study 
period: 6 weeks 
(3x2 weeks) 
Outcomes 
measured at day 
12 and 14 of each 
study period. 
Healthy 
volunteers 
Age: 22±3 
N= 18 
Dose: 15g raw & 
40g cooked ginger 
placebo, once per 
day. 
Contained within 
125g custard 
Thromboxane B2 
production (Payton 
Aggregation Module) 
Both types of ginger 
had no significant 
effect on maximum 
thromboxane B2 
production 
(p=0.616) 
Netherlan
ds 
II   
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Jiang et al. 
2004 
Randomized, 
open label, 
three-way 
cross-over  trial 
 
 
 
 
 
Total study 
period: 3x13 days, 
14 days washout 
period between 
each study period.  
Outcomes 
measured at 
multiple time 
points, starting 2 
days pre-warfarin 
consumption to 7 
days post-
consumption  
Healthy male 
volunteers 
Age: 20–36  
N= 12 
Dose: 3.6g (3x 
0.4g, thrice per 
day) 
Unstandardized 
capsules 
 
Consumed with 
25 mg dose of 
rac-warfarin, 
consumed once 
per study period. 
Platelet aggregation 
- Agonist(s): AA 
- Method (Device, if 
reported): Turbidimetric 
(Chrono-log) 
INR 
Plasma warfarin 
enantiomer protein 
binding & warfarin 
enantiomer 
concentrations  
Urinary S-7-
hydroxywarfarin  
No significant 
changes in any 
outcome 
Australia III-1 No placebo 
group was 
included in 
study 
Results 
relating to 
participants 
receiving 
ginkgo 
supplementati
on were 
excluded 
from table. 
P value not 
reported 
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Lumb. 1994 Randomised, 
double-blinded 
placebo-
controlled 
cross-over trial 
Total study 
period: 2x1 day, 
at least 14 days 
washout period.  
Outcomes 
measured 
immediately 
before, 3h, and 
24h post 
consumption of 
ginger 
Healthy male 
volunteers 
N= 8 
Dose: 2g 
(4x500mg) dried 
ginger per day 
Unstandardized 
capsules 
Platelet aggregation  
- Agonist(s): AA, 
collagen, ristocetin, ADP 
- Method (Device, if 
reported): Electrical 
impedance (Chrono-log) 
Bleeding time 
Platelet count 
Thromboelastography 
No significant 
changes in any 
outcome at any time 
point.  
UK II   
Srivastava 
1989 
Open-label 
single-arm trial 
Total study 
period: 7 days 
Outcomes 
measured at 
baseline and 7 
days post-
consumption 
Health female 
volunteers 
N= 7 
Dose: 5g raw 
ginger per day 
Platelet thromboxane B2 
production   
Ginger consumption 
resulted in a 37% 
inhibition of 
thromboxane B2 
production  (p<0.01) 
. 
Denmark III-3 Results 
relating to 
onion group 
excluded 
from table. 
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Verma et al. 
1993 
Randomised 
placebo-
controlled 
trial 
Total study period: 
14 days, high-calorie 
diet for first 7 days, 
high-calorie diet and 
ginger/placebo 
consumed for next 7 
days. 
Outcomes measured 
at baseline, 7, and 14 
days  
Health male 
volunteers 
N= 20 
Dose: 5g 
(4x625mg, twice 
per day) dry 
ginger powder 
Unstandardized 
capsules 
Consumed with 
100g (2x50g) 
butter, 2 cups of 
milk, 8 slices of 
bread.   
Platelet aggregation 
- Agonist(s): ADP and 
Epi 
- Method (Device, if 
reported):  turbidimetric 
(ELVI-840) 
Ginger significantly 
reduced platelet 
aggregation using 
both agonists when 
compared to placebo 
group (p<0.001). 
India II Platelet 
aggregation 
reduced close 
to baseline 
but did not 
decrease 
further. 
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Young et al. 
2006 
Cross-over trial Total study 
period: 72 days, 
4x washout period 
of 7-10 days, 5x7 
days intervention 
consumed 
Outcomes 
measured at 
baseline and 7 
days post-
consumption for 
each intervention  
Healthy & 
Hypertensive 
volunteers 
N= 10 for each 
group 
Dose: 1g dried 
ginger per day 
Either alone or in 
combination with 
10mg nifedipine 
Platelet aggregation 
- Agonist(s): ADP, Epi, 
collagen 
- Method (Device, if 
reported): Turbidimetric 
(Chronolog 560) 
Ginger combined 
with nifedipine 
resulted in a 
significant decrease 
in platelet 
aggregation 
(p<0.001). Ginger 
alone had no 
significant effect. 
Taiwan III-2 No placebo 
group 
Unclear if 
participants 
were blinded 
Abbreviations: AA, arachidonic acid; ADP, Adenosine Diphosphate; Epi, epinephrine; INR, International Normalised Ratio; 
TxB2, Thromboxane B2;. * Indicates some study details were missing and that scoring was based on details available. 
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In terms of the ginger preparation used, seven of the eight studies tested a dose 
of 3.6g to 5g, while one cross-over study investigated larger doses of ginger with each 
participant receiving either 10g or 40g per day.[30] Most studies delivered ginger at 
either one time point or once per day, depending on the trial timeframe; however, 
Jiang et al.[26] and Verma et al.[29] delivered ginger thrice and twice per day, 
respectively. All studies used an unstandardized ginger preparation, either dried, 
cooked or raw ginger, delivered in an unprocessed form, within capsules, or mixed 
into a medium (i.e. custard).  
Measures of platelet aggregation varied between studies. The majority (6/8) 
used light transmittance aggregometry or impedance aggregometry,[24, 26-29] while 
two studies assessed thromboxane B2 production.[19, 25] Three studies also recorded 
multiple additional outcomes including INR,[26] fibrinogen and fibrinolytic 
activity,[24] bleeding time, thromboelastography and platelet count.[27] Of the six 
that used aggregometry, there was a mix of agonists used with ADP (5/6) and 
epinephrine (4/6) being the most common. Three studies also used one or more of the 
following agonists: collagen, AA, or ristocetin.[26-28]   
The reported effect of ginger on platelet function were equivocal. Two studies 
reported inhibition of platelet aggregation.[24, 29] The first study found that ginger 
significantly inhibited platelet aggregation in healthy males after consumption of a 
high-calorie diet.[29] The second study reported that ginger the co-administration of 
1g of ginger with nifedipine resulted in an inhibition of platelet aggregation in normo- 
and hypertensive subjects.[28] However, in this study, when ginger was administered 
alone, there was no significant effect.  
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In contrast, two studies reported that 2-3.6g of ginger had no effect on 
measures of platelet aggregation in health adults.[26, 27] Moreover, Jiang et al.[26] 
found that the co-administration of 3.6g of ginger with 25mg of warfarin had no effect 
on the international normalized ratio (INR) or the pharmacokinetics and 
pharmacodynamics of warfarin in healthy male participants. Lumb et al.[27] also 
reported no significant effect on bleeding time, platelet count, and 
thromboelastography in a similar population. Bordia et al.[24]  reported that 4g/day 
of ginger for three months did not affect platelet aggregation, fibrinogen, or 
fibrinolytic activity in patients with coronary artery disease; however, when 
participants were given a bolus dose of 10g ginger, there was a significant inhibition 
of platelet aggregation in patients with coronary artery disease.  
The two studies that investigated the effect of ginger on thromboxane B2 
generation in healthy adults reported conflicting results. Srivastava et al.[19] reported 
that 5g of ginger over 7 days resulted in a 37% inhibition of thromboxane B2 
production (p<0.01), while Janssen et al.[25] found that 15g and 40g of raw and 
cooked ginger, respectively, had no effect when each were consumed for two weeks 
(p=0.616). 
 Observational data 
Two observational studies investigated the association of ginger use and 
platelet-related adverse effects. Shalansky et al.[31] conducted a 16-week longitudinal 
study of 171 participants prescribed warfarin. During this period, participants were 
asked to record bleeding events as well as factors that the investigators hypothesised 
could influence INR and bleeding risk, including a selection of complementary 
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therapies. Of the 171 participants, 87 reported bleeding events with excessive bruising 
(41%) and nosebleeds (15%) being the two most commonly-reported events. The 
study reported a significant association between self-reported bleeding events and 
ginger (OR 6.63, 95% CI 3.49–12.61), as well as cayenne (OR 8.0, 95% CI 3.57–
17.92), willow bark (OR 9.00, 95% CI 6.42–12.62), St. John’s wort (OR 4.70, 95% 
CI 1.49–14.79), and coenzyme Q10 (OR 3.91, 95% CI 2.09–7.31). Upon further 
analysis, ginger (OR 3.20, 95% CI 2.42–4.24) and coenzyme Q10 (OR 3.69, 95% CI 
1.88–7.24) were independently associated with self-reported bleeding events in a fully 
adjusted multivariate model. No complementary therapies were associated with a risk 
of abnormal INR.  
In contrast, Leung et al.[32] surveyed 314 patients prescribed warfarin 
therapy, in which they retrospectively assessed self-reported bleeding events and 
exposure to factors that could influence bleeding risk and INR in the previous month. 
While only two patients reported using ginger during this period, the study authors 
determined that ginger, along with all other assessed complementary therapies, was 
not associated with bleeding risk or abnormal INR.  
 Discussion 
Despite consistent in vitro data demonstrating that ginger compounds interact 
with several steps involved in platelet aggregation, the results of human studies are 
inconsistent. It is difficult to draw conclusions from these studies as a whole, due to 
the limited number of studies and their heterogeneous methods. These inconsistencies 
include the dose, dosing regimen, and formulation of ginger used, the timeframe 
studied, and the characteristics of subjects recruited (e.g. healthy vs. patients with 
chronic diseases).  
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Of the eight clinical trials analysed for this review, three found ginger affected 
measures of platelet aggregation[24, 28, 29] and one study found ginger reduced 
thromboxane B2 production.[19] When the included studies were separated by patient 
medical background (e.g. healthy, hypertensive), no consistent treatment effect could 
be elucidated. However, there are several limitations that could limit the real-world 
applicability of these results.   
First, Young et al.[28] reported that ginger had an effect only when it was 
combined with nifedipine, but not when it was ingested by itself. While not fully 
elucidated, it is thought that the anti-aggregation effect of nifedipine results from the 
inhibition of intracellular Ca2+, which attenuates platelet hyperactivity. [33] Other 
anti-platelet medications are not reported to possess this mechanism of action and 
therefore, these results might only be applicable to this combination. 
Second, Verma et al.[29] found that ginger reduced a rise in platelet 
aggregation after a two week high-calorie diet when compared to control (high calorie 
diet plus placebo). However, it should be noted that this diet exceeded the participants’ 
normal dietary intake (approximately 1600kcal increase in dietary intake, according 
to USDA food data[34]), which might make these results difficult to compare to 
patients who consume a eucaloric diet.  
The third study reported a significant reduction in platelet aggregation when a 
bolus of 10g ginger was administered to patients with a confirmed myocardial 
infarction.[24] However, the same authors found a lower dose of 4g ginger had no 
effect in the same population when taken daily over three months.  
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A primary limitation of the studies reviewed is the lack of quantification or 
standardisation of bioactive compounds in the ginger preparations used. This could 
partly explain the inconsistent results. Previous research indicates that the 
concentration of the principal compounds within ginger, namely gingerol and 
shogaols, varies greatly depending on the storage and preparation of ginger 
products.[35, 36] This variation could result in significant differences in bioactive 
compounds between studies. For example, 6-shogaol is only present in appreciable 
amounts in dried or heated ginger as it is a degradation product of 6-gingerol.[37] 
Hence, preparations that used dried ginger are likely to have significantly different 
effects compared to raw ginger.  
A final limitation relates to the clinical significance of ginger’s potential anti-
platelet effect. Several studies have reported that ginger is effective for nausea in 
multiple settings including morning sickness, motion sickness and chemotherapy-
induced nausea and vomiting (CINV).[4, 5, 38] However, the majority of these studies 
used ginger doses that were considerably lower than those used in the studies included 
in this review. For example, in two recent reviews of the effect of ginger on morning 
sickness[5] and CINV[1], from a total of 19 studies, no study used a dose above 2g 
with most studies using a dosage around 1g. In contrast, the majority of studies in this 
review that found a significant effect on platelet aggregation used doses above 5g.[19, 
24, 29] Young et al.[28] were the only exception in reporting 1g in combination with 
nifedipine to have an effect on platelet aggregation; however, when 1g of ginger was 
administered alone, there was no significant effect. Hence, further research in this area 
should investigate the effect of lower doses of ginger on platelet aggregation in order 
to determine if the potential effect of ginger on platelet aggregation is clinically 
141 
relevant when used as an adjuvant anti-nausea treatment during chemotherapy at 
doses shown to be effective in previous studies.  
The two observational studies included in this review also reported conflicting 
results.[31, 32] This could be due to the differences in their study designs. One study 
undertook a retrospective analysis that could have resulted in recall bias,[32] while 
the other study undertook a prospective approach.[31] In the retrospective study,[32] 
only two patients from a cohort of 314 participants reported consuming ginger, both 
of whom reported experiencing bleeding events. Due to the limited sample of 
participants who consumed ginger, it is difficult to draw meaningful conclusions.  
Information regarding the dose of ginger consumed by participants was not reported 
in either observational study, which might further account for the difference in results.  
While there was only one clinical trial investigating the interaction between 
ginger and warfarin, Jiang et al.[26] found no significant change to patient INR when 
ginger was administered for seven days. This is partially corroborated by the results 
of a study of Wistar rats in which a proprietary ginger formulation, in combination 
with warfarin, had no additive effect on whole blood clotting time, prothrombin time 
or activated partial thromboplastin time.[10] This is a particularly relevant finding, as 
ginger is routinely cited as potentially interacting with warfarin therapy.[39, 40] While 
further studies are required to investigate interaction of ginger and blood thinning 
medication, current evidence does not support an interaction. 
The results of this review indicate that the role of ginger in platelet aggregation 
is unclear and therefore, future clinical trials are needed to further investigate this area, 
particularly in at-risk populations such as chemotherapy patients. However, until these 
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trials are undertaken, the effect of ginger on platelet aggregation cannot be confidently 
dismissed. Previous research has indicated that patient use of dietary supplements is 
often not reported to treating physicians. For example, a review of surveys that 
investigated the rate of non-disclosure of complementary and alternative medicines in 
chemotherapy patients found that between 40-50% of patients did not discuss these 
therapies with their physician.[41] Hence, where patients are at particular risk of 
bleeding, clinicians should ascertain patient consumption of dietary supplements and 
screen for any known potentiator of bleeding risk.  
 Conclusion 
Due to the potential effects of ginger on platelet aggregation, ginger is a 
commonly-cited example of an herbal supplement that should be avoided in patients 
with thrombocytopenia, platelet function defects or coagulopathy, such as populations 
using ginger for its antiemetic effect in cancer chemotherapy. While in vitro data, as 
well as some clinical studies and epidemiological evidence suggest that ginger inhibits 
platelet aggregation, the evidence is equivocal with multiple limitations, particularly 
within the clinical data, which prevents firm recommendations being made. 
Limitations include the lack of standardisation of ginger preparations used, significant 
variations in dosage and time frame studied, and the high level of bias in the study 
designs used. Therefore, further research is needed to clearly define the safety, or 
otherwise, of ginger in patient population at increased risk of bleeding. 
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Part Two: Research studies and 
results 
The results of the systematic literature reviews included in Part One of this thesis 
identified multiple areas where further research is required. In Part Two of this thesis, the 
aim was to address these gaps in the literature by conducting four research studies. To 
summarise the nature of these four studies, using an in silico model of the murine 5-HT3 
receptor, the binding characteristics of the principle compounds within ginger were 
explored in Chapter 7. Chapter 8 describes the results of an HPLC analysis that quantified 
the concentration of bioactive compounds within a variety of commercial ginger 
products. The effect of a standardized ginger extract was investigated in Chapter 8 and 9 
by conducting a double blind, randomized, placebo-controlled trial. Finally, in Chapter 
10, current barriers, needs and behaviours relating to the implementation of potentially 
therapeutic dietary supplements such as ginger were elicited from a survey of 370 
healthcare professionals. The referencing style and manuscript structure of each chapter 
are in accordance with the respective journal guidelines.  
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 In silico investigation into the interaction between 
murine 5-HT3 receptor and principle compounds of 
ginger (Zingiber officinale). 
X-ray crystallography produces a three-dimensional map of the atomic 
coordinates of biomolecules with or without their associated ligands, providing a basis 
for further computation analysis of biomolecular interactions. For example, molecular 
docking is a computer-based tool commonly used in drug design whereby the potential 
binding affinity of potential drug candidates to a biological target can be investigated. 5-
HT3 antagonism is thought to be one of the primary mechanisms by which the active 
compounds (e.g gingerols and shogaols) within ginger potentially reduce CINV. 
However, it is currently unclear how these active compounds interact with this receptor, 
with some evidence suggesting these compounds bind to a currently unidentified site that 
differs to serotonin and other known 5-HT3 antagonists (e.g. ondansetron). Recently, the 
crystal structure of the murine 5-HT3 receptor was solved, allowing for an in silico 
investigation of the binding characteristics of the primary ginger compounds within the 
newly-solved 5-HT3 receptor. As discussed in detail in this chapter, the binding affinities 
of several bioactive ginger compounds, along with an array of relevant compounds of 
interest, were investigated in two potential binding sites. The results of this study provide 
information regarding favourable binding sites, potential binding conformations and key 
residues required for binding. These are discussed in relation to previously cited residues 
identified as potential important for binding.  
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 Abstract 
Gingerols and shogaols are the primary compounds within ginger (Zingiber 
officinale) and have been demonstrated in vitro to exert 5-HT3 antagonism which could 
benefit chemotherapy-induced nausea and vomiting. However, the site and mechanism 
of action on the receptor by which these compounds bind to the 5HT3 receptor has not 
been fully elucidated although research indicates they may bind to a currently unidentified 
allosteric binding site. Using in silico analyses of the recently available murine 5-HT3 
receptor, we conducted a GRID analysis ofsite environment and characteristics of these 
compounds along with other positive and negative controls within the serotonin binding 
site. Docking results were compared to those using a proposedallosteric binding site 
situated at the interface between the transmembrane region and the extracellular domain. 
Our results correlated well with previous site-directed mutation studies in identifying key 
binding site residues. We have identified residues which may be important for binding 
the ginger compounds. Overall, our results suggest that the ginger compounds and their 
structural analogues possess a high binding affinity to both sites. . While these compounds 
contain structural moieties which likely contribute to their high docking scores in silico 
and, notwithstanding the limitations of theoretical analyses, it is also conceivable that 
these compounds could act both competitively or non-competitively as has been shown 
for other modulators of CYS loop receptors.  
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 Introduction 
One of the primary pathways in the pathology of chemotherapy-induced nausea 
and vomiting is the stimulation of vagal afferent nerves via the 5-HT3 receptors due to 
abnormally high levels of serotonin released from the mucosal enterochromaffin cells of 
the gut.1 Serotonin acts allosterically to activate the receptor since its binding site is 
distinct from the transmembrane region where channel opening occurs. A number of 
agonists and antagonists have been identified which are able to displace serotonin.2 The 
“setron” class of anti-emetic medications, including ondansetron as well as the more 
recently introduced polanosetron and granisetron, have significantly improved control of 
chemotherapy-induced nausea and vomiting due to their action as a competitive 
antagonist of the 5-HT3 receptor.
1 Additionally, as established for other CYS loop 
receptors, allosteric modulators have been observed which exert an effect on the activity 
of the receptor while in the presence of serotonin (or other compounds) bound at the 
orthosteric binding site.3,4 For example, reports of a putative ‘alcohol’ binding site 
followed observations of enhancement of agonist displacement of 3H-granisetron in the 
presence of trichloroethanol at 5-HT3 receptor conductance by alcohols following 
displacement by other agonists. These effects were however species dependent.4  
Empirical evidence from in vitro and clinical data suggest that ginger may be an 
effective treatment against several types of nausea including morning sickness, motion 
sickness and chemotherapy-induced nausea and vomiting.5,6 Gingerols are the principle 
class of compounds within non-volatile component of ginger. Thermal treatment during 
dehydration or other manufacturing processes convert some gingerols to the more 
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oxidised shogaols or dehydroshogaols.7 Both shogaols and gingerols contain a second 
double bond on the opposite site of the carbonyl. In contrast to the gingerols, both the 
shogaols and dehydroshogaols are α,β-unsaturated carbonyl compound.8 
Preclinical studies have also begun to elucidate the mechanisms by which these 
compounds may exert a potentially beneficial effect on nausea and have found multiple 
viable pathways.9-11 Previous studies have demonstrated that the principle compounds in 
ginger, gingerols and shogaols, are able to inhibit 5-HT3 mediated signaling and that this 
interaction could be mediated through a currently unidentified binding site.9,10 Abdel-
Aziz et al.9 conducted a series of in vitro studies which found that [6]-shogaol, [8]-
gingerol, [10]-gingerol, and [6]-gingerol were able to inhibit 5-HT3-induced contractions 
of the isolated guinea-pig ileum and that this was likely via a distinct binding site due to 
the same compounds inability to displace the competitive antagonist, [3H]GR65630 from 
its binding site. These findings were corroborated by an in vitro study by Walstab et al.10 
that investigated the effect of three ginger extracts as well as [6]-gingerol and [6]-shogaol 
on the activation of human 5-HT3 receptors. The results indicated that ginger was able to 
inhibit the activation of 5-HT3 receptors and this was likely via non-competitive 
mechanisms. As Walstab et al.10 noted, when combined with standard 5-HT3 antagonists, 
the non-competitive binding of ginger could potentially provide an additive effect to the 
control of nausea and vomiting in clinical practice.  
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The 5-HT3 receptor is a pentameric, neurotransmitter-gated ion channel of the 
CYS loop family. Five distinct subunits (A to E) have been identified to date whereby A, 
B, C & E are similar while subunit 5-HT3D lacks an amino terminal CYS loop. The 
arrangement of subunits in the functioning unit has five-fold symmetry of subunits, either 
arranged homo or heteromerically around a cation-specific, water filled central pore. Only 
the A subunit has been shown to form functional homomeric receptors and, importantly, 
the presence of the A subunit was required in all receptors. It is noteworthy that 
heteromeric receptors contain more possible sites for allosteric modulation than 
homomeric receptors.12 
Recently, the crystal structure of the murine 5-HT3 receptor in the apo (or 
unbound) form was solved using X-ray crystallography at 3.5Å resolution.13 VHH 
nanobodies, derived from single subunit llama immunoglobulins, were used to help 
 Figure 6-1 Homopentameric murine 5-HT3 receptor with VHH nanobodies. Top  view (A) and side view (B) of 
homopentameric murine 5-HT3 receptor with VHH nanobodies (orange ribbons) (pdb entry 4pir). The backbone of 5-HT3 is 
depicted as a purple ribbon except for the principle subunit extracellular domain (ECD) in cyan ribbon and the complementary 
subunit ECD in beige ribbon. Pore-lining M2 helices in the transmembrane domain of principle and complementary subunits 
in green ribbon (C); Two of the 5 subunits extracted for analysis representing principle and complementary subunits (A+A-). 
 
(A) (B) (C) 
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stabilize the receptor during crystallization. In the crystal structure, these are shown to 
bind radially at the intersubunit interface (Figure 6-1in orange). Hassaine et al.13 found 
that the binding of the VHH nanobodies resulted in inhibition, possibly stabilizing a non-
conducting conformation. Despite the relatively low resolution, knowledge of the three 
dimensional structure provides the necessary information to conduct an in silico study 
with the aim of investigating the binding characteristics of the primary compounds within 
ginger on the 5-HT3 receptor. In particular, this study compared the binding interactions 
of the active ginger compounds at the serotonin site with those at the proposed allosteric 
binding site. This will provide additional insight into the nature of the binding 
characteristics of gingerol and shogaol compounds in relationship to the 5-HT3 receptor.   
 Results and discussion 
The binding interactions of each compound were investigated using the recently 
solved crystal structure of the murine 5-HT3 receptor (PDB entry 4pir). Although the 
crystal structure depicts a homomeric 5-HT3A pentamer, two subunits (A+A-) were 
extracted for analysis since both the serotonin and allosteric binding sites are located at 
or near this interface.  
As shown in Figure 6-2, the serotonin binding site is at the interface between two 
adjacent subunits.2,13 The proposed allosteric binding site is situated at the interface 
between the transmembrane region and the extracellular domain.14 The location of the 
latter site was delineated from site-directed mutagenesis studies14  
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EC
D 
Serotonin 
binding 
site 
Proposed 
allosteric 
site 
M2 TM helices 
(pore lining) 
 
IC
(C) 
R219 
F222 
K54 
P274 
I139 
Y140 
(B) (A) 
Figure 6-2 (A) Principle (cyan ribbon) and complementary (beige ribbon) subunits of 5HT-3A receptor (A+A-). ECD 
(extracellular domain containing orthosteric binding site and allosteric site at interface with TMD; TMD (transmembrane domain 
containing M1-M4 TM helices with M2 in green containing pore-facing residues ion magenta);  ICD Intracellular domain. (B) 
Orthosteric (serotonin) binding site: Principle subunit (cyan ribbon): Loop A (N97,N101 green); Loop B (T52,54, W156 green-
blue); Loop C (F199, Y207 blue). Complementary subunit (beige ribbon): Loop D (W63, R65, Y68 yellow); Loop E (Y124 
orange); Loop F (D177, S179, V180 red-orange); Loop G (D42, 44 red). (C) Proposed allosteric site: Principle subunit (cyan 
ribbon) Complementary subunit (beige ribbon). Key residues thought to be important for binding non-competitive antagonists 
(blue ball & stick). 
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A ligand database of 25 compounds was prepared comprising 6,8 and 10-
gingeraol and 6 and 10-shogaol, serotonin as well as a number positive and negative 
controls (Figure 6-3).  
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6-gingerol, n=2; 8-gingerol, n=3; 10-
gingerol, n=4 
6-shogaol, n=2; 8-shogaol, n=3; 10-
shogaol, n=4 
serotonin 
granisetron dolasetron romasetron 
capsaicin VUF10166 varenicline 
curcumin picrotoxin gingkolide 
acetylcholine bicuculline -hydroxybutyruic acid 
(GABA) 
6-dehydroshogaol, n=2; 8-dehydros-hogaol, 
n=3; 10-dehydroshogaol, n=4 ondansetron 
 
(6-[(1-naphthylmethyl)thio] 
-9H-purine) (PU02) 
Figure 6-3 Structural diagrams of included ligands 
palonosetron 
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Positive controls included known competitive antagonists such as ondansetron 
known to bind at the serotonin binding site as well as known non-competitive antagonists, 
such as picrotoxin, which are likely to bind at an allosteric or alternate site. In addition, 
we included structural analogs of the gingerols (capsaicin and curcumin) and decoy 
molecules such as bicuculline not known to bind to the 5-HT3 receptor. 
A GRID analysis was performed to identify sites of strong binding interaction 
between the receptor and a range of small probes simulating various functional groups of 
the ligands (see appendix for GRID data). Ligands were subsequently docked into the 
two sites to compare binding interactions at each site.  
The docking results are presented in Table 6-1. Surflex-Dock ranks ligands in 
order of highest binding interaction to lowest by applying scoring functions, taking into 
account non-bonded interactions between the ligand and target, including hydrophobic, 
polar, electrostatic, van der Waal and entropic considerations. Consensus scoring (Cscore) 
calculates scores across all 4 scoring functions. Cscores are between 0-5, with a Cscore of 5 
reflecting complete consensus of the pose binding score across all scoring functions while 
a lower score indicating less consensus. The total score is expressed as -logKD to represent 
binding affinity. The lower the dissociation constant, KD, the stronger the binding. When 
expressed as –logKD a higher positive value reflects stronger binding. 
Total scores comprise the sum of a positive ‘polar’ contribution and a negative 
‘crash’ score. The ‘crash’ factor denotes the degree of inappropriate penetration of ligand 
atoms within the binding site. While the ‘polar’ contribution incorporates the hydrogen 
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bonding and other non-bonded interaction terms. Those ligands able to interact strongly 
to target residue atoms are likely to have higher total scores unless negative steric factors 
predominate. The degree of hydrogen bonding is included in Table 6-1 as one 
contributing factor towards overall total score. 
Table 6-1 Surflex-Dock results for Serotonin and Allosteric Sites 
  Serotonin Site  Allosteric Site 
Name 
Total 
score 
Cscor
e 
HBa 
Key 
residuesb 
Total 
score 
Cscor
e 
HB
a 
Key 
residuesb 
Ginger Ligands 
6-gingerol 8.7 1 3 
E209 
8.26 1 4 
R219 
R65 Q56 
 F222 
  E53 
8-gingerol 10.25 5 4 
T154 
E209 
R65 
8.84 5 3 
E53 
R219 
F222 
10-gingerol 10.81 4 5 
T154 
8.26 1 5 
T280 
E209 I139 
K211 E53 
T152 Q56 
6-shogaol 8.38 0 2 
N101 
W156 
6.52 0 3 
E53 
F222 
Q56 
8-shogaol 9.06 5 4 
R65 
S155 
T154 
7.19  2 2 
K54 
F222 
10-shogaol 9.34 2 2 
T152 
N101 
8.29 5 1 F222 
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6-
dehdroshoga
ol 
6.97 0 3 
T152 
K211 
N101 
6.28  0 3 
E53 
Q56 
K54 
8-
dehdroshoga
ol 
8.56 0 3 
L157 
6.61 0 1 
E186 
Y207   
N101   
10-
dehdroshoga
ol 
9.07 2 2 
L157 
N101  
6.85  4 3 
E53 
Q56 
K54  
Native Ligand 
Serotonin (5-
hydroxytrypt
amine) 
5.63 0 5 
E173 
6.02 0  4 
Q184 
S176 E53 
D42 D138 
D177 L137 
Competitive Antagonists 
Ondansetron 5.22 0 1 T154 4.85  0 1 Q56 
Granisetron 5.51 0 1 E209 4.87 0 0   
Dolasetron 6.9 0 3 
R65 
5.43  1 0 
  
T154   
Ramosetron 6.48 2 1 T154 5.65  2 2 
P274 
Q56 
Palonosetron 5.74 0 1 R65 5.10 0 0 
 
VUF10166 5.13 1 1 R65 5.80 4 0 
  
  
Varenicline 
(from 
5AIN.pdb) 
5.09 3 2 
R65 
N101 
4.23  3 1  P274  
PU02 5.8 5 3 
D177 
4.33 2 1 D138 
S179 
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Structural Analogues of ginger actives 
Capsaicin 8.54 4 4 
R65 
N101 
9.23 1 3 
K54 
R219 
F222 
Curcumin 8.77 1 9 
R65 
7.02  0 3 
R219 
T154 E53 
S155   
D177 E186 
S179   
Non-Competitive Ligands 
Picrotoxin 4.77 1 4 
E102 
S150 
S136 
N148 
4.96 0 4 
Y46 
N183 
S136 
Ginkgolide 4.25 5 7 
K211 
3.94  3 3 
T280 
S150 D138 
E102 I139 
T152   
N101   
Decoys  
Acetylcholin
e 
4.9 1 0  4.95 3 1 Q56 
Bicuculline 7.09 2 1 R65 6.01  1 3 
F222 
T280 
Q56 
GABA 4.9 1 3 
W156 
R65  
4.76 1 3 
Q56 
K54 
E53 
 
 
a number of hydrogen bonds; b target residues hydrogen bonding to ligand; Blue colour indicates 
residues previously identified as important for binding.13 
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Overall the cscores for the ginger compounds were consistently higher at the 
allosteric site while the cscore was more variable at the serotonin site for the ginger 
compounds overall. This trend was repeated with the structural analogs inferring that this 
structural family of compounds binds more favorably at the allosteric site. In contrast, 
there was a higher consensus for serotonin and the setron antagonists at the serotonin 
curcumin G 
S 
DHSG 
ACh 
romasetron 
ondansetron 
picrotoxin 
gingkolide 
GABA 
VUF10166 
5-HT 
dolesetron 
capsaicin 
varenicline 
granisetron 
bicuculine 
Allosteric binding site 
Serotonin binding site 
Figure 6-4 Structural similarity maps at each binding site coloured by total score. 
Cyan, blue and purple indicate low total scores. Green and yellow indicate 
moderate scores while magenta/red ere high scoring. G = gingerols, S = shogaols, 
DHSG = hehydroshogaols; Ach = acetylcholine; 5-HT = serotonin..  
PU02 
Ach 
varenicline 
capsaicin 
VUF10166 
5-HT 
palonosetron 
G 
S 
DHSG 
curcumin 
Granisetron 
bicuculline 
ondasetron 
romasetron 
dolasetron 
picrotoxin 
gingkolide 
PU02 
GABA 
palonasetron 
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binding site. Consensus was high at both sites for the decoys, consistently performing 
poorly in their total scores.  
Figure 6-4 is a structural similarity plot depicting the relatedness of molecules in 
the database and coloured according to total scores in each site. The plots represent a 
principle component analysis based on UNITY molecular fingerprints. Each molecule is 
characterized by a set of fragments (represented in binary). Points near one another 
represent similar compounds (a similar UNITY fingerprint). Points far from one another 
represent dissimilar compounds. Points around the edge of the map represent compounds 
that are not like any other compounds used to generate the map. The colours range from 
magenta/red as high scoring through to blue and cyan lowest scoring (see appendix for 
colour key). Structurally, the two non-competitive antagonists (NCA), gingkolide and 
picrotoxin are clearly most distinctly unrelated to the other ligands though somewhat 
similar to each other. These two scored the lowest in the serotonin site which is consistent 
with their action as NCAs. The ginger compounds are clustered with curcumin although 
capsaicin, another structural analog, is clustered elsewhere. This is most likely due to 
presence of the amine functional group. Serotonin is clustered with the amine-containing 
GABA, capsaicin, acetylcholine as well as one of the setrons, dolasetron. Of all the 
setrons, dolasetron is the only one with an indole moiety similar to serotonin which may 
explain the positioning of this ligand. The remaining larger ring system ligands were 
clustered together with bicuculline and VUF1016. A cluster analysis of 20 poses for each 
ligand at both sites showed that where there was one preferred orientation and that the 
highest scoring pose from each cluster was found within the preferred orientation.   
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 Serotonin binding site  
It is established that serotonin site has a high degree of hydrophobic character and 
our results are in agreement with this description.13 Figure 6-5-A depicts the GRID results 
predicting strong sites of interaction with a hydrophobic probe. A contour level of -
1.5kcal/mol is indicative of a lipophilic region. Serotonin is observed to dock into a more 
polar region than the setron compounds which is as expected given their greater degree 
of lipophilicity. A strong site of interaction correlates well with the position of the 
aromatic ring and alkyl chain of docked [6]-gingerol (Figure 6-5-B).  
The orientation of all docked ligands are presented in Figure 6-6-A. Serotonin 
bound to a distinctly polar location closer to complementary subunit and shared common 
binding interactions only with curcumin and dolasetron (Figure 6-6-B).  
The majority of ligands, including the ginger compounds, occupied a site more 
interior and hydrophobic than that bound by serotonin (Figure 6-6-B and C). Despite the 
3 apparent hydrogen bonds with D177 and one each between S179 and W165, the total 
score for serotonin was lower than all ginger compounds, structural analogs, granisetron, 
dolasetron and romasetron.  
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Figure 6-5. Serotonin binding site with (A) Docked ginger compounds (atom types) and 5HT (magenta). Hydrophobic 
probe contoured at -1.5kcal/mol. (B) Serotonin docked with amine probe contoured at -15kcal/mol (C) Docked poses 
of 6,8 and 10G with alkyl hydroxyl probe contours (-10.5kcal/mol,greenblue). (D) Docked poses of 6,8 and 10S with 
alkyl hydroxyl probe contours (-10.5 kcal/mol, yellow) (E) Docked poses of 10G with carbonyl oxygen  probe 
contours (-7 kcal/mol, redorange) 
(A) (B) 
(C) (D) 
(E) 
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The serotonin site is lined with a number of aromatic residues (an aromatic box). 
A GRID analysis showed the three particularly strong sites of interaction with a 
hydrophobic probe. (Figure 6-5-A) and correlate well with the docked positions of 
hydrophobic moieties of the ligands such as the alkyl tails of the ginger compounds and 
the aromatic ring systems of other compounds. A GRID analysis using an amine cationic 
probe showed excellent correlation to the site of the docked ammonium group of 
serotonin (Figure 6-5-B).  
Serotonin 
Serotonin 
(A) (B) 
(C)  
Figure 6-6. Serotonin binding site with key residues labelled. (A) Superimposition of highest scoring poses of all 
gingerols compounds (B) Serotonin (atom colours) docked within the site showing hydrogen bonds (yellow dashes). S(C) 
Serotonin (magenta) docked in a polar site closer to complementary subunit (blue surface) compared to the more interior, 
hydrophobic site (green surface) occupied by most other ligands. 
Serotonin 
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The gingerols compounds are distinguished from the other more oxidized ginger 
compounds by the presence of an alkyl hydroxyl group. Sites of polar interactions with 
an alkyl hydroxyl group; this correlate well with the position of alkyl hydroxyl probe of 
[6]-gingerol. Predicted sites of binding interactions of a phenyl hydroxyl probe is less 
well correlated with the position of the same group in [6]-gingerol. (Figure 6-5-B)  
A GRID analysis with an alkyl hydroxyl probe shows a site of strong interaction 
within this site at the position of the docked gingerol’s hydroxyl group (Figure 6-5-C). 
Similarly the docked positions of an aryl hydroxyl and carbonyl oxygen correlated well 
with the sites predicted by GRID (Figure 6-5-D and E). 
 
Figure 6-7. (A) Ligand rotatable bonds compared to total score and polar surface area. (B)  
Ligand clogP values versus total score and coloured by volume. 
5-HT 
[8]-gingerol (A) 
(B) 
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Unexpectedly, the ginger compounds scored highest in the serotonin binding site. 
In terms of drug-like characteristics, the ginger compounds have a high non-covalent 
interaction potential meaning that they possess a range of structural moieties required for 
maximizing binding affinity. These include an aromatic ring (pi stacking), alkyl tail 
(hydrophobic and Van der Waal interactions), hydrogen bond donors (phenol and 
hydroxyl) and acceptors (carbonyl and hydroxyl oxygens) for maximizing hydrogen 
bonding interactions. In addition, the ginger compounds have a high degree of flexibility 
as illustrated by the observed correlation between rotatable bonds and total score in Figure 
6-7-A.  
The same features are similarly found in the structural analogs, capsaicin and 
curcumin which also scored highly in the serotonin binding site. In addition to flexibility, 
there is a clear correlation between hydrophobic character and total score with all the top 
scoring ginger compounds and structural analogs having high, positive clogP values 
(Figure 6-7-B).  Volume is similarly positively correlated with total scores (Figure 6-7-B).  
The abilities of most current molecular docking algorithms to accurately model 
all factors present in vivo is still somewhat limited. Target flexibility, explicit solvent and 
some types of non-covalent interactions, for example, are often not considered or are dealt 
with poorly. As a result, caution in the interpretation of these results is required. 
Interactions between both competitive and non-competitive antagonists with the receptor 
have been described by Thompson et al.2 to undergo a pathway as they progress from 
bound to unbound which may involve several transient sites. Furthermore, the nicotinic 
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receptor, AChBP, also of the CYS loop receptor is known to undergo substantial 
quaternary twisting of the subunit interface upon activation of the ion channel and 
bending of the extracellular domain.15 It is feasible then to consider similar 
conformational movements of the 5-HT3 receptor and concomitant changes to binding 
sites. In this light, it is not surprising that we see the ginger compounds binding well to 
this site. The crystal structure was assumed to have adopted a closed conformation upon 
binding of the inhibitory VHH nanobody.13 It is possible that serotonin may have scored 
higher had the receptor been in a more open channel conformation and ligand ranking 
likely to be quite different. 
Binding studies reveal a complexity in mechanisms of action with respect to how 
particular ligands may interact with different subunit stoichiometry. The potent inhibitor, 
Vuf1066 for example, was found to displace granisetron at the orthosteric binding site in 
an A+A- binding site but acted at an alternate site at an A+B- binding.14 The 5HT3A crystal 
structure used in this study is homomeric (A+A-).  
Prior to the determination of the mouse crystal structure, site directed mutagenesis 
studies revealed a number of residues important for activation of the 5HT receptor or 
binding of serotonin.16 These included Y46, F103, S136 and D138 (mouse numbering). 
These residues are more posterior to the serotonin site shown in the mouse structure and 
were not seen to interact with any of the ligands. In the crystal structure, however, 
Hassaine et al.13 further identified several key residues in the crystal structure as important 
for serotonin binding. For example, we found that R65 played a key role in binding 
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ligands at the serotonin site and supports experimental observations. Several ginger 
compounds, structural analogs and competitive antagonists interacted with this residue 
through hydrogen bonding. In addition, N101 and T154 were also important for 
stabilizing ligands via hydrogen bonding. Serotonin was found to interact with D42 and 
D177 as well as S179. These residues were implicated by Hassaine et al.13 as forming the 
serotonin binding site. The residues forming the most hydrogen bond interactions with 
the ligand database were R65, N101 and T154. Ginger ligands formed hydrogen bonds 
with several residues, predominantly R65, T154 and N101. We found previously 
unidentified residue, E102, contributed to stabilization of [10]-dehydroshogaol. The 
setron group of ligands docked into two main regions within the site. Ondasetron and 
dolasetron bound closer to the complementary site where 5-HT3 was found to interact 
while granisetron and romasetron bound closer to the primary subunit face. Palonasetron 
was somewhere in between these regions (Figure 6-8A).  
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Y207 was identified as a residue able to add stability to ligand binding through pi 
stacking interactions observed with ginger ligands such as [8]-gingerol (Figure 6-9B). 
Other competitive antagonists interacted predominantly with R65 and T154; both of 
which also interacted with gingerols. Our docking results are in agreement with these 
residues as important for hydrogen bonding with the site (Table 6-1). Figure 8-C clearly 
depicts the aromatic box of the serotonin site created by the residues Y126, and W63 of 
the complementary subunit and Y207 and W156 of the primary subunit. The high scoring 
Figure 6-8 (A)-Granisetron (atom colours) ondasetron (orange) dolasetron (green) romasetron (yellow) 
palonasetron (red). (B) -Curcumin (atom colours) docked into serotonin site. Additional stability by 
possible pi stacking interaction with Y207. (C) Capsaicin docked into serotonin site depicting the aromatic 
box created by Y207, W156 (primary subunit, blue) andY126 & W63 (complementary subunit, beige). (D) 
Serotonin (atom colours) and [10]-G (magenta). Hydrophobic probe contoured at -1.5 kcal/mol for C and 
D 
A B 
C D 
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ginger compounds and their structural analogs were observed to dock in a similar 
orientation with their aromatic ring embedded in this box permitting hydrogen bonding 
with the side chain cationic amine of R65. In contrast serotonin’s aromatic ring appears 
to take advantage of a cation-pi interaction with R65 (Figure 6-8-D). This interaction was 
proposed by Hassaine et al.13 with granisetron. We further purport that a second cation-
pi interaction on the opposite face of serotonin’s aromatic ring is possible with R169.  
Of the ginger compounds, gingerols had the highest total score. A contributing 
factor towards the high score is likely to be the advantage taken of hydrogen bonding 
opportunities within the site. Both the shogaols and dehydroshogaols lack an alkyl 
hydroxyl group and have less flexibility due to the double bond. Due to their flexibility 
the length of their carbon chains did not negatively impact on their total scores. Non-
competitive ligands and decoys, acetylcholine and GABA had the lowest score measured.  
 Allosteric binding site 
Allosteric modulation facilitates fine tuning of ion permeation through the 
channel by signal dampening, for example, depending on the stoichiometry of the 
subunits and the number of serotonin ligands able to bind one receptor. Multiple modes 
of regulation have been noted in other CYS-loop receptors and is similarly likely in the 
serotonin receptor and involve a number of allosteric binding sites. Endogenous 
membrane lipids have been suggested to modulate ion permeation by binding to specific 
regions of the transmembrane channel. The exact location of binding for non-competitive 
antagonists of the 5HT3 receptor is yet to be fully elucidated. The transmembrane domain 
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of the CYS-loop receptors are functionally similar with key regions along the length of 
the ion permeation pathway being designated with a prime notation such that the pre-M2 
region, identified as -20’ contains a ring of cationic residues.17 Certain residues of the M2 
helix face in toward the channel (Figure 6-9) and site-directed mutagenesis studies have 
identified a number of residues important for channel function.  
Furthermore non-competitive antagonists (NCAs) such as picrotoxin can 
differentiate different subunit compositions in the receptor.18 The most likely position for 
many of the exogenous NCAs is the intersubunit interface at the top of the transmembrane 
domain. Another allosteric site is proposed in the pre-M2, ECM intersubunit interface. 
Anesthetics and small alcohols have been shown to interact at a similar site in GABA and 
glycine receptors.19 These compounds illicit similar effects on the 5-HT3 receptor.
12 Since 
Figure 6-9. Docked ligands within the allosteric binding site at the ECM/TM 
interface between primary and complementary subunits. Side view with M2 
TM helix (green) 
M2 helix 
Ion 
permation 
Outer ECM 
region 
TM domain 
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the structure of one such anesthetic, lidocaine, has a degree of structural similarity to 
serotonin and the ginger compounds, our study focused on the latter allosteric site. 
The orientation of the docked ligands within the allosteric binding site docking 
experiment are depicted in Figure 6-10. Note that picrotoxin is bound to a unique site 
midway between the serotonin and allosteric sites. This ligand may bind to a different 
allosteric site with the A+B- subunit interface. The allosteric binding site depicted 
occupies a greater volume than that of the serotonin binding site enabling some ginger 
Figure 6-10 Superimposition of  all ligands in allosteric site  with 8G (magenta). 
Docked picrotoxin indicated position closer towards serotonin binding site.  Alkyl 
tails of [8],[10]-S and [6],[10-DHSG. Surface contour coloured by lipophilic 
character (decreasing order of lipophilicity: brown, green, blue). 
 
Picrotoxin 
Alkyl tail of 
[8],[10]-S and 
Serotonin 
binding site 
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compounds to adopt a more extended conformation. This appears to facilitate a 
favourable hydrophobic interaction between the alkyl moiety of these ligands with the 
hydrophobic region found closer to the transmembrane domain.  
The ginger compounds and structural analogs also scored highest in this binding 
site with capsaicin attaining the highest total score. As demonstrated by the lower level 
of contouring for the hydrophobic probe, the allosteric site is more polar than the 
serotonin cavity although there are particular regions with hydrophobic character which 
correlate well with hydrophobic moieties of the ligands (Figure 6-11-A). Figure 6-11-B 
shows sites of strong interaction with a water probe which correlate well with the docked 
positions of polar groups on the ligands. 
Comparison between the different ginger compounds showed the gingerols 
generally scoring higher as a group (Figure 6-12) with all three adopting a similar 
orientation within the site. This trend is continued with the shogaols scoring generally 
Figure 6-11. Allosteric site with highest scoring ligand, capsaicin.A: GRID contours for a hydrophobic probe (-
0.5kcal/mol). B- GRID contours for a water probe (-11kcal/mol). Surface coloured by lipophilic character. 
(A) (B) 
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higher than the dehydroshogaols. This trend correlates with the higher polarity of the 
gingerols compared to the other ginger compounds and, in this context, would therefore 
bind with higher affinity in a more polar site.  
Serotonin and the competitive antagonists ranked moderately at this site with all 
setron ligands binding in a similar location to the gingerols (Figure 6-13-A and B). PU02 
occupied a unique site lower down toward the transmembrane region forming a pi 
stacking interaction with Y140. (Figure 6-13-C) 
Figure 6-12 Superimposition of  6G (atom colours), 8G (yellow), 10G (violet) in allosteric site with key 
residues labelled. Primary subunit (cyan ribbon); Complementary subunit (beige ribbon) 
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Our analysis identified R219, Q56, F222, E53, K54 and T280 as the key binding 
residues for this site with minor contributions from I139, P279 and E186. The key 
residues important for forming hydrogen bonds with the ginger compounds were I139, 
R219, Q56, F222, and Q53. F222, in particular, was involved with hydrogen bonding 
with all shogaols and most gingerols. Compared to serotonin and the ginger compounds, 
other competitive antagonists exhibited relatively low levels of hydrogen bonding 
interactions within the allosteric site suggesting less available hydrogen bond 
donors/acceptors at this site compared to the serotonin site. Flexibility played a positive 
role in how well the ligands scored at this site as it did within the serotonin site (Figure 
6-14-A). Volume and increasing hydrophobicity were observed to play a similar role in 
contributing to a higher total score. (Figure 6-14-B). 
 
Figure 6-13 Allosteric site: (A)-Serotonin docked into allosteric site with amine cation probe contoured at -
15kcal/mol (B) Setrons (granisetron (atom colours), ondasetron (orange), dolasetron (green), romasetron 
(yellow) palonosetron (red ) (C)- PU02 docked into a unique orientation within allosteric site forming a pi 
stacking interaction with Y56. 
 (A)  (B)  (C) 
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An alignment (see appendix) was performed between the mouse and human 
5HT3A and B receptors. Human and mouse A subunits share 84.7% sequence identity. 
Human and mouse B subunits share 73.2% sequence identity. Human A and B subunits 
share 44.75% identity whereas mouse A and B share 42.4% identity. 
It was found that all key residues important for binding the ginger compounds (as 
well as serotonin) in the serotonin site were conserved between human and mouse A 
subunits. The newly identified E102 was similarly conserved. For the allosteric site, all 
residues noted as important for binding the ginger compounds were conserved between 
mouse and human sequences. Given the high degree of sequence similarity between the 
mouse and human subunits and the conservation of those important receptors, it is 
Figure 6-14. (A) Scatter plots of rotatble bonds Vs Total score with colour axis, clogP B) Scatter plots of 
Volume Vs Total score with colour axis, clogP 
 (A) 
 (B) 
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unlikely that the species difference would account for the finding that the ginger 
compounds bound well in both sites. 
 Summary 
In this study, we investigated the binding interactions of ginger [6], [8] and [10]-
gingerol, [6], [8] and [10]-shogaol and [6], [8] and [10]-dehydroshogaol, as well as 
several known competitive and non-competitive antagonists at the orthosteric and 
allosteric binding sites on the 5-HT3 receptor. Notably the ginger compounds scored 
highly at both sites along with the structural analogs, capsaicin and curcumin. It has been 
proposed that the ginger compounds elicit their effect through an allosteric modulation of 
the 5-HT3 receptor. Our results support this hypothesis. Within the serotonin site, a high 
degree of hydrogen bonding and flexibility was proposed to contribute to their high score. 
Additionally, they also scored higher than other non-competitive antagonists at the 
allosteric site. Likewise, at the allosteric site, a high degree of hydrogen bonding and 
flexibility likely contributed to their overall high total scores (Table 6-1). The finding that 
the ginger compounds outscored serotonin and other competitive antagonists at the 
serotonin site may have a number of possible explanations.  
In a saturation study performed by Walstab et al,10 a competitive antagonist was 
present and likely bound at the orthosteric site. Under these conditions, due to their 
flexibility and relative non-specificity for a particular binding site, the ginger compounds 
may bind at the allosteric site to illicit their effect since they were unable to displace 
GR10655. A similar dual role has been observed for amide-type local anaesthetics, 
lidocaine and bupivacaine.19 Structural characteristics of the ginger compounds which 
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could contribute to their capacity to bind well in different environments are their 
flexibility and combination of both a degree of polarity and hydrophobic character. These 
features could endow the compounds to take full advantage of the specific 
complementarity at each site. 
Our results could reflect the structural changes that occur in the transition from 
open to closed channel conformations. Serotonin binds with high affinity to the open 
conformation. Hassaine et al,13 speculated that the crystal structure they produced is in 
the closed conformation. Thus it is possible that the overall score of serotonin was lower 
than what may have been observed for the open conformation. Additionally, the crystal 
structure depicts a A+A- subunit homomeric structure. Given the five currently identified 
subunits, varying degrees of binding affinity would be expected by all ligands with the 
concomitant changes to the binding site. Allosteric modulators are more potent in the 
heteromeric receptors. To test this idea in the absence of another crystal structure, work 
is in progress to prepare a homology model of an A+B- and a B-A+ receptor using a three 
dimensional template from the current 5-HT3 receptor.  
To date, no 5-HT3 crystal structures exists with a ligand bound to either the 
serotonin binding or the allosteric site 5-HT3 receptor. High resolution, three dimensional 
structures of other cation selective CYS loop receptors, such as the nicotinic acetylcholine 
receptor have been published, which share a high degree of similarity to the 5-HT3 
receptor. It is likely that they share a degree of functional similarity as well. While we 
investigated the two key sites identified to date in this study, it is also possible that 
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additional binding sites for allosteric regulation exist. Future studies could explore other 
areas of the receptor such as the transmembrane region.  
We also acknowledge the following limitations. Only one crystal structure of the 
5-HT3 receptor is currently available and while this allows for in silico investigation of 
this receptor, the crystal structure is not highly resolved making positioning of target 
atoms/side chains difficult. Since rigid docking approaches of this kind relies on the 
accurate position of the sidechains, this will restrict the ability to test conformation space 
sufficiently well to find the most realistic binding poses. The effects of the low resolution 
X-ray imaging has been somewhat reduced by conducting energy minimisation on the 
target prior to docking to relieve any initial strain in the conformation of the protein 
although gross misplacement of atoms/residues side-chains will not be compensated for 
by this measure. Since some of the key binding residues have long, flexible side chains 
(R219, K54, R65) and thus have a high degree of mobility, docking algorithms 
incorporating more flexible approached would be preferable. In addition, quantum 
mechanical molecular dynamics simulations incorporating explicit solvent could also 
offer improved results. 
 Experimental procedures  
All modelling work was performed using SYBYL-X version 2.1.20  
 Target and ligand library preparation  
One principle and one complimentary subunit of the 5-HT3 receptor were 
extracted. Hydrogens were added and Gasteiger-Huckel charges were assigned to the 
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atoms of each compound prior to energy minimization (Amber FF99) to a convergence 
of 0.5 kcal per mol. Extraneous ligands were removed prior to docking. 
Known competitive antagonists, structural analogs to gingerols, non-competitive 
antagonists and decoys (molecules known not to bind to the 5-HT3 receptor) were 
included in the analysis in order to compare binding characteristics with the ginger 
compounds.  
 Docking 
The Surflex-Dock 2.1 algorithm, based on a multi-channel protomol generational 
methodology, was employed for the serotonin binding site while a residue-based 
protomol was used for the protomol generation at the allosteric binding site. The protomol 
at each serotonin and allosteric site was generated using a threshold value of 0.5 and 0.9 
and a bloat of 10 and 10, respectively to create a protomol which sufficiently covered the 
site of interest.  
(A)  
 
Figure 6-15 The protomol of the (A) serotonin binding site and (B) the allosteric binding site 
(B) 
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Figure 6-15 depicts the size and orientation of the protomol for the serotonin and 
allosteric binding sites respectively within which the set of 25 ligands were docked. The 
protomol was checked to ensure all ligands were included therein. Consensus scoring 
(Cscore) was included to identify structures obtaining high scores across all 4 scoring 
functions. Cscores are between 6-5. A  Cscore of 5 reflects complete consensus of the pose 
binding score across all scoring functions. 
 GRID Contouring 
Peter Goodford’s program, Grid,21 was employed to discover sites of potentially 
strong binding interaction between a target and probe.  A number of single atom and 
multi-atom probes were selected to best reflect the functional group characteristics of 
serotonin and the ligands of interest. A box of dimensions (topx,y,z; botx,y,z) was 
generated around the two sites of interest on the receptor (see appendix). The resolution 
(number of grid points at which to calculate the interaction energy between probe and 
target) was set to (0.33Å). The LEAU parameter was set to 1 where the probe contained 
2 or more hydrogen bond donor/acceptors, otherwise it was 0. Other settings were left at 
default values. The following probes were used: water (OH2), aromatic carbon (C1=), 
methyl carbon (C3), phenolic hydroxyl oxygen (O1), alkyl hydroxyl oxygen (OH), 
carbonyl oxygen O, hydrophilic (DRY) and amphipathic (BOTH). 
 
 
 
188 
 References 
 
1. Hesketh P. Chemotherapy-induced nausea and vomiting. N Engl J Med. 
2008;358:2482 - 2494. 
2. Thompson AJ, Lummis SCR. 5-HT(3) Receptors. Current pharmaceutical 
design. 2006;12(28):3615-3630. 
3. Nelson DR, Thomas DR. [3H]-BRL 43694 (Granisetron), a specific ligand for 5-
HT3 binding sites in rat brain cortical membranes. Biochemical pharmacology. 
1989;38(10):1693-1695. 
4. Downie DL, Hope AG, Belelli D, et al. The interaction of trichloroethanol with 
murine recombinant 5-HT3 receptors. British Journal of Pharmacology. 
1995;114(8):1641-1651. 
5. Marx W, Kiss N, Isenring L. Is ginger beneficial for nausea and vomiting? An 
update of the literature. Current Opinion in Supportive and Palliative Care. 
2015;9(2):189-195. 
6. Marx WM, Teleni L, McCarthy AL, et al. Ginger (Zingiber officinale) and 
chemotherapy-induced nausea and vomiting: a systematic literature review. Nutr. 
Rev. 2013;71(4):245-254. 
7. Bhattarai S, Tran VH, Duke CC. The stability of gingerol and shogaol in aqueous 
solutions. J Pharm Sci. 2001;90(10):1658-1664. 
189 
8. Tian-Shung W, You-Cheng W, Pei-Lin W, Ching-Yuh C, Yann-Lii L, Yu-Yi C. 
Structure and synthesis of [n]-dehydroshogaols from Zingiber officinale. 
Phytochemistry. 1998;48(5):889-891. 
9. Abdel-Aziz H, Windeck T, Ploch M, Verspohl E. Mode of action of gingerols and 
shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor 
channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 
2006;530:136 - 143. 
10. Walstab J, Kruger D, Stark T, et al. Ginger and its pungent constituents non-
competitively inhibit activation of human recombinant and native 5-HT3 
receptors of enteric neurons. Neurogastroenterol Motil. 2013;25(5):439-447, 
e302. 
11. Marx W, Ried K, McCarthy AL, et al. Ginger-Mechanism of Action in 
Chemotherapy-induced Nausea and Vomiting: A Review. Crit Rev Food Sci Nutr. 
2015:0. 
12. Davies PA. Allosteric modulation of the 5-HT3 receptor. Current opinion in 
pharmacology. 2011;11(1):75-80. 
13. Hassaine G, Deluz C, Grasso L, et al. X-ray structure of the mouse serotonin 5-
HT3 receptor. Nature. 2014;512(7514):276-281. 
14. Trattnig SM, Harpsoe K, Thygesen SB, et al. Discovery of a novel allosteric 
modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor 
signaling through a conserved transmembrane intersubunit site. The Journal of 
biological chemistry. 2012;287(30):25241-25254. 
190 
15. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: 
allosteric transitions and therapeutic targets in the nervous system. Nature 
reviews. Drug discovery. 2009;8(9):733-750. 
16. Del Cadia M, De Rienzo F, Weston DA, Thompson AJ, Menziani MC, Lummis 
SC. Exploring a potential palonosetron allosteric binding site in the 5-HT(3) 
receptor. Bioorganic & medicinal chemistry. 2013;21(23):7523-7528. 
17. Thompson AJ, Lester HA, Lummis SC. The structural basis of function in Cys-
loop receptors. Quarterly reviews of biophysics. 2010;43(4):449-499. 
18. Thompson AJ. Recent developments in 5-HT3 receptor pharmacology. Trends in 
pharmacological sciences. 2013;34(2):100-109. 
19. Ueta K, Suzuki T, Sugimoto M, Uchida I, Mashimo T. Local anesthetics have 
different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg 
Anesth Pain Med. 2007;32(6):462-470. 
20. SYBYL-X 2.1 [computer program]. 1699 South Hanley Rd., St. Louis, Missouri, 
63144, USA.: Tripos International. 
21. Goodford PJ. A computational procedure for determining energetically favorable 
binding sites on biologically important macromolecules. Journal of medicinal 
chemistry. 1985;28(7):849-857. 
 
 
 
191 
 The concentration of major active constituents within 
commercial ginger products using reverse phase-high 
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 Abstract 
Background: The rhizome of ginger (Zingiber officinale) contains many bioactive 
compounds, primarily gingerols and their degradation products, shogaols. Studies suggest 
that these compounds could exert a beneficial effect on the symptoms of several chronic 
conditions (e.g. diabetes, arthritis) and in the reduction of nausea associated with morning 
and motion sickness, and chemotherapy. However, it is unknown if ginger supplements 
and food products contain sufficient quantities of these active ingredients to achieve a 
therapeutic effect. 
Aim: The aim of this study was to determine the concentration of [6]- [8]- and 
[10]- gingerol and [6]- and [10]-shogaol within 20 commercially available ginger 
products including ginger dietary supplements, ginger spices (ground dried ginger) and 
ginger-containing drinks and food products.  
Method: Samples were extracted prior to separation by reverse phase-high 
performance liquid chromatography. UV detection was conducted at 205nm. Component 
peaks were identified by retention time of a set of standards. 
Results: Per gram, ginger supplements, particularly the standardized extracts, 
contained the greatest concentration of measured compounds (2.60±1.38 mg), while the 
concentration of compounds within spices (1.86± 1.35 mg), beverages (0.32± 0.21 mg), 
confectionary (0.09± 0.07 mg), and teas (0.03± 0.0002 mg) was considerably lower. 
When the concentration of compounds was measured per standardised serve, four ginger 
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confectionary and beverage products contained total gingerol and shogaol concentrations 
that were similar to the analyzed dietary supplement.  
Conclusion: The results of this study demonstrate that per standardised serve, 
certain beverages and confectionary contained similar or greater concentrations of the 
primary bioactive compounds of ginger compared to a selection of supplements. Future 
clinical trials investigating ginger should ensure that the consumption of other ginger 
products are monitored so as to avoid confounding results. In addition, inconsistent 
concentrations of active compounds within various ginger supplements demonstrate the 
need for standardized extracts with concentrations that have been confirmed using 
technologies such as high performance liquid chromatography prior to undertaking 
clinical trials of ginger to ensure sufficiently potent interventions.  
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 Introduction 
The rhizome of ginger (Zingiber officinale) contains many bioactive compounds. 
The gingerol class of compounds is the primary bioactive element within the non-volatile, 
pungent component of ginger. Shogaols are the degradation product of gingerols. These 
are present in low concentrations in fresh ginger but increase when gingerols are exposed 
to heat, due to the presence of the -hydroxy ketone group in the gingerol structure.1 The 
shogaols and gingerols are differentiated by the presence of either a hydroxyl group on 
the alkyl chain (gingerols) or oxidation of the hydroxyl group for a double bond 
(shogaols, Figure 7-1). These compounds have been studied in clinical and pre-clinical 
studies for their effect on several chronic conditions (e.g. diabetes and arthritis). 2-4 The 
potentially beneficial effect of ginger on nausea has also been an area of significant 
research interest. A growing body of clinical trials has provided preliminary support for 
its use in multiple types of nausea such as motion sickness, morning sickness and 
chemotherapy-induced nausea and vomiting.5-7 Studies that have investigated the 
antioxidant, anti-inflammatory, and chemo-preventive effect of individual compounds 
contained in ginger have reported different levels of activity depending on the chain 
length and presence of an alpha, beta-unsaturated ketone group. For example, when 
several gingerol and shogaol compounds were compared, Dugasini et al.8 reported [6]-
shogaol to be the most potent inhibitor of inflammation and reactive oxygen species 
production and [10]-gingerol to be the most potent gingerol.  
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Figure 7-1 Chemical structures of gingerols (A) and shogaols (B). 
A, n = 0, 2, 4 corresponds to [6]-, [8]- and [10]- gingerol. In image B, n = 0, 4 corresponds to [6] 
and [10]- shogaol. 
Because of purported medicinal effects, ginger products are often used by the 
general population as complementary medicines and are sometimes recommended by 
healthcare professionals as adjuvants to standard therapy.9-11 However, there are currently 
few studies that have investigated the concentration of active compounds in commercially 
available products, thereby providing a reliable guide to appropriate use of these 
products.12,13 Due to the increasing public use of complementary treatments such as 
dietary supplements, information regarding the potency of available ginger preparations 
will also be of interest to healthcare professionals seeking these products for their 
adjuvant medicinal properties to determine their potential to produce side effects and 
interactions. Due to the differing biological activity of the gingerol and shogaol 
compounds, it is also prudent to measure the concentration of each of these individual 
compounds within widely available ginger products. 
The aim of this study was to determine the concentration of [6]-, [8]- and [10]- 
gingerol and [6]- and [10]-shogaol within commercially available ginger products, 
including dietary supplements and ginger-containing drinks and food products using 
Reverse Phase-High Performance Liquid Chromatography (RP-HPLC). 
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 Methods 
 Chemicals and Materials 
HPLC grade water, methanol, ethyl acetate, and acetonitrile were purchased from 
ThermoFisher (Massachusetts, USA) and Sigma Aldrich (Missouri, USA). [6]- [8]- and 
[10]- gingerol and [6]- and [10]-shogaol standards (Table 7-1) were purchased from 
Chromadex (Irvine, CA, U.S.A). Ginger products were purchased from one local 
supermarket (Gold Coast, Australia) and one online store (based in New Zealand) in 
April, 2014. In addition, one supplement was supplied by the respective manufacturer for 
use in this study. In total, 20 products were purchased, including dietary supplements, 
beverages, spices (ground ginger), teas, and confectionary.  
Table 7-1 Physical properties of analyzed compounds 
Compound IUPAC nomenclature Chemical 
Formula 
MW cLogP* 
[6]-gingerol (5S)-5-hydroxy-1-(4-hydroxy-3-
methoxyphenyl)decan-3-one 
C17H26O4 292.37 2.489 
[8]-gingerol (5S)-5-hydroxy-1-(4-hydroxy-3- 
methoxyphenyl)-3-dodecanone 
C19H30O4 320.42 3.547 
[6]-shogaol (E)-1-(4-hydroxy-3-
methoxyphenyl)dec-4-en-3-one 
C17H24O3 276.37 3.811 
[10]-gingerol (5S)-5-hydroxy-1-(4-hydroxy-3- 
methoxyphenyl)-3-tetradecanone  
C21H34O4 348.48 4.605 
[10]-shogaol (E)-1-(4-hydroxy-3-
methoxyphenyl)tetradec-4-en-3-
one 
C21H32O3 322.48 6.027 
(*Calculated logP obtained from SYBYLX-2.1) 
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 Sample preparation 
Due to the variety of types of ginger products analyzed, two extraction protocols 
were required. All samples were prepared in triplicate. Percentage yield from each 
extraction protocol was determined by conducting each extraction protocol with a 0.08 
mg/ml standard mix.  
 Ethyl acetate extraction  
In order to analyze the ginger supplements, biscuit, and spices, ethyl acetate 
(10mL) was added to 500mg samples of spices, pierced supplements or crushed biscuit. 
Samples were vortexed then sonicated for 30 minutes using a CamLab TransSonic 
T310 sonicator. Samples were centrifuged (20 minutes at 2500rpm and 25 degrees 
Celsius) using a Beckman Coulter Allegra X-15R centrifuge. The supernatant was 
subjected to second pass extraction using an additional ethyl acetate (10 mL). The 
supernatants of both extractions from each product were combined and evaporated to 
dryness. The samples were reconstituted in methanol (1.5ml) and stored at 4ºC. 
Serving sizes for the supplements and biscuit were in accordance with suggested 
serving sizes by the manufacturer. The serving size for the spices was set at one gram. 
 Liquid/liquid extraction 
Beverage samples (50ml, degassed) and confectionary samples (500mg) were 
diluted in HPLC water (15ml). For the tea products, three tea bags were infused in HPLC-
grade water (50ml, room temperature) for three minutes. All samples were left overnight 
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and then extracted in ethyl acetate (10ml). A second pass extraction was conducted. The 
supernatants of both extractions from each product were combined and evaporated to 
dryness. The samples were reconstituted in methanol (1.5ml) and stored at 4ºC.  
The serving size of the beverages was set at 250ml and confectionary serving size 
was defined as 5g, as this was found to be the approximate weight of a single piece of 
confectionary.  
 Standard preparation 
Stock solutions (10mL) of each standard were prepared from the 5mg material 
supplied by the manufacturer Chromadex (Irvine, CA, U.S.A). A 0.4 mg/mL stock 
solution that contained each standard was prepared. A dilution series of the standard mix 
were prepared as needed between 0.50 ug/mL to 200 ug/mL. Working standards were 
prepared in the range of 0.0005 to 0.2 mg/mL and stored at 4ºC.  
 HPLC analysis  
Ginger samples were separated on a Waters Alliance e-2695 Separations System 
RP-HPLC and detected with a 2489 Dual-Beam UV detector. A 150x4.6mm C-18 
reversed phase column (Luna C18 5µM; Phenomenex, USA) was fitted with a guard 
column. 
The mobile phase consisted of HPLC-grade water (A) and acetonitrile (B) at 
starting conditions of 90% A. Analytical conditions included an injection volume of 
10µL, flow rate of 1.5ml per minute and a column temperature of 27ºC. A binary gradient 
elution system was applied as follows: 0.0–1.85 min, 10–50% B; 1.86–7.88 min, 55% B; 
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7.89–11.59 min, 66% B; 12–17.6 min, 100% B. 17.61-25 min 10% B. The ultraviolet 
absorbance was measured at 205nm. Peak identification was based on the retention time 
of the standards. 
 Results 
Figure 7-2 Standard curves of each analyzed compound 
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The standard curves for [6]-gingerol, [6]-shogaol, [8]-gingerol, [10]-shogaol, and 
[10]-gingerol (Figure 7-2) were linear from 10.0 to 1000.0 g/mL (correlation coefficient 
for each compound were ≥0.9992).  
Figure 7-3 depicts a sample chromatogram for the standard mix and a sample from 
each product category. In accordance with the lipophilicity of each compound (Table 
7-1), the elution order for analysis was: [6]-gingerol, [8]-gingerol, [6]-shogaol, [10]-
gingerol, [10]-shogaol. 
Figure 7-3 Sample chromatogram from each product category and standard mix 
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The results demonstrated that the liquid/liquid extraction procedure provided a 
greater yield when compared to the ethyl acetate extraction procedure for all compounds 
except for [6]-gingerol (Table 7-2).   
Table 7-2 Percentage yield of liquid/liquid and ethyl acetate extraction procedure 
 6G (%) 8G (%) 6S (%) 10G (%) 10S (%) 
Liquid/Liquid 
extraction 25 74 76 59 74 
Ethyl acetate 
extraction 32 33 33 28 37 
The mean concentration of [6]-gingerol, [6]-shogaol, [8]-gingerol, [10]-gingerol 
and [10]-shogaol of all ginger products are tabulated per gram (Table 7-3) and per serving 
(Table 7-4) after they had been adjusted by the percentage yield as determined by the 
validation protocol 
In all samples, [6]-gingerol was consistently detected in the highest concentration 
when compared to all other compounds investigated while [8]-gingerol and [10]-shogaol 
were found in the lowest concentration. In descending order, the total concentration of 
each compound from all analyzed products was [6]-gingerol (67.420mg), [6]-shogaol 
(20.175mg), [10]-gingerol (15.517mg), [10]-shogaol (7.784mg), [8]-gingerol (7.575mg). 
This order of [6]-gingerol, [6]-shogaol, and [10]-gingerol remained consistent for each 
product; however, some products contained slightly higher concentrations of [8]-gingerol 
than [10]-shogaol.  
.
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Table 7-3. Mean ± standard deviation concentration of [6]-gingerol, [6]-shogaol, [8]-gingerol, [10]-gingerol and [10]-shogaol in 
analyzed products per gram. 
Supplements  Total 
(mg/capsule) 
6-gingerol 
(mg/L)  
8-gingerol 
(mg/L)  
10-gingerol 
(mg/L) 
6-shogaol 
(mg/L)  
10-shogaol 
(mg/L)  
Nature’s Own Travel Well 1000 0.66 0.47±0.02 0.00±0.00 0.02±0.01 0.14±0.01 0.03±0.00 
Lifestream Ginger capsules 7.44 4.59±0.73 0.35±0.20 0.88±0.15 1.22±0.21 0.38±0.07 
Nature's Sunshine Ginger  7.02 2.32±0.03 0.43±0.02 0.89±0.02 2.20±0.05 1.17±0.04 
BlueBonnet Ginger root extract 23.57 12.76±0.01 1.74±0.01 2.89±0.01 4.63±0.01 1.55±0.01 
Blackmores Travel Calm Ginger 7.36 4.35±0.15 0.61±0.02 1.00±0.04 1.03±0.03 0.37±0.02 
Helsinn Integrative Care 
Ginpax 40mg soft gel capsule 
14.46 11.08±1.49 0.14±0.04 2.77±0.44 0.02±0.01 0.44±0.05 
Spices  Total 
(mg/g) 
6-gingerol 
(mg/L)  
8-gingerol 
(mg/L)  
10-gingerol 
(mg/L) 
6-shogaol 
(mg/L)  
10-shogaol 
(mg/L)  
Woolworth's Ginger Spice Powder 13.42 5.64±0.02 1.34±0.00 3.11±0 2.13±0.00 1.19±0.0 
Coles Ginger Spice Powder 12.93 5.50±0.17 1.21±0.04 3.12±0.1 2.01±0.0 1.09±0.04 
Hertz Ginger spice 1.53 0.88±0.13 0.14±0.02 0.22±0 0.21±0.03 0.08±0.01 
Beverages  Total 
(mg/L) 
6-gingerol 
(mg/L)  
8-gingerol 
(mg/L)  
10-gingerol 
(mg/L) 
6-shogaol 
(mg/L)  
10-shogaol 
(mg/L)  
Coles Dry Ginger Ale 1.94 1.58±0.66 0.04±0 0.18±0.1 0.10±0.08 0.04±0.04 
Bundaberg Diet Ginger Beer 0.61 0.53±0.02 0.02±0.00 0.00±0 0.05±0.0 0.00±0.0 
Saxby Dry Ginger Beer 2.20 1.85±0.21 0.04±0.03 0.14±0 0.11±0.01 0.06±0.01 
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Cascade Ginger Beer 3.23 2.86±0.41 0.07±0.04 0.13±0 0.12±0.01 0.04±0.0 
Tiger Ginger Beer 0.86 0.50±0.66 0.04±0.03 0.18±0.1 0.10±0.08 0.04±0.04 
Confectionary  Total 
(mg/L) 
6-gingerol 
(mg/L)  
8-gingerol 
(mg/L)  
10-gingerol 
(mg/L) 
6-shogaol 
(mg/L)  
10-shogaol 
(mg/L)  
Gin Gins Candies 0.68 0.60±0.05 0.02±0.00 0.02±0 0.03±0.0 0.01±0.0 
Buderim Crystallised Ginger 0.70 0.63±0.06 0.00±0.00 0.02±0 0.04±0.0 0.00±0.0 
Buderim Ginger bears 0.34 0.32±0.02 0.01±0.00 0.00±0 0.01±0.00 0.00±0 
Arnotts GingerNut Biscuits 0.02 0.02±0.00 0.00±0.00 0.00±0 0.00±0 0.00±0 
Teas Total 
(mg/L) 
6-gingerol 
(mg/L) 
8-gingerol 
(mg/L) 
10-gingerol 
(mg/L) 
6-shogaol 
(mg/L) 
10-shogaol (mg/L) 
Twinings Ginger & Lemon Tea 0.13 0.13±0.00 0.00±0.00 0.00±0 0.00±0 0.00±0 
Nerada Ginger & Lemon Tea 0.13 0.13±0.01 0.00±0.00 0.00±0 0.00±0 0.00±0 
  
204 
The concentration of analyzed compounds, particularly within the beverages, 
varied considerably (Figure 7-4). When compared per gram, with one exception, 
ginger supplements (particularly those that were made from standardized extracts) 
contained the largest concentration of analyzed compounds when compared to all 
other ginger products. Ginger spices also tended to contain a large concentration of 
compounds per gram while the ginger biscuit contained the lowest amount. When the 
concentration of each product was compared per serve, standardized extracts still 
contained some of the largest concentration of compounds. Excluding the tea samples, 
products from other categories (i.e. beverages, spices, and confectionary) contained 
concentrations of compounds similar to the standardized extracts.  
Figure 7-4 Total mean gingerol and shogaol content of ginger products per gram 
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Table 7-4 Mean ± standard deviation concentration of [6]-gingerol, [6]-shogaol, [8]-gingerol, [10]-gingerol and [10]-shogaol in 
analyzed products per serving size. 
Supplements  Estimated serving size (g)  Total 
(Per serving) 
6-gingerol 
(Per serving) 
8-gingerol 
(Per serving) 
10-gingerol 
(Per serving) 
6-shogaol 
(Per serving) 
10-shogaol 
(Per serving) 
Nature’s Own Travel Well 1000 0.85g 1.68 1.19±0.05 0.00±0 0.36±0.03 0.05±0.026 0.08±0 
Lifestream Ginger capsules 0.66g 18.92 11.68±1.86 0.90±0.51 3.11±0.53 2.25±0.381 0.98±0.17 
Nature's Sunshine Ginger  0.60g 12.58 4.16±0.05 0.76±0.03 3.95±0.1 1.60±0.037 2.10±0.07 
BlueBonnet Ginger root extract 0.52g 36.43 19.72±0.02 2.69±0.02 7.15±0.02 4.46±0.016 2.39±0.02 
Blackmores Travel Calm 
Ginger 
0.51g 11.16 6.60±0.22 0.92±0.03 1.56±0.05 1.51±0.055 0.57±0.03 
Helsinn Integrative Care 
Ginpax 40mg soft gel capsule 
0.24g 21.68 16.63±2.23 0.21±0.05 0.03±0.02 4.16±0.665 0.65±0.08 
Spices   Total 
(Per serving) 
6-gingerol 
(Per serving) 
8-gingerol 
(Per serving) 
10-gingerol 
(Per serving) 
6-shogaol 
(Per serving) 
10-shogaol 
(Per serving) 
Woolworth's Ginger Spice 
Powder 
1g 40.25 16.92±0.05 4.03±0 9.34±0 6.39±0.007 3.57±0.01 
Coles Ginger Spice Powder 1g 38.80 16.50±0.52 3.64±0.12 9.35±0.26 6.04±0.178 3.28±0.11 
Hertz Ginger spice 1g 4.58 2.64±0.38 0.41±0.06 0.67±0.1 0.63±0.103 0.23±0.04 
Beverages  
  
  
  
Total 
(Per serving) 
6-gingerol 
(Per serving) 
8-gingerol 
(Per serving) 
10-gingerol 
(Per serving) 
6-shogaol 
(Per serving) 
10-shogaol 
(Per serving) 
Coles Dry Ginger Ale 250ml 4.56 3.98±0.13 0.18±0.01 0.03±0 0.35±0.016 0.01±0 
Bundaberg Diet Ginger Beer 250ml 16.50 13.89±1.61 0.31±0.2 1.02±0.12 0.80±0.083 0.47±0.06 
Saxby Dry Ginger Beer 250ml 24.23 21.49±3.05 0.51±0.31 1.01±0.13 0.90±0.077 0.32±0.03 
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Cascade Ginger Beer 250ml 6.48 3.76±4.98 0.30±0.24 1.32±0.89 0.77±0.61 0.33±0.28 
Tiger Ginger Beer 250ml 5.09 4.48±0.41 0.14±0.02 0.18±0.02 0.22±0.037 0.07±0.02 
Confectionary 
  
  
  
Total 
(Per serving) 
6-gingerol 
(Per serving) 
8-gingerol 
(Per serving) 
10-gingerol 
(Per serving) 
6-shogaol 
(Per serving) 
10-shogaol 
(Per serving) 
Gin Gins Candies 12g 25.12 22.85±2.20 0.15±0.03 0.65±0.07 1.40±0.141 0.08±0.02 
Buderim Crystallised Ginger 25g 5.16 4.74±0.25 0.16±0.01 0.00±0.00 0.19±0.008 0.06±0 
Buderim Ginger bears 48g 11.88 10.38±0.84 0.58±0.02 0.45±0.02 0.43±0.025 0.04±0 
Arnotts GingerNut Biscuits 1 biscuit 2.14 1.28±0.03 0.14±0.00 0.29±0.00 0.24±0 0.19±0.03 
Teas     Total 
(Per serving) 
6-gingerol 
(Per serving) 
8-gingerol 
(Per serving) 
10-gingerol 
(Per serving) 
6-shogaol 
(Per serving) 
10-shogaol 
(Per serving) 
Twinings Ginger & Lemon Tea 1 teabag 0.15 0.11±0.01 0.01±0.00 0.01±0.00 0.01±0.00 0.01±0.00 
Nerada Ginger & Lemon Tea 1 teabag 0.04 0.04±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
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 Discussion 
In this study, the concentration of the principle gingerol and shogaol compounds 
was analyzed in 20 commercially available ginger products. The amount of each 
compound was relatively consistent across all products with [6]-gingerol and its 
degradation product, [6]-shogaol detected in the greatest concentrations and [8]-gingerol 
and [10]-shogaol in the smallest concentrations. The greater concentration of [6]-gingerol 
is to be expected as [6]-gingerol is the primary non-volatile pungent compound within 
the oleoresin of ginger.  
This analysis also demonstrated a substantial variation in bioactive compounds 
between products. Per gram, ginger supplements, particularly the standardized extracts, 
contained the greatest concentration of measured compounds, while the concentration of 
compounds within other product categories varied considerably. These findings are 
similar to the results of previously published analyses by other groups.12,13 The results of 
the current study expand on these previous studies by increasing the range of analyzed 
products and by including an additional compound, [10]-shogaol, in the analysis. [10]-
shogaol has not been extensively studied; however, in vitro research suggests that it exerts 
anti-inflammatory properties and might aid wound healing14,15 Furthermore, as part of the 
study protocol, the yield of the two extraction procedures used in this study was validated 
using a mix of ginger standards of a predetermined quantity. This processes improves the 
accuracy of our results and is a significant strength as this procedure has not been 
conducted consistently in previous studies. 
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Previous studies reported that the total concentration of active components within 
commercially available dietary supplements varied considerably from the manufacturers’ 
claims.16,17 In contrast, we found that the concentrations of gingerols and shogaols in three  
of the standardized extracts included in this analysis were consistent with those published 
by the manufacturers. 
When analysed in terms of the approximate concentration that would be 
consumed in one recommended serve of each product, there were dietary supplements as 
well as some confectionary and beverage products that contained large concentrations of 
the analysed compounds. Ginger ales and confectionary are often recommended by health 
professionals to treat nausea. Although the smallest effective dose of ginger is yet to be 
elucidated, these results demonstrate that it is feasible to achieve an intake of the principle 
active compounds of ginger by consuming certain commercially available products that 
is comparable to the majority of dietary supplements analyzed in this study. For example, 
a large RCT (N=576) reported that two dosages of a standardized ginger extract, 0.5 and 
1g, were effective in reducing chemotherapy-induced nausea and vomiting.18 The 
effective daily dose of gingerol and shogaol for each dosage was 17mg and 34mg, 
respectively. In our analysis, four confectionary and beverage products contained a total 
gingerol and shogaol concentration similar to the dosage used by Ryan et al.18 and the 
dietary supplements included in the current analysis.  Therefore, these results also suggest 
that it is indeed feasible to attain equivalent amounts of gingerol and shogaols through 
dietary intake as indicated by in previous clinical trials.18 This demonstrates the need for 
the consumption of ginger products to be monitored during future clinical trials 
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investigating ginger because the consumption of additional ginger products is likely to 
influence the effective total intake of ginger compounds. Furthermore, previous studies 
have demonstrated a potential ceiling effect with higher doses (2g) of ginger 
supplementation resulting in less or no control of symptoms compared to lower doses.2 
The consumption of additional ginger products could potentially increase the total 
consumption of active compounds in excess of a therapeutic dosage.  
In addition, as previously noted by our group as well as other authors, the lack of 
analysis of ginger preparations and the lack of standardized extracts used in clinical trials 
could be responsible for the sometimes conflicting results reported due to the variability 
in active compounds.2,13,19 The results of this study support this concern as there was a 
large difference in the detected concentration of each investigated product, including the 
ginger supplements. Hence, the measurement of the concentration of the active 
compounds within ginger products is indicated in future trials. 
It should be noted that ginger contains a wide variety of bioactive compounds that 
have potentially beneficial properties.20 Therefore, while this study was able to determine 
the concentration of an expanded range of these principle compounds compared to 
previous studies, other potentially important ginger compounds were not able to be 
analyzed due to the lack of commercial standards. Investigation of the concentrations of 
other compounds such as zingibain and dehydroshogaols in commercial products is 
recommended in future studies as these compounds have also demonstrated biological 
activity relevant to chronic conditions.20 A second limitation of this study is that some of 
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the samples used were purchased commercially from nearby stores. The concentration of 
compounds could have been influenced by factors such as storage conditions; therefore, 
the results of this analysis might not be representative of the product when stored in 
different conditions. There is also the possibility that there was a variation in the 
concentration of analyzed compounds between different batches of the same product, 
particularly if different batches are sourced from multiple locations. This study analyzed 
a single sample of each product and so future trials may benefit from analyzing multiple 
batches of the same product. 
 Conclusion 
Using RP-HPLC technology, an analysis of 20 commercially available ginger 
products demonstrated wide variation in the total amount of gingerols and shogaols 
within different ginger products, with standardized ginger extracts and spices containing 
the largest concentration of compounds. Biscuits and teas contained the least 
concentrations of the relevant compounds. When calculated by serving, certain beverages 
and confectionary contained similar or greater concentrations of the analysed compounds 
to the ginger supplements; hence future clinical trials investigating ginger formulations 
should ensure that the consumption of other ginger products is monitored so as to not 
confound the study results. In addition, the inconsistent concentration of active 
compounds within ginger supplements demonstrates the need for standardized extracts 
and the use of RP-HPLC in clinical trials to ensure sufficiently potent interventions. 
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 Can ginger ameliorate chemotherapy-induced 
nausea? Protocol of a randomized double blind, 
placebo-controlled trial 
Using the information gleaned from the systematic literature review in Chapter 2, 
this chapter details the protocol and methods of a randomized, double-blind, placebo-
controlled clinical trial. This chapter was published in BioMed Central Alternative and 
Complementary Medicine (2014 Impact factor: 2.02) and received a ‘Highly Accessed’ 
classification due to the high volume of views (>1000) within the first months of 
publication. It had been cited three times (07/08/2015; Scopus) at the time of submission 
of this thesis. 
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 Abstract 
 Background 
Preliminary research shows ginger may be an effective adjuvant treatment for 
chemotherapy-induced nausea and vomiting but significant limitations need to be 
addressed before recommendations for clinical practice can be made. 
 Methods/design 
In a double–blinded randomised-controlled trial, chemotherapy-naïve patients 
will be randomly allocated to receive either 1.2 g of a standardised ginger extract or 
placebo per day. The study medication will be administrated as an adjuvant treatment to 
standard anti-emetic therapy and will be divided into four capsules per day, to be 
consumed approximately every 4 hours (300 mg per capsule administered q.i.d) for five 
days during the first three cycles of chemotherapy. Acute, delayed, and anticipatory 
symptoms of nausea and vomiting will be assessed over this time frame using a valid and 
reliable questionnaire, with nausea symptoms being the primary outcome. Quality of life, 
nutritional status, adverse effects, patient adherence, cancer-related fatigue, and CINV-
specific prognostic factors will also be assessed. 
 Discussion 
Previous trials in this area have noted limitations. These include the inconsistent 
use of standardized ginger formulations and valid questionnaires, lack of control for 
anticipatory nausea and prognostic factors that may influence individual CINV response, 
and the use of suboptimal dosing regimens. This trial is the first to address these issues 
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by incorporating multiple unique additions to the study design including controlling for 
CINV-specific prognostic factors by recruiting only chemotherapy-naïve patients, 
implementing a dosing schedule consistent with the pharmacokinetics of oral ginger 
supplements, and independently analysing ginger supplements before and after 
recruitment to ensure potency. Our trial will also be the first to assess the effect of ginger 
supplementation on cancer-related fatigue and nutritional status. Chemotherapy-induced 
nausea and vomiting are distressing symptoms experienced by oncology patients; this 
trial will address the significant limitations within the current literature and in doing so, 
will investigate the effect of ginger supplementation as an adjuvant treatment in 
modulating nausea and vomiting symptoms. 
 Trial registration 
ANZCTR.org.au Identifier: ACTRN12613000120774. 
 Keywords 
Ginger, CINV, Nausea 
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 Background 
 Chemotherapy-induced nausea and vomiting places a significant burden on the 
patient 
Despite the efficacy of cytotoxic interventions in the treatment of cancer, these treatments 
are often accompanied by a variety of adverse effects. Chemotherapy-induced nausea and 
vomiting (CINV) is a relatively common side effect of this treatment and has been 
repeatedly rated as one of the most distressing symptoms in this setting [1,2]. While there 
have been multiple classes of medications developed to treat this symptom, nausea and 
vomiting persists in a large number of patients. The incidence of vomiting has been 
significantly reduced through combinations of anti-emetic medications, but efforts to 
control nausea have been less successful. Affecting upwards of 60% of patients [3], CINV 
has also been shown to significantly impact on patient quality of life (QoL). Moreover, 
although it happens rarely, CINV can be so severe that it can lead to dose reduction or 
treatment discontinuation, and subsequently increase the risk of disease progression [3-
5]. 
 Ginger extract appears beneficial in treating chemotherapy-induced nausea 
and vomiting 
Ginger (Zingiber officinale) has been used for centuries by many cultures as a folk-
remedy for gastrointestinal-related conditions [6]. Previous clinical trials have provided 
support for its use in the treatment of nausea in multiple settings including CINV [7-9] 
and two previous clinical trials have found ginger supplementation to be as effective as 
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metoclopramide in reducing symptoms of CINV [10,11]. Furthermore, animal and cell 
culture data have demonstrated a viable mechanism of action for its anti-nausea effect 
[12]. 
The rhizome of ginger possesses an array of bioactive compounds (i.e. gingerols, 
shogaols, zingiberene, zingerone, and paradol) that may be responsible for the reported 
beneficial effects of ginger use. Cell culture and animal studies suggest that these 
constituents stimulate oral and gastric secretions [13], regulate gastrointestinal motility 
[14,15], interact with the 5-HT3 and NK-1 receptors implicated in the CINV 
reflex[16,17], and assist in rescuing intracellular redox metabolism [18]. Of note, the 
interaction of ginger with 5-HT3 and NK-1 receptors is particularly promising as the 
success of modern anti-emetic medications (i.e. 5-HT3 and NK-1 antagonists) are due to 
similar interactions with these same receptors. Furthermore, animal studies provide 
preliminary support for the role of ginger supplementation in the prevention of cisplatin-
induced emesis [19,20]. 
A recent review found seven clinical studies have investigated ginger supplementation in 
this setting [21]. These studies present a contentious picture of the efficacy of ginger as 
an anti-CINV treatment in patients administered chemotherapy, with three demonstrating 
a positive effect, two in favour but with caveats, and two reporting no effect on measures 
of CINV. However, multiple limitations were identified within the existing literature that 
need to be resolved before clinical recommendations can be made. 
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 Chemotherapy-induced nausea and vomiting poses a significant risk to 
patients’ nutritional status and treatment outcomes 
Previous studies report that approximately 50% of patients in the oncology setting are 
malnourished [22]. Malnutrition is a serious concern for oncology patients as it can 
significantly and severely affect QoL and treatment-related outcomes. Malnutrition can 
result in compromised immune function, reduced functional status, decreased 
performance status, and impaired treatment response [23-25]. Nausea and vomiting in 
this setting are of significant concern in patients diagnosed with cancer, as these 
symptoms can adversely affect dietary intake, increasing the risk of malnutrition during 
treatment. 
It is feasible then to suggest that interventions that improve nausea and vomiting during 
chemotherapy may consequentially aid in improving and maintaining nutritional status. 
However, to date, there are no studies that have investigated the influence of ginger on 
patient nutritional status in this setting. Therefore, this protocol assesses nutritional status 
after each cycle using the validated questionnaire, the Patient Generated- Subjective 
Global Assessment, performed by an accredited dietitian. 
 Chemotherapy-induced nausea and vomiting might exacerbate or be 
physiologically related to chemotherapy-related fatigue 
Like nausea and vomiting, chemotherapy-related fatigue (CRF) is both highly prevalent 
in this population and can significantly influence the patient’s quality of life [26,27]. The 
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results from a number of studies that have investigated CRF have found nausea and 
vomiting to be a strongly associated set of symptoms [28]. The reason for this is not fully 
elucidated but due to this significant correlation, treatment options that have been 
traditionally targeted at treating CINV should be further investigated as these modalities 
may also provide benefit to patients experiencing CRF. Using the Functional Assessment 
of Chronic Illness Therapies- Fatigue (FACIT-F) subscale, our study will be the first to 
investigate the effect of adjuvant ginger supplementation on self-reported measures of 
fatigue. 
 Comprehensive, validated questionnaires are required to assess chemotherapy-
induced nausea and vomiting 
In order to assess CINV, the instrument used needs to be able to accurately capture 
the relevant aspects of CINV. Nausea, vomiting and retching, while temporally related, 
are distinct phenomena and therefore, are required to be measured as separate entities. In 
addition to this, a well-developed questionnaire should be able to provide a detailed 
picture of each phenomena. Widely used questionnaires in this setting include questions 
that measure multiple domains of CINV such as the severity, the perceived intensity of 
CINV; frequency, the amount of times CINV occurred over a time period; duration, the 
length of time that these symptoms persisted; and distress, the perceived burden that these 
symptoms place on the patients daily function and QoL [29]. 
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There have been several questionnaires developed for the use of measuring nausea 
and vomiting, not only in the chemotherapy setting but also in other areas. A recent 
review identified 25 instruments that have been developed to measure nausea and 
vomiting in the clinical setting [29]. The authors used a list of criteria to determine the 
scope of nausea and vomiting that each questionnaire was able to capture. Of all 
questionnaires reviewed, no one tool fulfilled all criteria; however, the Index of Nausea, 
Vomiting, and Retching (INVR) tool was found to best meet this criteria [30]. 
A recent review found that only one previous study that investigated the effect of 
ginger on CINV used the INVR questionnaire [21]. This poses a significant limitation to 
the current literature as it is plausible that in these previous studies, ginger may have 
provided some benefit to domains of CINV that were not captured by the questionnaires 
employed in these respective studies. 
Therefore, in order to ensure that our study is able to capture all relevant factors 
involved in CINV, it is important to use a questionnaire that is both validated and 
comprehensive and so it was decided that this study will incorporate the INVR 
questionnaire. 
 Predisposing factors influence individual susceptibility to chemotherapy-
induced nausea and vomiting 
Multiple factors are reported to influence the individual risk of a patient 
developing CINV [31]. These factors relate not only to the treatment protocol but also the 
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patient’s lifestyle, mental state, and previous experience with nausea and vomiting in 
other settings [32-34]. Consequently, while the emetogenicity of the treatment protocol 
is the major determinant of CINV risk, a patient with multiple predisposing factors can 
experience significant levels of CINV despite being prescribed a low emetogenic 
chemotherapy regimen. Of particular concern is the development of anticipatory nausea 
and vomiting, a conditioned response that is difficult to treat, and the gradual resistance 
to anti-emetic therapy after multiple chemotherapy cycles [35]. 
These factors represent a significant set of potential confounding variables for 
RCTs in this setting. To date, all trials in this area have recruited patients that have already 
experienced nausea and vomiting in previous chemotherapy cycles. This allows for the 
potential recruitment of patients with an already established resistance to additional anti-
emetic therapies. Furthermore, if lifestyle factors such as alcohol intake and previous 
experience of motion sickness, which have been shown to influence CINV risk, are not 
screened for, this may result in a study comprised of two groups with a predisposed 
heterogeneous response to CINV. To date, this has not been thoroughly controlled for 
and therefore, may account for some of the difference in the results between previous 
trials. We have developed a short questionnaire that aims to assess these factors and will 
be the first study to factor this into our post-study statistical analysis. 
 
224 
 Previous dosing regimens and formulations of ginger may not have been 
optimal 
In two recent studies that investigated the pharmacokinetics of multiple ginger 
compounds, it was found that these compounds have a relatively short half-life of 
approximately 1.5-3 hours [36,37]. In order to ensure that there are sufficient plasma 
levels of the active compounds throughout the day, the dosage in this study is divided 
between 4 capsules that will be consumed approximately every 4 hours. 
The dosage of 1.2 g was selected for the following reasons: 1) it is within the 
typical dosage utilised in previous literature; 2) a lower dose, divided into multiple 
capsules, might not reach adequate concentrations to be effective; and 3) concerns that 
higher doses would reduce CINV control. Previous studies indicated higher doses were 
either less effective or possibly interfered with standard anti-emetic medications [38]. 
An additional limitation in the existing literature is the inconsistent use of 
standardized ginger extracts. Of the seven studies included in a recent review, only two 
studies used a ginger formulation that had been standardised to the relevant bioactive 
compounds while the remaining five used a crude ginger powder in capsule form [21]. 
The concentration of active compounds found within preparations of ginger has been 
found to be highly variable and can be influenced by the storage, location, and type of 
processing involved in the manufacturing of a specific ginger product [39]. Due to the 
majority of previous studies using unstandardized formulations, the inconsistent results 
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reported in the literature may be attributed to the differences in compounds the 
formulations used in each study. 
To control for this limitation, we are using a ginger extract that has been 
standardised to contain 5% gingerols. We have also arranged for a sample of our ginger 
capsules to be independently analysed at the commencement and completion of our study 
to ensure the potency of the formulation. 
Incorporating the results of these studies, we are expanding on the current 
literature as the majority of previous trials have used dosing regimens that are inconsistent 
with these findings. 
 Purpose of study and objectives 
 Purpose of study 
Despite advances in anti-emetic medication, CINV continues to be a significant 
problem for many patients undergoing chemotherapy and is often rated as one of the most 
deleterious side-effects of cancer chemotherapeutic treatments. There is evidence from 
international trials that ginger formulations, in conjunction with standard anti-emetic 
medication, can be effective in the treatment of CINV. However, this therapy is not 
routinely used in oncology clinics due to its novelty and the lack of information about 
how patients will tolerate ginger in the clinical setting. 
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 Hypothesis 
It is hypothesised that in chemotherapy-naïve medical oncology patients about to 
commence treatment of any emetogenicity, adjuvant ginger supplementation compared 
with placebo will: 
1. Reduce the frequency, distress and duration of chemotherapy-induced nausea (i.e. 
acute, delayed and anticipatory) during each chemotherapy cycle (up to 3 cycles). 
2. Reduce frequency, distress and duration of chemotherapy-induced vomiting and 
retching 
3. Result in improved nutritional status, physical function and quality of life 
4. Be adhered to (>80% consumption of supplements) and well tolerated (no 
significant adverse events related to ginger supplementation). 
 Outcomes 
8.3.3.1 Primary outcomes 
 The frequency, severity, duration of acute and delayed nausea 
8.3.3.2 Secondary outcomes 
 The frequency and severity of acute and delayed vomiting 
 The frequency and severity of acute and delayed retching 
 Change in ratings of cancer-related fatigue 
 Adequacy of supplement blinding 
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 Change in nutrition status 
 Incidence and severity of symptoms associated with treatment 
 Change in quality of life 
 Change in quality of life caused by nausea and vomiting 
 Patient adherence to intervention 
 Influence of previously identified factors that affect the generation of CINV 
 Investigational plan 
 Overall study design 
This study will be a double-blinded, randomised, placebo-controlled trial. 
Outcomes will be assessed at three days prior to chemotherapy, one day prior to 
chemotherapy, on the day of chemotherapy, and during the 4 days post-chemotherapy. 
Participants will consume the study medication for 5 days per chemotherapy cycle, 
commencing on the day of chemotherapy. This will be repeated over 3 chemotherapy 
cycles. 
 Setting 
The trial will be initially conducted at the Princess Alexandra Hospital, Brisbane, 
Australia. Additional sites will be utilised if further funding is obtained. 
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 Eligibility criteria 
8.4.3.1 Inclusion criteria 
The following inclusion criteria will apply: 
 Chemotherapy-naive patients receiving chemotherapy of any emetogenicity 
level [40]. 
 >18 years old 
 Life expectancy >3 months 
 Baseline Karnofsky score >60 
 No concurrent neoplasms or illness that induces nausea independent of 
chemotherapy 
 No self-prescribed therapies or complimentary products used for nausea 
8.4.3.2 Exclusion criteria 
The following exclusion criteria will apply: 
 Patients requiring radiotherapy 
 Pregnant or lactating 
 Concurrent use of other ginger-containing supplements and ingestion of large 
quantities of ginger 
 History of adverse reactions to ginger 
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 Patients with malignancies of gastrointestinal tract / gastrointestinal diseases 
or nausea and vomiting due to reasons other than chemotherapy 
 Thrombocytopenia or patients undergoing chemotherapy that, according to 
physician discretion, is likely to cause thrombocytopenia (platelets <50 × 
10^9/L) 
 Currently prescribed warfarin or on anti-coagulant therapy 
 Study treatment 
 Ginger extract 
The experimental treatment will be a commercial ginger extract manufactured by 
Bluebonnet Nutrition [41]. This preparation is in capsule form, and is standardised to 
contain 5% gingerols. Each capsule contains 300 mg of ginger extract with 15 mg of 
active ingredient per capsule (60 mg per 1.2 g) within white gelatine capsules. 
A regimen of 4 capsules per day will be selected in order to incorporate the 
pharmacokinetics of ginger [36,37]. 
 Placebo 
The placebo capsules will be identical to the ginger capsules in appearance and 
will contain 300 mg of an inert filler. 
 
 
230 
 Independent analysis 
The ginger capsules will be independently analysed for the active compounds 
(gingerols and shogaols) by the Southern Cross Plant Science Department at Southern 
Cross University using a standardised HPLC analysis method by the US Pharmacopeia 
(USP). Three random samples will be analysed at the beginning of the trial as well as at 
the end of the trial in order to assess the stability of the bioactive ingredients. 
 Concomitant treatment 
All anti-emetic medication prescribed by the patient’s medical team, including 5-
HT3 antagonists (e.g. ondansetron), corticosteroids (e.g. dexamethasone), and NK1 
receptor antagonists (e.g. aprepitant), will be permitted during this trial. 
Participants will be advised to avoid consuming large amounts of dietary ginger 
or additional ginger capsules as well as any other adjuvant or alternative therapy for 
nausea and vomiting (excluding prescribed anti-emetic medication) during the study 
period. 
Large amounts of ginger is defined as consumption of one serve of either ginger 
ale, crystallized ginger, or ginger containing meals/products most days (4/7) of the week 
for the past month; particularly within the week before and during chemotherapy. 
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 Withdrawal criteria 
Any participant who has been randomised and then withdraws will be included in 
the study on an intention to treat basis with patient consent. If a participant withdraws 
consent, data will be collected up until their time of withdrawal. Primary outcome data 
will be collected in these participants where possible. 
Any participant who withdraws before being randomised (i.e. allocated to a 
particular study treatment) will be replaced, so that the next consenting participant 
receives the randomisation sequence and that participant’s allocated study treatment. 
 Study duration 
Participants will be enrolled in the study from the time of entry into the trial, 
through to 4 days after their third chemotherapy session. It is anticipated that it will take 
one year to recruit the necessary number of participants. 
 Treatment assignment and randomisation 
Participant numbers will be assigned sequentially to participants as soon as they 
sign the informed consent form. Participants will be randomly assigned using a computer 
generated randomisation sequence. The randomisation sequence will be kept separately 
from the study investigators and will be generated by an independent researcher. 
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 Methods 
 Recruitment 
Participants will primarily be recruited through the daily chemotherapy education 
sessions that are offered by the hospital to patients who have been recently prescribed 
chemotherapy. Additionally, oncology nursing staff and chemotherapy-scheduling staff 
will be made aware of the study and will be encouraged to refer patients who may be 
interested in the study for further screening. 
 Screening 
Patients will be assessed to ensure that they meet the inclusion and exclusion 
criteria. All patients who meet the criteria will be invited to participate in the study and 
be given a participant information sheet. This process may occur at any stage up to seven 
days prior to chemotherapy. 
At the screening, patients will be informed that if they consume large amounts of 
dietary ginger or additional ginger capsules, as well as any other adjuvant or alternative 
therapy for nausea and vomiting (excluding prescribed anti-emetic medication), that this 
should be stopped at least 1 week prior to chemotherapy. 
 
 
 
233 
 Questionnaires used 
8.10.3.1 Rhodes Inventory of Nausea, Vomiting and Retching (INVR) 
The INVR is a self-report questionnaire that measures nausea, vomiting and 
retching as separate entities based on 8 items with 5-point Likert scales [30]. The 
frequency and distress of all entities is measured as well as the duration of nausea and the 
amount of vomitus. The tool is suitable for use during each phase of CINV (i.e 
anticipatory, acute, and delayed) and is designed to measure symptoms over a 12 hour 
period; however, for the purpose of this trial, this period was extended to 24 hours to 
reduce the study burden on patients. It takes less than 5 minutes to complete. 
8.10.3.2 The Functional Living Index – Emesis – 5 Day Recall. (FLIE-5DR) 
The FLIE-5DR is a validated nausea and vomiting-specific self-reported outcome 
measure that investigates the specific impact of chemotherapy-related nausea and 
vomiting on patients’ activities of daily living [42]. It has 9 items in each of the nausea 
and vomiting scales, the first item of which rates the extent of nausea or vomiting 
experienced in the previous 5 days. The remaining items examine patients’ social, 
recreational and leisure activities, ability to do normal tasks, their enjoyment of eating 
and drinking, and the hardship caused by their nausea and vomiting on themselves and 
their carers. Each response is ranked on a seven point scale. The FLIE score is determined 
by summing the responses to the 9 questions in each scale. Therefore, the range of total 
scores possible per scale is 9 to 63, with a higher score responding to less hardship and 
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less impact of nausea or vomiting on daily life [42]. No or minimal impact on daily life 
is defined as an average FLIE item score of no more than 6 on the 7 point scale or a total 
FLIE score of more than 54 [42]. The FLIE has excellent internal reliability, with a 
Cronbach’s α > 0.90 for both sub-scales on all assessment points [43,44]. The FLIE takes 
less than 2 minutes to complete. 
8.10.3.3 CINV susceptibility questionnaire 
This questionnaire has been developed for use in this trial to determine 
participants’ predisposition to CINV. Previous research has reported several factors 
correlated with susceptibility to CINV. These include lifestyle factors (e.g. alcohol 
intake); previous experience of nausea and/or vomiting from causes other than 
chemotherapy (e.g. motion sickness, pregnancy); and participant characteristics (e.g. age, 
gender). It is estimated that the questionnaire takes approximately 5 minutes to complete. 
8.10.3.4 Edmonton Symptom Assessment System (ESAS) 
The ESAS is a validated and reliable tool used to assess the severity of common 
symptoms experienced by cancer patients including pain, anxiety and drowsiness. It 
includes 10 items that are self-assessed by the patient using individual 10-point scales. 
This tool has been validated in this population and has reported a Cronbach’s α of 0.79 
[45]. The tool will be administrated at -1 day and at 4 days post-chemotherapy for each 
cycle in order to determine treatment related side-effects. The tool should take 
approximately 5 minutes to complete. 
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8.10.3.5 Patient Generated - Subjective Global Assessment (PG-SGA) 
Nutritional status will be measured using the valid and reliable scored PG-SGA. 
[46]. Using the data gained from this tool, statistical analysis will be conducted to 
determine the impact of CINV on the participants’ nutritional status. The PG-SGA will 
be conducted by a dietitian who has undergone training and testing for inter-rater 
reliability on nutritional status measures. The PG-SGA is specifically designed to assess 
the nutritional status of cancer patients. This tool provides a global rating of either A (well 
nourished), B (suspected or moderately malnourished) or C (severely malnourished). This 
global rating is based upon weight change, dietary intake, GI symptoms, a physical 
examination and the patient’s functional capacity. A total PG-SGA score is also 
calculated. A higher score reflects a higher risk of malnutrition and an increased need for 
nutrition intervention and symptom management. 
8.10.3.6 Functional Assessment of Cancer Therapy- General (FACT-G) and Fatigue 
(FACIT-F) subscale 
The participants’ self-assessed QoL will be measured using the FACT-G 
questionnaire, a validated tool that has been widely used in this setting [47]. It contains 
27 questions with a 5-point scale, which assesses four domains of patient QoL: physical 
well-being, social/family well-being, emotional wellbeing, and functional well-being. 
Strong concurrent validity with the Functional Living Index-Cancer tool was 
demonstrated with a Pearson coefficient of 0.79 [47]. Additionally, we have included the 
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Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-F) subscale, a 13 
item Likert scale, to assess self-reported symptoms of fatigue before and after each 
chemotherapy cycle. It is estimated to take between 5-10 minutes to complete. 
8.10.3.7 Adherence questionnaire 
To assess the level of adherence to the study protocol, a questionnaire was 
developed for patients to record if and when they consumed the ginger/placebo doses per 
day. This is achieved by either recording the time or marking an X, depending on whether 
they consumed each dose, in the box corresponding to the dose in question. This is to be 
completed each day and is expected to take less than 2 minutes to complete. 
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 Timeline 
The details of the study procedure are detailed below in chronological order. This 
timeline contains the details of the study process per cycle and will be repeated for 3 
cycles (Figure 8-1). 
 
 
Figure 8-1 Study Flow Diagram 
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 Pre chemotherapy – 7 Days prior to chemotherapy 
The researcher will see patients as close as possible to 7 days prior to 
chemotherapy to determine their eligibility. If the patient is a viable candidate, informed 
consent will be obtained, the details of the study will be explained, and the supplements 
and questionnaire booklet will be delivered. Participants will be provided with written 
information and educated regarding the consumption of the supplement.  
Participants will be randomised and provided with a 5 day (4 × 300 mg capsules 
per day) supply of ginger extract (20 capsules) or the placebo control (20 capsules) to be 
consumed daily with liquid in addition to their usual diet for 4 days, starting on the day 
of chemotherapy. The supplement will be provided in a sealed plastic container that will 
be packed by a researcher not involved in data collection. 
Participants will be given a booklet containing the self-report questionnaires for 
CINV, QoL, adverse events, and blinding for the full study period per chemotherapy cycle 
(5 days).  
Each booklet will contain: 
 One INVR questionnaire per day: one on the day of chemotherapy, and one 
each of the 4 days post-chemotherapy. 
 Two FACT-G/FACIT-F questionnaires per cycle. 
 One FLIE-5DR questionnaire per cycle. 
 Two ESAS questionnaire. 
 One CINV susceptibility questionnaire. 
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 One Adherence Questionnaire for each day the participant receives the study 
medication: one on the day of chemotherapy, and one for each of the 4 days 
post-chemotherapy. 
 Instructions on how and when to complete these questionnaires will be 
included, as well the contact details of the study investigators. 
During this consultation, the participant’s nutritional status will also be assessed 
using the PG-SGA assessment tool. 
 Pre chemotherapy – 1 day prior to chemotherapy 
The following tools will be completed by the participant 24 hours before 
chemotherapy: 
 One FACT-G/FACIT-F questionnaire 
 One ESAS questionnaire 
 Day of chemotherapy 
The following tools will be completed by the participant on the day of 
chemotherapy: 
 One INVR questionnaire will be completed before chemotherapy commences. 
 One CINV susceptibility questionnaire will be completed any time after 
chemotherapy has commenced. 
 One adherence questionnaire. 
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Additionally, the participant is to consume one ginger/placebo capsule 1 hour 
before the administration of chemotherapy and then once every 4 hours after that for the 
remaining 3 capsules. The timing will be discussed with the participant to help ensure the 
participant understands the regimen. 
 Post-chemotherapy – Day 1-4 Post-chemotherapy 
During the 4 days post-chemotherapy, participants will be asked to complete: 
 One INVR questionnaire per day. The timing of completion should be at the 
same time of day as when they completed their previous questionnaire. This 
will ensure that 24 hours is assessed per questionnaire. 
 One adherence questionnaire. 
 The participant will consume 4 capsules per day. One before breakfast, one 
before lunch, one during an afternoon snack, and one before dinner. These 
capsules are to be consumed one hour before each meal. 
 Post-chemotherapy – Day 4 Post-chemotherapy only 
At the end of day 4, participants will be asked to complete: 
 One FACT-G/FACIT-F questionnaire 
 One FLIE-5DR questionnaire 
 One ESAS questionnaire 
 One adherence questionnaire 
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Supplements are consumed using the same schedule as above. 
At the end of day 4, participants will no longer be required to consume the oral 
supplements and any unconsumed supplements, along with the questionnaire booklet, 
will either be collected by the research team, along with the participant questionnaire 
booklet, during the participant’s next visit to the hospital or sent directly to the researchers 
using a reply-paid envelope. Unconsumed supplements of each individual will be counted 
in order to determine their level of adherence to the study protocol. 
 Assessment of blinding 
At the end of day 4, the investigator will contact each participant to obtain 
information regarding the study blinding. This will be determined by asking each 
participant the following questions: “Do you think you received the placebo or the ginger 
supplement and why do you think this?”. Participants will also be asked if they have any 
comments or queries regarding the trial so as to gather feedback for the improvement of 
the study protocol for future trials. 
The timing of the participant’s next chemotherapy cycle will also be discussed 
and arrangements will be made to meet within the week before chemotherapy in order to 
dispense additional supplements and assessments. 
 Statistical analysis 
Analyses will be conducted according to intention-to-treat principles i.e. the 
consent process will maximise outcome data collection and attempt to assess nausea 
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symptoms for everyone, and will retain original group allocation despite actual 
compliance levels. 
Participants will be block stratified by chemotherapy category (i.e. minimal, low, 
moderate and high emetogenicity) then randomised within strata into intervention and 
control groups (Figure 8-1) [48]. 
Descriptive statistics will be presented as mean ± standard deviation, or median 
with range, as appropriate. Parametric analyses will be used for all continuous variables. 
Chi-square analyses will determine associations between categorical variables. For 
example, the incidence, severity and type of nausea and vomiting between the two groups. 
Pearson correlation analysis of continuous variables will be performed. Repeated 
measures analyses will be conducted to detect between group differences over time as per 
our statistician recommendations. Statistical significance will be set at p < 0.05 level 
(two-tailed). Data will be analysed using SPSS for Windows version 22 (Statistical 
Package for Social Sciences, IL, USA). 
 Sample size 
A sample size calculation for comparing two means with unpaired t-tests based 
on the reductions in the prevalence of chemotherapy-induced nausea reported by Panahi 
et al. [49], estimates that 73 participants would be required in the intervention and control 
groups (i.e. total of N = 146) to detect this difference with 80 per cent power at the 95 per 
cent significance level (two tailed). 
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Approximately 250 patients receive moderately emetogenic chemotherapy and 
240 patients receive highly emetogenic chemotherapy at Princess Alexandra Hospital 
each six months (1/3-1/9/2012) which indicates that the required sample size is obtainable 
in this study. 
 Ethical considerations 
The study protocol has been approved by the Metro South Human Research Ethics 
Committee on the 4th of July, 2013. The trial has also been registered with the Australian 
New Zealand Clinical Trials Registry and has been assigned the identifier, 
ACTRN12613000120774. The study complies with the Declaration of Helsinki rules and 
the principles of Good Clinical Practice guidelines. Informed consent will be gained from 
all participants before commencing the trial and patient data will be stored securely. 
Participants will also be monitored for adverse effects and will be discontinued 
immediately if the study protocol is determined to be causing harm or if the participant 
chooses to withdraw. This study received grant funding from the Queensland Health – 
Health Practitioner Scheme. 
 Discussion 
This study protocol expands on the current literature regarding the efficacy of 
ginger as an adjuvant therapy for CINV. Recommendations for the use of ginger in the 
oncology setting are premature, as previous reviews have shown inconsistent results and 
have possessed several limitations. Primary concerns identified in the literature include 
the lack of control of anticipatory nausea, the inconsistent use of standardised ginger 
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extracts and validated assessments tools, and a lack of assessment for prognostic factors 
that may influence individual CINV response [21]. Additionally, recent pharmacokinetic 
studies demonstrate that the half-life of the active compounds within ginger are relatively 
short-lived, which suggests that the dosing regimens employed by previous studies may 
be suboptimal. Furthermore, multiple studies included in these reviews have used anti-
emetic therapies that are not congruent with current best practice and anti-emetic 
guidelines and therefore, the application of these previous findings to current practise are 
further diminished [21,48]. 
In designing our trial, we aimed to address these limitations while incorporating 
elements of rigorous study methodology that have been incorporated in previous trials in 
this area. For example, our trial will be using multiple, validated assessment tools along 
with a standardised ginger extract, both of which have been utilised in at least two 
previous trials [50,51]. We will, however, expand on this by independently analysing our 
extracts at both the beginning and end of our recruitment phase to ensure consistent 
potency. 
It should also be noted that one study by Ryan et al. [51] found ginger to reduce 
CINV when ginger supplementation was commenced three days before chemotherapy. 
We, however, decided against using this methodology and opted for ginger 
supplementation commencing on the day of chemotherapy due to the following reasons. 
Firstly, there have been multiple previous trials using ginger for CINV as well as other 
forms of nausea that did not use the regimen used by Ryan et al. [51] but rather a 
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timeframe and dosage more closely resembling the regimen in our protocol that yielded 
beneficial results [49,52-54]. In addition to this, to date, there has been no research that 
has investigated the regimen used in the Ryan et al. [51] study compared to the more 
typical dosing regimen that has been employed in our study, which restricts one from 
determining the superiority of said regimen. Lastly, the basis for said regimen, from our 
research and from the discussion in the Ryan et al. [51] paper, seems to have been 
implemented largely on a theoretical basis and therefore, until more evidence arises, we 
have decided to instead opt for the more patient-convenient regimen described in this 
manuscript. 
Our trial will also be the first to introduce multiple novel study design elements. 
Primarily, our study will be the first to recruit only chemotherapy-naive patients. This 
strategy should mitigate the significant limitation of anticipatory nausea. It is a response 
to previous research reporting that CINV control progressively deteriorates with each 
subsequent chemotherapy cycle, if not adequately controlled during the initial cycle [35]. 
Due to the association between fatigue and nausea in this setting, we will also investigate 
the effect that ginger has on this association in order to determine if ginger may be of 
benefit to patients also experiencing cancer-related fatigue. Finally, our study will also 
implement a dosing regimen that is consistent with the findings of the previously 
mentioned pharmacokinetic studies that will likely improve the CINV protection of this 
therapy. If successful, this trial will provide support for the efficacy of ginger as a viable 
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adjuvant anti-emetic therapy and in doing so, help manage chemotherapy symptoms and 
assist in improving patient QoL. 
 Abbreviations 
CINV, Chemotherapy-induced Nausea and vomiting; QoL, Quality of life; PG-
SGA, Patient generated - subjective global assessment; FACT-G, Functional assessment 
of cancer therapy- general; FACIT-F, Functional assessment of chronic illness therapy-
fatigue; INVR, Rhodes inventory of Nausea vomiting and retching; ESAS, Edmonton 
Symptom Assessment System; FLIE-5DR, The functional living Index – Emesis – 5 day 
recall 
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 The effect of a standardized ginger extract on 
chemotherapy-induced nausea and vomiting related 
quality of life in patients undergoing moderately and 
highly emetogenic chemotherapy: a randomized 
controlled trial. 
Chapter 9 presents the results of the main study of this thesis, a double-blind, 
randomized, placebo-controlled trial that investigated the use of adjuvant ginger 
supplementation for chemotherapy-induced nausea and vomiting. This chapter discusses 
the strengths and limitations of this study and provides recommendations for clinical 
practice and future studies. Supplementary information to this trial can be found in the 
appendices.  
The study protocol of this clinical trial was adapted from the protocol manuscript 
in Chapter 8. The only deviations are listed below: 
 The primary outcomes were changed from the frequency, severity, duration of 
acute and delayed nausea to chemotherapy-induced nausea-related quality of life 
(QoL). The most consistent effect of nausea that is reported in the literature is the 
significant decline in QoL.4,16,17 Therefore, in order to assess the effect of ginger 
supplementation on clinically-relevant outcomes, the primary outcome was 
changed in order to ensure the study was adequately powered to detect a 
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significant difference in the effect that CINV had on the participant’s daily living 
and wellbeing.  
 In order to investigate the feasibility of the published study protocol, a pilot study 
was undertaken at Princess Alexandra Hospital with 10 chemotherapy-naïve 
participants during their first cycle of chemotherapy. From this study, several parts 
of the study protocol were modified to improve the readability and participant 
acceptance of the questionnaires, the acceptability of the study capsules, and to 
streamline the recruitment process. In particular, a multidisciplinary approach was 
found to be the optimal strategy to identify potentially eligible patients. The final 
recruitment process involved the coordination with the chemotherapy nurses, 
haematology physicians, oncologists, dietitians, pharmacists, and cancer-care 
coordinators, who all provided assistance with this study. In addition, through this 
process, the hospital’s daily chemotherapy education sessions were identified as 
a regular avenue to introduce eligible patients to the study. In these sessions, this 
PhD candidate would provide a short, informal presentation about the study and 
then arrange to speak with interested patients after the education session. 
Furthermore, participant feedback regarding the questionnaire booklet resulted in 
several minor revisions that improved its readability. 
 Finally, the sample size was recalculated based on the results of the pilot study 
(N=10) and was revised to 77 participants. The previous sample size was 
calculated based on a previous study using the original primary outcome and a 
different questionnaire to that used in this study to capture the revised outcome. 
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 Abstract 
Ginger supplementation could be an effective adjuvant treatment for 
chemotherapy-induced nausea and vomiting (CINV); however, previous trials in this 
area have significant methodological limitations that preclude recommending the 
routine use of ginger in clinical practice.  
The aim of this double-blind randomised controlled trial was to overcome 
these limitations and thereby determine the effect of adjuvant time- and dose-
standardised ginger on chemotherapy-induced nausea (CIN)-related quality of life 
(QoL), compared to placebo, in chemotherapy-naïve patients over three cycles of 
moderately- and highly-emetogenic chemotherapy.  
Fifty-one patients were randomly allocated to receive either 1.2 g of a 
standardised ginger extract or placebo per day, in addition to standard anti-emetic 
therapy. The supplements were divided into four capsules per day, consumed every 
four hours for five days during the first three cycles of chemotherapy. The primary 
outcome was CIN-related QoL measured with the Functional Living Index- Emesis 
(FLIE) questionnaire. Secondary outcomes included acute and delayed nausea, 
vomiting, and retching as well as cancer-related fatigue, nutrition status, and CINV-
specific prognostic factors. 
Over three consecutive chemotherapy cycles, nausea was more prevalent than 
vomiting (47% vs 12% of all participants experienced symptoms, respectively). In 
cycle 1, intervention participants reported significantly higher ratings of CIN-related 
QoL (Median [25th, 75th percentile] = 61.5 [56.1, 63] vs 54 [46, 63]; p=0.029), CINV-
related QoL (Median [25th, 75th percentile] = 124.5 [113, 126] vs 111 [99.2, 126]; p= 
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0.043) and global QoL (Mean±standard deviation = 85.1±18.9 vs 71.9±18.3; p= 
0.003) and less fatigue (Mean±standard deviation = 41.8±13.1 vs 32.2±10.8; 
p=0.007) than placebo participants. There were no significant results in cycle 2. In 
cycle 3, global QoL (Median [25th, 75th percentile] = 83.6±15.0 vs 75.1±13.9; 
p=0.040) and fatigue (Mean±standard deviation = 42.4±10.2 vs 36.1±7.2; p=0.013) 
were significantly better in the intervention group compared to placebo. There was no 
difference in reported adverse effects. 
This trial suggests adjuvant ginger supplementation is associated with better 
chemotherapy-induced nausea-related quality of life and less cancer-related fatigue, 
with no difference in adverse effects compared to placebo.  
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 Introduction 
The prevention and management of chemotherapy-induced nausea and 
vomiting (CINV) is a priority in the oncology setting. While the development of a 
range of anti-emetic medications has considerably reduced the prevalence of CINV, 
vomiting and, in particular, nausea, are still experienced by up to 25% and 61% of 
cancer patients, respectively.1 CINV is also associated with poor quality of life (QoL), 
malnutrition, and if persistent, can result in cancer treatment delays and dose 
reductions, culminating in poorer treatment outcomes.2-4 Furthermore, when nausea 
and vomiting are measured separately, nausea is reported to affect QoL to a greater 
extent than vomiting. This suggests that additional interventions to control nausea are 
required.3 
Various interventions to reduce CINV have been investigated. These include 
pharmaceuticals (e.g. olanzapine), behavioural interventions (e.g. progressive muscle 
relaxation), and nutraceuticals including ginger supplementation.5-7 The compounds 
within ginger are understood to possess multiple properties relevant to the 
management of CINV, including 5-HT3 receptor antagonism, which is one of the 
cornerstones of modern antiemetic drug therapies such as ondansetron and 
granisetron.8  
Ginger has been trialled with some success for other types of nausea, including 
morning sickness and post-operative nausea and vomiting.9-11 There is also mounting 
evidence supporting the use of adjuvant ginger to reduce CINV.7 However, as 
discussed in our previous articles,7,12 extant research has multiple methodological 
limitations that must be addressed in studies of ginger before this intervention can be 
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recommended as a complement to routine clinical practice. These limitations include 
the lack of control for prognostic factors, potentially suboptimal dosing regimens, and 
inconsistent use of validated questionnaires and standardized ginger products.7,12 This 
study was designed to overcome these limitations. 
The primary aim of this double-blind randomised controlled trial was to 
determine the effect, from baseline, of adjuvant time- and dose-standardised ginger 
on chemotherapy-induced nausea (CIN)-related QoL, compared to placebo, in 
chemotherapy naïve patients over three cycles of moderately- and highly-emetogenic 
chemotherapy.  
Previously unexplored, but clinically important outcomes, were also 
investigated. Cancer-related fatigue and malnutrition are both prevalent in 
chemotherapy cohorts, are consistently associated with CINV, and are associated with 
significant decrements in patient QoL.2,13 Hence, fatigue and malnutrition were also 
investigated in this trial to determine if adjuvant ginger supplementation could benefit 
these outcomes. In addition, the potential correlation between ginger and the anti-
emetic medication aprepitant was assessed. This was prompted by the findings by 
Zick et al.14, who reported worse control of delayed CINV in patients receiving 2g of 
ginger and aprepitant. 
 Methods 
The design of this double-blind, randomised placebo-controlled trial is fully 
detailed in our published protocol manuscript.12 The study protocol was approved by 
the Metro South Human Research Ethics Committee, Brisbane, Australia and was 
registered with the Australian New Zealand Clinical Trials Registry 
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(ACTRN12613000120774). The CONSORT checklist for randomised controlled 
trials was used to prepare this manuscript.18  
 Sample and recruitment 
Patients were recruited if they were chemotherapy-naïve, were due to receive 
a moderately- or highly-emetogenic chemotherapy regimen, were at least 18 years 
old, had a baseline Karnofsky score >60,15 had no known concurrent neoplasms or 
illness that induces nausea independent of chemotherapy, and did not self-prescribe 
therapies or complementary products used for nausea. Patients were excluded if they 
were scheduled to receive radiotherapy during the study period, were pregnant or 
lactating, concurrently used other ginger-containing supplements or ingested large 
quantities of ginger, had a history of adverse reactions to ginger, and 
thrombocytopenia. These inclusion and exclusion criteria were applied equally to both 
the intervention and placebo groups. Chemotherapy regimens were categorized as 
highly- or moderately-emetogenic consistent with the Multinational Association for 
Supportive Care and Cancer anti-emetic guidelines.16 Written informed consent was 
obtained at time of enrolment. 
Patients were recruited from the Princess Alexandra Hospital, Brisbane, 
Australia from March 2014 to February 2015. Potentially eligible patients were 
identified by research staff during daily chemotherapy education sessions and through 
the hospital chemotherapy scheduling system within one week prior to the first cycle 
of chemotherapy. Eligible patients were randomly allocated to ginger or placebo 
capsules, and received three questionnaire booklets, one for each cycle, which were 
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either mailed back to the researchers upon completion or collected during the 
following cycle.  
 Intervention 
Participants were randomly assigned to receive either 1.2g (4 x 300mg) of a 
standardized ginger extract or placebo in conjunction with the standard antiemetic 
therapy prescribed by their physician. The ginger extract was standardised to contain 
5% gingerols in capsule form. Each capsule, containing 300 mg of ginger extract with 
15 mg of active ingredient per capsule (60 mg per 1.2 g), was double encapsulated to 
enhance patient blinding. Placebos were prepared with an inert filler and capsules that 
matched the intervention. De-identified supplements were randomised by an 
independent company prior to delivery to the recruitment sites. All staff members 
involved in recruitment were blinded to the results of randomisation. The gingerol and 
shogaol content of the ginger extract were independently analysed at the beginning 
and end of the trial by Southern Cross Plant Science Department at Southern Cross 
University and Bond University, respectively, using high performance liquid 
chromatography to ensure consistent potency of the intervention.   
 Procedure 
Patients were randomised into intervention or placebo groups using a 
computer generated randomisation sequence. Randomisation was undertaken by 
investigators who had no contact with participants. Participants were followed over 
three chemotherapy cycles in order to obtain results that reflected their experience of 
ginger supplementation and CINV over an extended period of their chemotherapy 
treatment. For each cycle, outcomes were assessed 3 days prior to chemotherapy until 
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4 days post-chemotherapy (i.e. over 7 days). Participants were asked to consume the 
study capsules 4 times per day, with each meal, for 5 days per chemotherapy cycle, 
commencing on the day of chemotherapy.  
 Outcome measures 
9.3.4.1 Primary outcome 
The primary outcome was chemotherapy-induced nausea-related (CIN) 
quality of life (QoL). This was measured using the Functional Living Index Emesis 5 
Day Recall (FLIE-5DR) questionnaire, a validated measure of the impact of CINV on 
patients’ general well-being.17 It comprises eighteen 7-point Likert scales that assess 
the separate effects of nausea and vomiting on QoL. Scores can range from 9 to 63 
for each domain (i.e. nausea or vomiting) and 18 to126 for the total CINV score. A 
higher score indicates better QoL. To the authors’ knowledge, no minimal clinically 
important difference has been established for the FLIE-5DR; however, using the 
parameters established by Martin et al,18 “no impact on daily life” was defined as an 
average item score greater than 6 on the 7-point scale. Therefore, a total score greater 
than 108 (out of a total score of 126) and a domain-specific score of 54 (out of a total 
score of 63) meant that CINV had minimal impact on daily life. Participants 
completed this questionnaire twice per chemotherapy cycle, at baseline and 4 days 
post-chemotherapy. 
9.3.4.2 Secondary outcomes 
A total score for CINV as well as separate scores for nausea, retching and 
vomiting were elicited using the validated, 8-item self-report tool, the Rhodes 
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Inventory of Nausea, Vomiting and Retching (INVR).19 The INVR assesses the 
frequency, duration and severity of nausea, vomiting and retching. It provides 
domain-specific scores for nausea, vomiting and retching as well as a total score for 
CINV calculated from the combined domains.  
The following operational definitions defined each phase of CINV. 
Anticipatory CINV was defined as any symptom occurring in the 24 hours prior to 
chemotherapy administration.20 Acute CINV was defined as any nausea and/or 
vomiting symptoms that occurred within 24 hours of the administration of 
chemotherapy, while delayed CINV was defined as any nausea and/or vomiting 
symptoms that occurred after the acute phase and for the following 5 days.20 In order 
to measure each of these phases of CINV, the INVR was administered one day before 
the commencement of chemotherapy (anticipatory CINV), on the day of 
chemotherapy (acute CINV) and during each of the 4 proceeding days to assess 
delayed CINV.  
The INVR is designed to measure symptoms over a 12 hour period; however, 
to minimise survey burden this period was extended to 24 hours so that participants 
would only need to complete one questionnaire per 24 hours. For each 24 hour period, 
a score (between 3-15 for nausea and vomiting, 2-10 for retching) is given for each 
symptom and a total score is derived from each symptom score (between 8-40). For 
delayed symptoms, scores from the three 24 hour periods after the acute phase were 
combined. If a participant reported no experience with a symptom, this was considered 
a “complete response”.  
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Nutritional status was assessed once per chemotherapy cycle, on the day of 
chemotherapy, by an appropriately-trained research dietitian (WM and LF) using the 
Patient Generated Subjective Global Assessment (PG-SGA) tool.21 The PG-SGA 
provides a global rating of either A (well nourished), B (suspected or moderately 
malnourished) or C (severely malnourished), as well as a continuous score that 
increases with the severity of symptoms and the concomitant need for symptom 
management.  
Global cancer-related QoL and cancer-related fatigue were assessed at 
baseline and 4 days post-chemotherapy using the Functional Assessment of Cancer 
Therapy-Global (FACT-G) and the Functional Assessment of Chronic Illness 
Therapy-Fatigue (FACIT-F) assessment questionnaires, respectively.22,23 Both 
questionnaires are valid and widely-used within the cancer setting. The FACT-G is a 
self-report questionnaire that contains 27 five-point Likert scales that assess four 
domains of global (as opposed to CINV-specific) QoL. These are physical well-being, 
social/family well-being, emotional wellbeing, and functional well-being. The 
FACIT-F comprises 13 five point Likert scales, and was used to capture self-reported 
symptoms of fatigue before and after each chemotherapy cycle. Possible scores for 
the FACT-G and FACIT-F range from 0-108 and 0-52, respectively, with higher 
scores indicating better QoL and less fatigue. A four-point difference between groups 
in FACT-G scores was considered a clinically meaningful difference.24 Participants 
were deemed clinically fatigued if they reported a FACIT-F score ≤34, with a 
difference of 3 points between groups considered a clinically meaningful difference 
in levels of fatigue.25,26 Exercise was not monitored and no guidelines regarding 
physical activity were provided to participants.  
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A new questionnaire was developed as part of this project to assess the 
prevalence of prognostic factors that previous studies had identified increased the risk 
of CINV. The rationale for implementing this questionnaire was that an uneven 
distribution of these prognostic factors between the intervention and placebo groups 
could influence the results of this study. The questionnaire included five items that 
assessed the patient’s history of morning sickness and motion sickness, their average 
weekly alcohol intake and history of anxiety.27-29 Additional prognostic factors 
including age, gender and emetogenicity of the chemotherapy regimen were retrieved 
during the initial patient interview.  
To determine participant adherence to the study protocol, participants were 
asked to record the number of capsules consumed each day during the study period. 
The quality of patient blinding was assessed at the end of each chemotherapy cycle 
during participant interviews, in which participants were asked to state the capsule 
(placebo or ginger) they believed they had received. 
 Adverse events 
Safety concerns and adverse events were monitored via telephone interviews 
during each cycle, five days post-chemotherapy. Participants were asked about any 
hospitalizations or adverse events during the study period. To assess possible negative 
effects of ginger supplementation, between-group differences in a range of symptoms 
were also assessed using the Edmonton Symptom Assessment Scale, which was 
administered each cycle, at baseline and 5 days post-chemotherapy.30 This is a 
validated 10-item questionnaire that measures the severity of common symptoms 
experienced by cancer patients including pain, anxiety and drowsiness.  
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 Statistical analysis 
Statistical analysis was conducted using SPSS Version 20®. Descriptive 
analysis of baseline participant characteristics was undertaken. Bivariate outcomes 
were assessed using chi-square analysis. Normally distributed continuous outcomes 
were assessed using independent sample t-tests. The Mann-Whitney U test was used 
for non-parametric outcomes. Prognostic factors were also assessed in this fashion. 
Data were analysed on an intention-to-treat basis. A P value <0.05 was deemed to 
indicate a statistically significant difference. Mean and standard deviation (SD) were 
reported for normally distributed data. Median and 25th percentile and 75th percentile 
were reported for non-parametric data. Missing data were handled using multiple 
imputation. In order to explore the association between ginger supplementation 
combined with aprepitant and worse delayed-CINV, a subgroup analysis in patients 
receiving aprepitant was also conducted.  
Sample size was calculated based on the ability to detect a clinically 
meaningful difference in the primary outcome of nausea-related QoL. Hence, using 
the standard deviations from a preliminary feasibility study of ten participants and a 
desired mean difference of 9 points on the nausea-related subdomain of the FLIE-
5DR, a sample size of 64 was estimated to provide sufficient power to detect a 
statistically and clinically significant difference in nausea-related QoL with 80% 
power and 5% significance. An additional 20% allowance was added to this sample 
size to allow for attrition, resulting in a final sample size of 77 participants. 
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 Results 
Table 9-1 Patient demographics at baseline 
 Total Intervention Group Control Group 
n 51 24 27 
Age (mean±sd, years) 58±12 57±14 59±11 
Gender (n, %female) 32 (63) 16 (66) 16 (59) 
Race (n, %Caucasian) 42 (82) 18 (75) 24 (88) 
Primary diagnoses    
Breast 13 7 6 
Colon 19 8 11 
Lymphoma 11 5 6 
Other 8 4 4 
Chemotherapy Emetogenicity    
HEC 8.0 4.0 4.0 
MEC 43.0 20.0 23.0 
Receiving aprepitant 18.0 7.0 11.0 
HEC=Highly Emetogenic Chemotherapy. MEC=Moderately Emetogenic Chemotherapy. 
These regimens were classified based on the Multinational Association of Supportive Care in Cancer 
guidelines. 31 
Patient demographics and adherence 
Fifty-one patients were enrolled in this study, of which 34 completed all three 
cycles (Figure 9-1). There were no significant differences in baseline patient 
characteristics between the intervention and placebo group (p > 0.05). The majority 
of patients (85%) were scheduled to undergo moderately emetogenic chemotherapy 
regimens (Table 9-1).  
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 CINV- related Quality of Life 
After cycle 1, participants assigned to the intervention group reported better 
nausea-related QoL (Median [25th, 75th percentile] = 61.5 [56.1, 63] vs 54 [46, 63]; 
p=0.029) and better total CINV-related QoL (Median [25th, 75th percentile] = 124.5 
[113, 126] vs 111 [99.2, 126]; p=0.043) compared to patients assigned the placebo. 
Examination of median CINV- and nausea- related QoL at cycle 1 in the placebo and 
intervention groups suggests that the clinically significant effect of total CINV and 
nausea on QoL was minimal in both groups (Table 9-2). No other significant effect 
was detected for vomiting-related QoL or for any outcome at cycles 2 and 3. 
 Nausea and vomiting symptoms 
Over the three chemotherapy cycles, acute and delayed CINV occurred in 39% 
and 65% of all participants (Table 9-3). In both groups, nausea was more common 
than vomiting during each cycle, with 47% vs 12% of participants overall reporting 
symptoms during at least one cycle, respectively. There were no significant 
differences in the prevalence and score of CINV between the intervention and placebo 
group at any time point.  
In a subgroup analysis of participants (n=18) assigned to the intervention with 
and without being prescribed aprepitant, there were no statistically significant 
differences in CINV between groups at any time point (Table 9-4).  
 Fatigue, nutrition status, and cancer-related quality of life 
Clinically significant fatigue and malnutrition were experienced by 36% and 
22% of participants over the study period. Ginger supplementation was associated 
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with improved measures of chemotherapy-related fatigue in cycles 1 (Mean±SD = 
41.8±13.1vs 32.2±10.8; p=0.001) and cycle 3 (Mean±SD = 42.4±10.2 vs 36.1±7.2; 
p=0.013) compared to placebo. There was also a statistically significant difference in 
cancer-related QoL at cycle 1 (Mean±SD = 83.6±15.0 vs 75.1±13.9; p=0.015) and 
cycle 3 (Mean±SD = 85.1±18.9 vs 71.9±18.3; p=0.040).  
Each of the significant associations reported for the cancer-related QoL (>4 
point difference) and cancer-related fatigue (>3 point difference) were also clinically 
significant differences. No significant difference in nutritional status was detected 
between the intervention and placebo group during the study period (p>0.05; Table 
9-2).  
 Participant blinding and adherence 
More participants in the intervention group were able to correctly guess their 
assigned group when compared to participants in the placebo group (63% compared 
to 30%, respectively). For participants in the intervention group who successfully 
identified their allocation, the most common rationale provided was a lack of nausea 
(60%), the smell of the capsules (20%), and ginger taste or reflux (10%). Adherence 
to the study intervention was moderate-to-high, with 70% of all participants (69% in 
ginger group and 75% in placebo group) consuming at least 3 of the 4 prescribed 
capsules per day.
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Table 9-2 Cancer- and CINV-related Qol, cancer-related fatigue, and nutrition status 
  Cycle 1 Cycle 2 Cycle 3 
  Total Placebo Intervent
ion 
P value Total Placebo Intervent
ion 
P value Total Placebo Intervent
ion 
P value 
CINV-QoL   124 [103, 
126] 
111 
[99.2, 
126] 
124.5 
[113, 
126] 
0.043* 124 [108, 
126] 
117 [109, 
126] 
124 [107, 
126] 
0.916 122 [107, 
126] 
120 [111, 
126] 
123 [107, 
126] 
0.931 
Complete response n(%) 37 (73) 17 (63) 20 (83) 0.104 40 (78) 22 (81) 18 (75) 0.574 38 (75) 21 (78) 17 (71) 0.57 
Nausea-related QoL 60 [50.7, 
63] 
54 [46, 
63] 
61.5 
[56.1, 
63] 
0.029* 61 [49, 
63] 
55.6 
[48.7, 
63] 
61 [52.1, 
63] 
0.494 56 [48.9, 
63] 
56 [48.9, 
63] 
56.5 [47, 
63] 
0.931 
Complete response n(%) 33 (65) 14 (52) 19 (79) 0.042* 30 (59) 15 (56) 15 (63) 0.615 31 (61) 16 (59) 15 (63) 0.813 
Vomiting-related QoL 63 [51.3, 
63] 
63 [50.7, 
63] 
63 [54.2, 
63] 
0.237 63 [51.9, 
63] 
63 [51.7, 
63] 
63 [54.4, 
63] 
0.663 63 [50.6, 
63] 
63 [53.6, 
63] 
58.9 
[50.1, 
63] 
0.414 
Complete response n(%) 37 (73) 19 (70) 18 (75) 0.712 37 (73) 19 (70) 18 (75) 0.712 34 (67) 20 (74) 14 (58) 0.234 
Global cancer-related 
QoL  
77.4±19.
5 
71.9±18.
3 
85.1±18.
9 
0.015* 70±14.8 67.6±10.
2 
74.9±17.
7 
0.075 79.3±15.
1 
75.1±13.
9 
83.6±15.
0 
0.040* 
Fatigue  36.2±12.
8 
32.2±10.
8 
41.8±13.
1 
0.007* 36.1±9.6 34.5±7.9 37.7±10.
8 
0.231 39.1±9.3 36.1±7.2 42.4±10.
2 
0.013* 
Nutrition status at start of 
cycle (n  well nourished) 
44 22 22 0.371 38 19 19 0.500 37 19 18 0.622 
Total response was defined as a score > 54 on the nausea- and vomiting- related quality of life scores and a score >108 on the chemotherapy-induced nausea and vomiting-related 
quality of life score 
Normally distributed measures were presented as mean±standard deviation and non-normally distributed measures were presented as median [25th percentile, 75th percentile]  
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Table 9-3 Participant INVR questionnaire scores and CINV prevalence 
 Cycle 1 Cycle 2 Cycle 3 
 Total Placebo Intervent
ion 
p 
value 
Total Placebo Intervention p 
value 
Total Placebo Intervent
ion 
p 
value 
Anticipatory CINV 
score   
8 [8,8] 8 [8,8] 8 [8,8] 0.49 8 [8,8.8] 8 [8,8.8] 8 [8,8.8] 0.40 8 [8,8.4] 8 [8,8.6] 8 [ 8,8.5] 0.23 
Acute CINV score 9.93 
[8.65,10.87] 
8 
[8,9.4] 
9.6 
[8,10] 
0.78 9.02 [8.5,9.6] 8 [8,9.6] 8.57 
[8,9.52] 
0.90 9.89 [8.65, 
10.87] 
8 [8,9.4] 8.8 
[8,10.1] 
0.17 
Complete response 
n(%) 
30 (59) 17 (63) 13 (54) 0.49 33 (65) 18 (67) 15 (63) 0.90 31 (61) 17 (63) 14 (58) 0.75 
Vomiting score   3 [3,3] 3 [3,3] 3[3,3.1] 0.79 3 [3,3] 3 [3,3] 3 [3,3] 1.00 3 [3,4] 3 [3,3.2] 3 [3,5.1] 0.31 
Complete response 
n(%) 
47 (92) 25 (93) 22 (92)  51 (100) 27 (100) 24 (100) 1.00 43 (84) 24 (89) 19 (79) 0.46 
 Nausea score   3 [3,5] 3 
[3,4.8] 
3.6 [3,5] 0.38 3.29 [3,4.33] 3 [3,4.27] 3.8 [3, 4.45] 0.62 3.2 [3,5] 3 [3,5] 3[ 3,4.8] 0.74 
Complete response 
n(%) 
33 (65) 19 (70) 14 (58) 0.47 33 (65) 18 (67) 15 (63) 0.90 35 (69) 19 (70) 16 (67) 0.64 
Retching score 2 [2,2] 2 [2,2] 2 [2,2.1] 0.75 2 [2,2] 2 [2,2] 2 [2,2] 1.00 2 [ 2,2] 2 [2,2] 2 [2,2.1] 0.30 
Delayed CINV 
score  
31.31 
[27.4,34.4] 
32 
[24,35] 
26 
[24,34.3] 
0.72 29.5 
[28.23,31.07] 
28.95 [24, 
33] 
28.67 
[24,29.95] 
0.24 28.81 
[27.13,30.35] 
27.4 
[24,31.8] 
28 
[24,30.6] 
0.90 
Complete response 
n(%) 
14 (27) 6 (22) 8 (33) 0.53 23 (45) 9 (33) 7 (29) 0.83 17 (33) 10 (37) 7 (29) 0.62 
Vomiting score   9 [9,10.11] 9 
[9,11.8] 
9 [9,9.7] 0.97 9 [9,9.89] 9 [9,10.17] 9 [9,9.88] 0.97 9 [9,9.40] 9 [9,9.66] 9 [9,9.4] 0.93 
Complete response 
n(%) 
41 (80) 21 (78) 20 (83) 0.75 42 (82) 22 (81) 20 (83) 1.00 46 (90) 24 (89) 22 (92) 0.50 
Nausea score   13 [9,19] 15 
[9,20] 
11 
[9,17.9] 
0.27 13 [9,15.48] 12.39 
[9,15.88] 
14.99 
[9,15.78] 
0.49 12 [9,16.32] 11.95 
[9,15.77 
12 
[9,16.43] 
0.39 
Complete response 
n(%) 
20 (39) 9 (33) 11 (46) 0.61 19 (37) 11 (41) 8 (33) 0.50 23 (45) 14 (52) 9 (38) 0.42 
Retching score 6 [6,6] 6[6,6] 6 
[6,6.05] 
0.40 6 [6,6.4] 6 [6,6.4] 6 [6,6.5] 0.91 6 [6,6] 6 [6,6] 6 [6,6] 0.89 
Normally distributed measures were presented as mean±standard deviation and non-normally distributed measures were presented as median [25th percentile, 75th percentile] 
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Table 9-4 Sub-group analysis of INVR scores of participants prescribed aprepitant 
Normally distributed measures were presented as mean±standard deviation and non-normally distributed measures were presented as median [25th percentile, 75th percentile] 
 
 Cycle 1     Cycle 2     Cycle 3     
 Placebo Intervention p value Placebo Intervention p value Placebo Intervention p value 
Acute CINV score 8 [8,9] 10 [8,23] 0.108 8[8,10.2] 8.8 [8,10] 0.449 8 [8,10] 10 [8, 13.2] 0.247 
Vomiting score   3[3,3] 3[3,8.2] 0.067 3[3,3] 3[3,3] 1 3 [3,4.5] 3 [3,5.1] 0.823 
 Nausea score   3[3,4] 5[3,9.4] 0.191 3[3,5.2] 3.8[3,5] 0.449 3[3,4.5] 4.8 [3,5] 0.393 
Delayed CINV score  24[24,26.5] 34[25,40.3] 0.069 28 [24,38.2] 32[24,41.7] 0.686 28 [25,44] 33[24,43.7] 0.929 
Vomiting score   9[9,9] 9[9,14.3] 0.067 9[9,9] 9[9,13.3] 0.105 3 [3,3] 3[3,4] 0.332 
Nausea score   9[9,11.5] 15[10.5,19.5] 0.068 13[9,24.5] 17[9,20.3] 0.857 4 [3.1,6.5] 4.4[3,5.5] 0.752 
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 Effect of prognostic factors on CINV-related outcomes 
The hypothesised prognostic factors of age, gender, anticipatory CINV, and 
chemotherapy emetogenicity were analysed with no significant associations detected 
(p>0.05) between these variables and any measure of CINV.  
 Adverse events 
Four patients in this trial experienced significant adverse events, none of which 
could reasonably be attributed to the ginger intervention. These include one participant 
whose lung collapsed, one allergic reaction to pegfilgrastim, and two emergency room 
admissions due to neutropenic fever. Three of the four adverse events occurred within the 
placebo group. The most commonly reported side-effects in the intervention group 
included constipation and reflux, which were reported by two and four participants, 
respectively.  
 Incomplete questionnaires 
Few participants completed the Edmonton Symptom Assessment Scale and 
CINV-prognostic questionnaire  hence the results from these questionnaires were not 
statistically meaningful. 
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Figure 9-1 CONSORT Flow Diagram 
 
 Discussion 
The results of this study indicate that, compared to placebo, adjuvant ginger is 
associated with better nausea-related QoL, less cancer-related fatigue and better cancer-
related QoL. Previous studies have reported that ginger reduces CINV; however, this is 
the first study to investigate whether this reduction translates into an improvement in 
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QoL. As CINV has been demonstrated to significantly reduce QoL,17 this study provides 
evidence that ginger supplementation could be a viable adjuvant to traditional 
pharmacotherapy for CINV that enhances patient’s wellbeing during their cancer 
treatment.  
Despite the significant effect of ginger on QoL, the findings indicate there was no 
significant effect on the prevalence or severity of CINV. While the majority of previous 
research has reported that ginger supplementation reduces the incidence and severity of 
CINV, not all studies have reported benefits.14,32 The prevalence of CINV during this 
study was high (39% and 65% of patients experienced acute and delayed CINV, 
respectively) which is consistent with the prevalence reported in other studies.1 However, 
similar to the results of Fahimi et al,32 while the prevalence was high, the average score 
derived from the INVR was low in both the intervention and placebo groups. This 
indicates that although a large proportion of participants experienced CINV, the average 
severity caused by these symptoms was low. Furthermore, the results of Ryan et al,33 the 
largest RCT conducted in this area to date (N=576), reported minor improvements in 
acute nausea. This could suggest that statistically significant group differences in CINV 
severity in this study could not be detected with the relatively smaller sample size.  
The statistically significant improvement in nausea-related QoL, could also be 
clinically relevant. However, as there is no established minimal clinically-important 
difference for the FLIE-5DR, the clinical significance of the better CINV- and nausea- 
related QoL in cycle 1 reported in the intervention group is not easily elucidated. A score 
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of 108 or greater was used in this study to indicate that CINV had no effect on QoL.18 
Using this cut-off, an examination of median CINV- and nausea- related QoL in the 
placebo group after cycle 1 (Median [25th, 75th percentile] = 111 [99.2, 126] and 54 [46, 
63], respectively) revealed that the placebo group experienced poorer CINV-related QoL. 
While these results indicate a significant difference between groups, due to the generally 
high level of CINV- and nausea- related QoL in both intervention and placebo groups, it 
is difficult to determine the clinical significance of the ginger supplementation used in 
this trial with respect to CINV- and nausea- related QoL. Similarly high ratings of QoL 
have been reported in previous observational studies.3,34 A possible explanation for this 
is that this trial was conducted at a hospital that adheres to international anti-emetic 
guidelines and prescribes current generation anti-emetic medications such as aprepitant 
and granisetron. In contrast, many previous studies that have reported severe CINV were 
conducted before the standard introduction of these anti-emetics into clinical practice.35,36 
Furthermore, the process of “response shift'” could have also influenced these results.37 
Response shift refers to the individual’s re-evaluation of the internal standards and the 
values with which they assess their quality of life, a process associated with repeat 
experiences of their treatment and its symptoms or comparison with other people’s 
experiences of it, which can appear comparatively worse than their own.37 CINV-related 
QoL within the placebo group gradually improved (Table 9-2) which suggests that a 
“response shift” in participant’s assessment of QoL could have occurred over the course 
of their chemotherapy treatment. 
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The significant improvement in fatigue reported in this study corroborates the 
results by Zick et al.38, who reported that fatigue was the most common adverse event in 
the placebo group but not in the ginger intervention group. While the exact mechanism 
underpinning this finding is unknown, future studies could investigate the role of ginger 
in cancer-related fatigue.  
Ginger supplementation was well-tolerated with no significant increase in adverse 
events and few side-effects reported. This is consistent with previous studies, which have 
reported minor adverse events.7 Ginger has been reported in some (but not all) clinical 
studies to interfere with platelet aggregation.39 During chemotherapy, this can potentially 
pose a significant concern due to the pre-existing risk of thrombocytopenia. Although 
there has been no indication of adverse clotting in this trial or previous studies, platelet 
function should be routinely monitored in this patient group.39  
Another potential concern is that ginger might reduce the effectiveness of anti-
emetic therapy when patients are prescribed aprepitant. This was identified in a subgroup 
analysis in one study, which reported that patients who received 2g of ginger and 
aprepitant experienced worse delayed CINV than patients who received 2g of ginger 
without aprepitant.14 This association, however, was not identified in patients prescribed 
aprepitant and a lower dose of ginger (1g) indicating that this might only occur with 
higher doses of ginger (2g).14 In the present study, participants receiving ginger 
supplementation and aprepitant reported worse control of delayed CINV (Table 9-4); 
however, this difference was neither statistically nor clinically significant. This 
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relationship should continue to be investigated in larger trials to ensure that patients’ anti-
emetic control is not compromised by ginger supplementation. 
Despite our ginger supplements being doubly encapsulated, the most commonly 
reported side-effect in the intervention group was ginger taste or reflux. While this was 
considered a mild side-effect by participants, it is a potential confounding variable for 
clinical trials investigating ginger as the unique taste is likely to reduce the efficacy of 
blinding, which could influence subjective measures of nausea. In order to improve 
blinding efficacy, testing of blinding efficacy in a small sample before the 
commencement of recruitment is recommended. 
This study has overcome limitations identified in previous studies by including 
the use of standardized extracts and chemical analysis of supplements that ensured 
potency throughout the study period, as well as the assessment of previously identified 
prognostic factors such as age and gender. Previous studies have not assessed the 
influence of these prognostic factors, which might have resulted in an imbalanced risk of 
CINV between the two treatment arms in these studies. Furthermore, in this study we 
controlled for anticipatory CINV, a conditioned response that develops via a pathway 
different to other types of CINV.29 This was achieved by recognising that the prevalence 
of anticipatory CINV increases with subsequent cycles; hence only chemotherapy-naïve 
patients were recruited.40 CINV was also assessed the day before each cycle of 
chemotherapy to capture anticipatory CINV. None of these prognostic factors were found 
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to be associated with CINV-related outcomes, which could be linked to the small sample 
size.  
A further strength of this study was the four-per-day dosing regimen in contrast 
to the once or twice per day regimens adhered to in previous studies, which accounted for 
the relatively short half-life of major ginger compounds.41,42 Based on our understanding 
of the pharmacokinetics of ginger, we hypothesised that more frequent consumption of 
ginger would ensure sufficient plasma levels of the active compounds which could result 
in a greater level of effect.41 Future studies that include additional arms are needed to 
determine the effect of different dosing regimens on the treatment effect. 
We acknowledge the following limitations. First, there was a high level of attrition 
after cycle 3 (33%) compared to previous studies, which have reported an attrition rate of 
approximately 20%,32,33,38 Due to the extended study time frame (3 cycles compared to 
1-2), the increased number of capsules ingested required per day, and the expanded 
number of outcomes that were measured, the relatively high attrition could be because 
the trial protocol was overly burdensome to participants. This is also demonstrated by the 
low completion rates of some questionnaires (CINV prognostic and ESAS 
questionnaires) which prevented meaningful statistical analysis of these outcomes. In 
addition, 75% (6/8) of participants prescribed highly-emetogenic chemotherapy regimens 
had withdrawn by cycle 3, compared to 25% of patients receiving moderately-emetogenic 
chemotherapy regimens. This suggests that participants undergoing more emetogenic 
regimens might have had difficulty completing the added duties required of participation 
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within this study for reasons not related to CINV, such as other symptoms. In future 
studies, it is recommended that particular consideration is taken to reduce the burden that 
is placed on participants by the study protocol such as by reducing the number of self-
reported outcome measures.  
Another limitation was that, while this trial was sufficiently powered to detect a 
significant difference in the primary outcome at cycle 1, due to timing constraints and 
attrition, the trial did not meet the required sample size for the second and third cycles. 
Introducing inflation factors in sample size calculations, as well as reducing study burden, 
is recommended in future studies to ensure sufficient power during subsequent cycles. 
 Conclusion 
In summary, the results of this clinical trial suggest that compared to placebo, 
adjuvant ginger is associated with better chemotherapy-induced nausea-related and 
cancer-related quality of life, and less cancer-related fatigue. The results confirm several 
previous studies that report ginger supplementation to be well-tolerated and without 
significant side-effects. Further studies with larger sample sizes are required to confirm 
these results and to further explore the safety profile of ginger supplementation during 
chemotherapy.  
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 The attitudes, beliefs and behaviours of 
Dietitians and Health Care Professionals regarding 
dietary supplements. 
This chapter presents the results of a survey that investigated the attitudes, beliefs 
and behaviours of 370 healthcare professionals regarding dietary supplements. The 
results of this survey were presented at the following conference: 
 Wolfgang Marx, Nicole Kiss, Daniel McKavanagh, Liz Isenring. 
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 Abstract 
Due to the high prevalence of dietary supplement use, there is a potential for 
misinformation, underestimation of side-effects, and drug-nutrient interactions. 
Therefore, it is pertinent to ask if healthcare professionals should play a greater role in 
the research, prescription, and education regarding dietary supplements. The aim of this 
study was to investigate the usage of dietary supplements in healthcare practise, barriers 
and enablers for their use, and the level of research interest and general knowledge by 
health practitioners. 
An advertisement to an online survey was disseminated through the mailing lists 
of multiple healthcare organisations. There were 370 healthcare professionals that replied 
to the survey. The majority of respondents were dietitians, accounting for 78% of 
responses. 
The results indicate that healthcare professionals are interested in dietary 
supplements (65%); however, due to the large number of barriers and 50% saying they 
do not regularly recommend dietary supplements (25% agreed, 25% neutral), the results 
also indicate that health care professionals are tentative about integrating dietary 
supplements into their clinical practice. Concerns regarding potential interactions with 
other treatments were reported as the number one barrier (67%) to utilizing dietary 
supplements as part of clinical practice. In addition, there was a strong interest in 
additional training in dietary supplements (81%), as well as the majority of respondents 
reporting that the current level of tertiary training in this area is inadequate (58%).  
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In summary, healthcare professionals are interested in the use of dietary 
supplements; however, due to current barriers, particularly concerns regarding drug-
nutrient interactions, few healthcare professionals utilize dietary supplements as part of 
clinical practice. The results indicate that further research and training is required to 
address current knowledge deficits.  
 Introduction 
The use of dietary herbal and vitamin supplements to treat or prevent chronic 
diseases has gained considerable interest both in academic research and amongst the 
general public. A large proportion of the population regularly use dietary supplements to 
help manage chronic conditions (e.g. arthritis, osteoporosis and heart health).1 Up to 73% 
of the general public within the United States consume dietary supplements and similar 
trends have been reported in other western counties.2 Hence, the rapid uptake of 
supplements by the public has created the potential for misinformation, underestimation 
of side-effects, and drug-nutrient interactions. There have been numerous studies that 
have highlighted the potential risks associated with inappropriate use of dietary 
supplements. In a study of 171 patients who were recently prescribed warfarin, 43% were 
found to be taking dietary supplements that have previously been reported to interact with 
anticoagulation therapy.3 Toxicity associated with inappropriate use of dietary 
supplements has been documented in numerous case-reports.4,5 There is also evidence 
that the long-term use of antioxidant supplements may increase the risk of cancer in 
specific populations.6 These issues are compounded by reports suggesting that a 
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significant percentage of certain patient populations are not discussing their use of dietary 
supplements with their physician.7  
While the use of certain vitamin and mineral supplements have demonstrated 
negligible benefits in healthy populations, support for other supplements for primary 
prevention of chronic diseases is increasing.8,9 Furthermore, the use of dietary 
supplements for specific conditions such as hypertension, antibiotic-associated diarrhoea, 
morning sickness, and in the critically ill have shown particular promise.10-13  
Healthcare professionals are in a key position to advise patients and the general 
public about the evidence and limitations of specific dietary supplements. The aim of this 
study was to determine the usage of dietary supplements in healthcare practice, barriers 
and enablers for their use, and the level of research interest, confidence and general 
knowledge regarding dietary supplement-related issues. The results of this study will aid 
in elucidating existing gaps in knowledge and provide information on how dietary 
supplements are perceived and utilised in current practice.  
 Methods 
The study sample was limited to healthcare professionals of any discipline who 
consult directly with patients and/or clients at the time of their participation in the study. 
Between August 2014 and August 2015, the survey was advertised online through the 
mailing lists and forums of the Dietitians Association of Australia, Dietitian Connection, 
the Multinational Association of Supportive Care and Cancer, and the Cancer Council 
Queensland. This study was approved by the Bond University Human Research Ethics 
Committee.  
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The survey format was designed and face validated by three senior dietitians in 
positions relevant to the study aim. The survey included 27 items to assess participants’ 
attitudes towards specific issues related to dietary supplements (e.g. efficacy, safety, and 
feasibility/current usage), respondents’ perception of professional and public perceptions, 
barriers and enablers for use, level of individual confidence and knowledge regarding 
dietary supplements. A pilot study (n=10) was conducted to detect feasibility issues with 
the survey. These issues were addressed in a revised version of the survey. Complete as 
well as partial responses were included in the results 
For the purpose of this study, dietary supplements were defined as possessing the 
following characteristics: a vitamin, mineral, herb or other botanical, amino acid, or 
combination of those and/or other substances or constituents; intended to be ingested by 
mouth; and found in forms such as tablets, capsules, softgels, gelcaps, liquids, or powders. 
In order to limit responses to those that address the aims of this study, respondents were 
asked to disregard the following types of dietary supplements when completing the 
survey: high energy, high protein oral nutritional supplements used to treat malnutrition 
or undesired weight loss; and vitamin or mineral supplements used to correct diagnosed 
deficiencies caused by insufficient dietary intake in order to meet established 
recommended daily intakes.  
 Results 
 Demographic 
There were 370 healthcare professionals that replied to the survey, of which there 
was complete data on 271 respondents. The majority of respondents were dietitians,  
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Table 10-1. Respondent demographics 
  Total  
  
Dietitians 
  
Doctors 
  
Nurses 
  
Allied Health Professional 
  
Miscellaneous  
Responses 370  269(74) 23(6) 31(9) 20(6)  27 
Age 
<30 138(38) 126(47) 0(0) 5(16) 5(25) 10(2) 
31-40 90(25) 65(24) 8(35) 3(10) 8(40) 30(6) 
41-50 59(16) 34(13) 5(22) 10(32) 5(25) 25(5) 
51-60 60(17) 32(12) 8(35) 12(39) 2(10) 30(6) 
>61 14(4) 10(4) 2(9) 1(3) 0(0) 5(1) 
Years worked in current profession 
0-2 45(12) 42(16) 0(0) 0(0) 1(5) 10(2) 
 2-5 82(23) 75(28) 1(4) 0(0) 3(15) 15(3) 
 5-10 82(23) 59(22) 7(30) 6(19) 7(35) 15(3) 
 10-15 45(12) 32(12) 2(9) 2(6) 4(20) 25(5) 
 15-25 54(15) 30(11) 8(35) 11(35) 210) 15(3) 
 >25 55(15) 31(12) 5(22) 12(39) 3(15) 20(4) 
Country of residence  
Australia 279(79) 228(87) 6(27) 23(77) 12(63) 67(10) 
USA 24(7) 15(6) 3(14) 1(3) 1(5) 27(4) 
Netherlands 8(2) 7(3) 0(0) 0(0) 0(0) 7(1) 
Other 40(14) 11(4) 13(59) 6(21) 6(32) 0(0) 
Highest level of education  
Diploma 18(5) 9(3) 1(4) 5(16) 0(0) 15(3) 
Bachelor 167(46) 128(48) 2(9) 18(58) 12(60) 35(7) 
Masters Degree 149(41) 124(46) 8(35) 5(16) 6(30) 30(6) 
PhD 29(8) 8(3) 12(52) 3(10) 2(10) 20(4) 
Area of practice 
Acute care 141(40) 102(39) 12(52) 9(29) 11(55) 35(7) 
Community 99(28) 72(27) 6(26) 13(42) 3(15) 25(5) 
Private Practice 67(19) 61(23) 1(4) 2(6) 2(10) 5(1) 
Industry 6(2) 3(1) 0(0) 1(3) 1(5) 5(1) 
Other 44(12) 25(10) 4(17) 6(19) 3(15) 30(6) 
Data presented as n(%row) 
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accounting for 78% of responses. The next most common professions were 
nursing, medical and allied health professionals, accounting for 9%, 6% and 6% of 
responses, respectively. Other professions responded to the survey; however, due to the 
low response rate of some disciplines, they were not included in discipline-specific 
analysis of results. The majority of respondents were aged less than 30 years old (39%), 
residing in Australia (80%), and working within the acute care setting (38%; Table 10-1).  
 Interest and perceived importance of dietary supplements 
When asked if they were interested in dietary supplements, the majority (65%) 
said that they agreed or strongly agreed. However, allied healthcare professionals were 
less decided when compared to the other respondents with 39% saying that they agreed 
or strongly agreed. When asked if dietary supplements were important to improving 
health outcomes, 49% agreed or strongly agreed while 35% said they were neutral.  
 Perceived efficacy and safety of dietary supplements 
When asked if dietary supplements are safe, 60% stated that they were neutral 
with 17% and 22% saying they agreed and disagreed, respectively. When asked if they 
felt that dietary supplements are effective, similar trends were found with 61% stating 
they were neutral.  
 Personal use of dietary supplements 
Respondents predominantly reported that they either never (34%) or occasionally 
(34%) consumed dietary supplements (Table 10-2). Doctors were the least likely to 
consume dietary supplements with 53% saying that they never consume dietary 
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supplement. Nurses were the next least likely profession to consume dietary supplements 
with 41% reporting never consuming dietary supplements. A small proportion (6%) of 
respondents also indicated that they sold dietary supplements as part of their clinical 
practice, these respondents were predominantly doctors.  
 Sources and perceived access to information  
Fifty-five percent of respondents stated that they have access to reliable 
information regarding dietary supplements. When asked about where respondents access 
information regarding dietary supplements, over half of respondents listed the following 
sources: evidence-based databases, guidelines published by their professional body, 
academic journals, and their colleagues. When separated by profession, allied health 
professionals differed from this overall trend and instead reported the internet and their 
colleagues to be the most commonly reported sources of dietary supplement-related 
information. The majority of respondents said that in order for them to utilise a particular 
dietary supplement as part of their clinical practise, they required at least two to four 
favourable randomised controlled trials to be published.  
 Adequacy of training 
In response to the statement “I was well trained in dietary supplements”, 58% said 
they either disagreed or strongly disagreed. The majority (80%) of respondents, 
particularly dietitians, indicated that they were interested in more training regarding 
dietary supplements and that universities should offer more training in this area (81%).  
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Table 10-2 Respondent attitudes, behaviours and use regarding dietary supplements 
  Agree or 
Strongly 
Agree 
Neutral Disagree or 
Strongly 
Disagree 
I am knowledgeable about dietary supplements. 56(187) 29(96) 15(50) 
I am interested in dietary supplements. 65(216) 25(83) 10(34) 
People in your profession are knowledgeable about 
dietary supplements 
42(141) 35(116) 23(76) 
I was well trained in dietary supplements. 16(53) 26(86) 58(194) 
This area is important to improving health outcomes. 49(164) 34(113) 17(56) 
Dietary supplements are effective. 35(115) 52(172) 14(46) 
My profession should be knowledgeable about 
dietary supplements. 
91(302) 6(20) 3(11) 
My profession should be considered an authority on 
dietary supplements. 
67(222) 18(60) 15(51) 
There is a high demand for dietary supplements. 74(248) 20(66) 6(19) 
I am often asked about dietary supplements by 
patients or clients. 
79(264) 10(33) 11(36) 
I feel confident in answering questions regarding 
dietary supplements. 
47(155) 29(98) 24(80) 
I am interested in further training on dietary 
supplements. 
79(263) 14(46) 7(24) 
Dietary supplements are safe. 17(57) 60(200) 23(76) 
My profession should play a greater role in the 
prescription of dietary supplements. 
58(193) 23(77) 19(63) 
My profession should play a greater role in the 
education regarding the use of dietary supplements. 
85(282) 9(30) 6(21) 
My profession should play a greater role in research 
regarding the use of dietary supplements. 
83(276) 11(37) 3(20) 
I think universities should offer more training in 
these areas as part of their curriculum. 
80(266) 13(43) 7(24) 
I am able to access trustworthy information regarding 
dietary supplements. 
56(185) 26(88) 18(60) 
I regularly recommend dietary supplements to 
clients/patients. 
25(84) 24(81) 50(168) 
All values presented as row%(n) 
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In response to the statement “I am knowledgeable about dietary supplements”, 
56% said they either agreed or strongly agreed. Approximately half (47%) of respondents 
felt that they were confident in answering questions about supplements. However, allied 
health professionals were the least likely to report that they were confident or 
knowledgeable about dietary supplements. Respondents cited a wide variety of areas in 
which they would like to improve their knowledge. 
These included drug-supplement interactions and adverse effects of dietary supplements, 
reliable sources of information regarding dietary supplements, and the usage of dietary 
supplements for specific diseases (e.g. cancer) or goals (e.g. sports performance). 
 Perceived barriers for use 
Respondents listed a wide selection of barriers to recommending supplements 
(Table 10-3). Concerns regarding potential interactions with other treatments (67%) was 
the most commonly indicated barrier for use. However, when responses were categorised 
by profession, there was a wide variation in the ranking of concerns. 
 Perceived public and organisational opinions 
The majority of respondents believed that their viewpoints regarding dietary 
supplements would be similar to the viewpoints of dietitians (80%), their professional 
governing body (70%), and doctors (55%). The groups they believed were least likely to 
agree with their position were naturopaths (62%), followed by the general public (30%). 
When separated by profession, respondents indicated that members of their own 
profession would agree with their viewpoint; however, doctors were less decided as to 
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whether their governing professional body would agree (39% responded as agreed 
compared to 70% total sample). A greater number of nurses also indicated that 
naturopaths would agree with their viewpoints (68% compared to 18% of total sample)  
Table 10-3 Perceived Barriers for use of dietary supplements by respondents 
 Barriers %(n) 
  
Concerns regarding potential interactions with other 
treatments 
68(208) 
A lack of training in this area 59(180) 
Concerns about the regulation of dietary 
supplements 
54(166) 
Concerns regarding potential negative effects of 
dietary supplements 
49(150) 
Perceived lack of efficacy of dietary supplements 49(148) 
A lack of confidence in this area 48(145) 
Lack of authority to recommend dietary supplements 
to patients/clients 
38(117) 
Concerns regarding financial burden on patient 35(108) 
It may conflict with the advice of other members 
from the patients/clients medical team 
23(70) 
Perceived Lack of quality dietary supplements on the 
market 
22(67) 
A lack of interest in this area 7(21) 
Other 3(10) 
No barriers, I recommend the use of dietary 
supplements. 
3(8) 
 
Respondents believed that the general public should primarily source dietary 
supplement-related information from dietitians (93%), doctors (76%), and pharmacists 
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(71%). However, close to half of nurses (44%) and allied health professionals (55%) 
indicated that naturopaths should also be a primary source of information. When 
respondents were asked who they believed the general public currently considers their 
primary source for information regarding dietary supplements, the most common 
responses were naturopaths (78%), the internet (73%), friends and family (65%), 
television and radio (64%).  
 Discussion 
This study explored the attitudes, beliefs and behaviours of healthcare 
professionals in regards to issues related to dietary supplements. The results demonstrate 
that healthcare professionals are interested in dietary supplements; however, due to the 
large number of barriers health care professionals are tentative about integrating dietary 
supplements into their clinical practice.  
Due to the potential concerns regarding the safety and contraindications that come 
with dietary supplement use, there is a need to ensure that the public is able and willing 
to access reliable information on this topic. Respondents believe that the general public 
do not prioritize healthcare professionals as their primary source of information regarding 
dietary supplements. Surveys that have specifically surveyed the general public’s primary 
sources of dietary supplement-related information have reported healthcare professionals 
to be one of the common sources of information.14,15 However, large use of other 
potentially less reliable sources such as the internet and magazines have also been 
reported.14 Previous studies that have investigated the potential reasons for the public 
seeking other sources for dietary supplement-related information have found that patients 
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generally feel that their physicians are unsupportive of dietary supplement use or that a 
conversation about dietary supplements does not occur during consultation.16 
Our survey found that only half (47%) of respondents considered themselves to 
be confident in this area, a figure that has been reported in similar surveys. For example, 
a previous survey of healthcare professionals also found that healthcare professionals 
were moderately confident in answering a set of questions regarding dietary 
supplements.17 This level of confidence might be related to the large proportion of 
respondents that stated that tertiary training in this area is lacking (81%) and the high 
level of interest in further education (80%). This is supported by previous studies which 
reported similarly high levels of interest in further training.18,19 For example, in a study 
of 162 dietitians, Lee et al.19 reported that 75% of respondents were interested in further 
training. The introduction of evidence-based training to university curriculum would 
provide a reputable and widely-accessible avenue for reliable information regarding 
dietary supplements and would inform healthcare professionals regarding effective and 
responsible use of dietary supplements. 
Concerns regarding potential interactions with other treatments was reported as 
the number one barrier (68%) to utilizing dietary supplements as part of clinical practice. 
From a perusal of the evidence base for various supplements, it is understandable how 
this may pose a significant concern. Many dietary supplements have potential safety 
concerns that have been identified through in vitro or animal studies but few have 
adequate clinical data that has explored the real-world impact of these concerns. A 
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pertinent example of this is the data regarding the potential anticoagulant effect of ginger 
consumption. In vitro data has consistently shown this to be a possible effect but clinical 
data has been inconsistent and has suffered from numerous limitations.20 An additional 
limitation in the current literature is that the majority of studies on dietary supplements 
have been focused on the efficacy of the intervention while safety data has not been as 
thoroughly investigated. Furthermore, a possibly related finding of the survey was that 
70% of respondents stated they would like to learn more about reliable sources of 
information regarding dietary supplements. A previous survey of military physicians 
found similar results with 65% stating that they did not feel they had reliable sources of 
information in this area.21 There are a number of evidence-based databases that are aimed 
at informing clinicians about the effects of dietary supplements, promotion of these 
resources (e.g. through tertiary courses) would provide an easily-accessible source of 
information that would aid in addressing this barrier.  
The results of this survey suggest that future interventions are required in order to 
evaluate the adequacy of current training regarding dietary supplements and investigate 
ways of improving education that is targeted towards healthcare professionals. In 
addition, future studies should explore the reasons that individuals access particular 
information sources over healthcare professionals so that approaches can be designed to 
address this. 
We would like to acknowledge the following limitations of this study. First, a 
large proportion of respondents were dietitians compared to other healthcare 
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professionals. While the separation of results by profession was able to partially mitigate 
the overrepresentation of dietitians, the smaller cohort of non-dietitian healthcare 
professionals might have reduced the generalisability of the results. Second, the term 
“dietary supplements” encompasses a wide range of compounds and formulations, each 
with their own evidence base, safety and efficacy profile. It is conceivable that 
participant’s responses may have been influenced by the restriction of questions to this 
definition as opposed to particular types of dietary supplements.   
 Conclusion 
In summary, healthcare professionals are needed to effectively manage the 
widespread use of supplements by the general public. This survey study investigated the 
attitudes, beliefs, and behaviours of healthcare professionals and identified multiple 
barriers, implications for practice, and areas of future research. Primarily, future studies 
should evaluate current training approaches and to investigate ways of improving training 
and education that is targeted towards healthcare professionals. In addition, strategies to 
improve the confidence of healthcare professionals regarding this area should also be 
investigated.  
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Part Three: Discussion and future 
directions 
The aims of this thesis were to investigate the efficacy, safety, and feasibility of 
adjuvant ginger supplementation for CINV. In Part Three, the major results of the 
included studies are presented in relation to the study aims and hypotheses (Chapter 11), 
their methodological limitations and strengths of the individual studies are also discussed 
(Chapter 12), and finally, the implications for clinical practice and future research studies 
are presented in Chapter 13.  
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 Study results in relation to thesis aims and 
outcomes 
The primary research question driving this PhD program described in this thesis 
was:  
What is the efficacy, safety, and feasibility of ginger as an adjuvant treatment for 
chemotherapy-induced nausea and vomiting in chemotherapy-naïve patients undergoing 
highly- and moderately- emetogenic chemotherapy? 
 In this chapter, the major findings of each study are discussed in relation to the 
outcomes and hypotheses stated in the introduction (page 1). 
Aim: To determine the efficacy of ginger as an adjuvant treatment for CINV 
Outcomes: 
 To describe the mechanisms of action by which ginger could improve chemotherapy-
induced nausea and vomiting.  
In Chapter 4, the various mechanisms by which ginger could modify CINV were 
discussed. Before the publication of this manuscript, there had been no review of the 
potential mechanisms of action of the active constituents of ginger with respect to 
CINV. This review identified that the effect of ginger on the 5HT3 receptor was a 
likely mechanism that required further investigation.  
316 
In Chapter 6, the binding affinities of the principle ginger compounds within two 
binding sites on the murine 5-HT3 receptor were investigated in order to reveal a 
preference for allosteric modulation. 
The results demonstrated that that investigated ginger compounds had a high affinity 
to both binding sites and shared common residues with other known competitive 
antagonists including the setron class of compounds. These results provide further 
evidence that ginger compounds could act as 5-HT3 antagonists. 
 To determine the optimal form of ginger to be used as an adjuvant therapy in clinical 
trials 
This outcome was investigated in Chapter 7, where HPLC analysis determined the 
forms of ginger that contained therapeutic doses of bioactive compounds. Per gram, 
ginger supplements, particularly the standardized extracts, were found to contain the 
greatest concentration of measured compounds (Mean±SD: 2.597±1.380 mg), while 
the concentration of compounds within spices (Mean±SD: 1.858± 1.346 mg), 
beverages (Mean±SD: 0.317± 0.210 mg), confectionary (Mean±SD: 0.093± 0.071 
mg), and teas (Mean±SD: 0.025± 0.0002 mg) was considerably lower. Hence, 
standardized ginger extracts were determined to be the most suitable form of ginger 
for adjuvant use, due to the high content of bioactive compounds within the analysed 
products.  
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 To determine the effect of ginger on i) CINV-related QoL and ii) the incidence, 
frequency and severity of chemotherapy-induced nausea and vomiting in 
chemotherapy-naïve patients receiving moderately or highly emetogenic 
chemotherapy regimens. 
o H1: The standardized ginger extract will provide a significant reduction 
in measures of CINV-related QoL in patients receiving moderately or 
highly emetogenic chemotherapy regimens compared to placebo.   
During the first chemotherapy cycle of the randomized controlled trial undertaken 
for this thesis (Chapters 8 and 9), the addition of a standardized ginger extract to 
standard anti-emetic medications was associated with a statistically significant 
improvement in nausea-related QoL (median [25th, 95th percentile]: 61.5 [56.1, 63] 
vs 54 [46, 63]; p=0.029) and CINV-related QoL (median [25th, 95th percentile]: 124.5 
[113, 126] vs 111 [99.2, 126]; p= 0.043) when compared to placebo. These results 
suggest that the improvement in QoL was driven by an improvement in nausea-
related QoL. However, these significant results did not continue during cycle 2 and 
3. Possible explanations for this include: 1) a reduction in statistical power due to the 
number of dropouts during cycle 2 and 3; and 2) participants could have experienced 
a “response shift” in their perception of QoL (see Chapter 9 discussion). Therefore, 
while the results reported in Cycle 1 are sufficient to accept hypothesis H1, this 
outcome requires further exploration in larger sample sizes.  
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o H2: The standardized ginger extract will provide a significant reduction in 
measures of acute chemotherapy-induced nausea in patients receiving 
moderately or highly emetogenic chemotherapy regimens compared to 
placebo. 
Previous studies in this field have reported significant reductions in acute nausea 
in patients who received ginger supplementation. It was therefore expected that 
ginger supplementation would provide the same significant benefit to patients in 
this study. However, no clinically or statistically significant difference in any 
measure of nausea was detected. Potential reasons for this difference include the 
generally low severity of symptoms reported by participants, which could indicate 
that the study was insufficiently powered to detect such differences. Because of 
these factors, the efficacy of ginger supplementation to reduce acute 
chemotherapy-induced nausea could not be adequately answered and hypothesis 
H2 could neither be confirmed or rejected.  
Aim: To determine the safety of ginger as an adjuvant treatment for CINV 
Outcomes: 
 To determine the dose of bioactive ginger compounds within a variety of ginger 
products 
As illustrated in Figure 11-1, there is considerable variation in bioactive compounds 
within the different categories of ginger products analysed in Chapter 7. When ginger 
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products were analysed in terms of the approximate concentration that would be 
consumed in one recommended serve of each product, there were dietary supplements 
as well as some confectionary and beverage products that contained large 
concentrations of the analysed compounds. Although the smallest effective dose of 
ginger is not yet elucidated, these results demonstrate that it is feasible to achieve an 
intake of the principle active compounds of ginger by consuming certain 
commercially available products that is comparable to the majority of dietary 
supplements analyzed in this study and therefore, ginger intake from food products 
should be controlled in future clinical trials. 
Figure 11-1 Average concentration of analysed gingerol and shogaol compounds 
within each product category 
 
 To assess the safety profile of ginger in a clinical setting, including adverse effects 
and contraindications. 
In the clinical trial (Chapter 9), ginger supplementation was well-tolerated with no 
significant increase in adverse events and few reported side-effects. This is consistent 
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with previous studies, which have reported minor adverse events.8 Another potential 
concern is that ginger might reduce the effectiveness of anti-emetic therapy when 
patients are prescribed aprepitant. In the included study, participants receiving ginger 
supplementation in combination with aprepitant reported worse control of delayed 
CINV; however, this difference was not statistically significant. This relationship 
should be investigated in larger trials to ensure that patients’ anti-emetic control is 
not compromised by ginger supplementation. 
Aim: To determine the feasibility of ginger as an adjuvant treatment for CINV 
Outcomes:  
 To determine the perceived confidence, reported use, and barriers for the use of 
dietary supplements such as ginger in clinical practice. 
In Chapter 10’s survey study, the attitudes, barriers and beliefs of 370 healthcare 
professionals were explored. Respondents were mixed in their rating of confidence. 
Approximately half (47%) of respondents felt that they were confident in answering 
questions about supplements but they considered their lack of confidence a barrier to 
using dietary supplements as part of clinical practice.  
Half of the respondents stated that they did not regularly recommend dietary 
supplements (25% agreed, 25% neutral). When asked if there were any enablers to 
recommending the use of dietary supplements, the most common response was “No 
enablers, I do not currently recommend the use of dietary supplements.”  
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The results of the survey indicate that there are numerous barriers that prevent 
healthcare professionals recommending dietary supplements as part of clinical 
practice. More than half of the respondents expressed numerous barriers. Concern 
regarding potential interactions with other treatments was the number one reported 
barrier (67%). Healthcare professionals were also undecided regarding the efficacy 
and safety of dietary supplements. When asked if they agree with the statement 
“Dietary supplements are safe”, 60% responded as neutral. Similarly, when asked if 
they agree with the statement “Dietary supplements are effective”, 52% stated that 
they were neutral (35% agreed and 14% disagreed). In addition, approximately 50% 
or more of the respondents expressed concerns regarding insufficient training, 
regulation, adverse effects, and lack of confidence.  
 To assess the adherence of a standardized ginger regimen in a clinical setting. 
Adherence to the study dosing regimen within the included clinical trial was 
moderate-to-high, with 70% of all participants (69% in ginger group and 75% in 
placebo group) consuming at least 3 of the 4 prescribed capsules per day. The results 
suggest that patients are generally able to adhere to the regimen included in this 
study. However, due to the attrition rate, it is possible that this dosing regimen, in 
combination with the questionnaires, could have contributed the perceived study 
burden. 
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 Limitations and strengths of studies undertaken 
during this research program 
 In silico investigation of principle ginger compounds on 5-HT3 
receptor binding 
Using in silico modelling techniques, the potential binding affinities of the 
primary ginger compounds was investigated using the X-ray crystal structure of the 
murine 5-HT3 receptor released in 201419. Previous work in this area was restricted to 
homology models created from crystal structure of other CYS loop receptors.  This study 
is the first in silico investigation to investigate the interactions between ginger compounds 
and the 5-HT3 receptor and therefore, provides new information which can be used to 
further elucidate the potential mechanisms of action of ginger. Furthermore, this is the 
first in silico analysis investigating the binding affinities of several other competitive 
antagonists (such as serotonin and ondansetron) using the crystal structure of a 5-HT3 
receptor. By contrasting the orientations and theoretical binding affinities of the ginger 
ligands with known agonists, competitive and non-competitive antagonists known to 
interact with the 5-HT3 receptor as well as decoys compounds, this study was able to 
provide further support for the action of these compounds as modulators of 5-HT3 
receptor activity. Furthermore, we were able to identify potentially key binding residues 
at both the serotonin and allosteric sites and corroborate with other research the 
importance of previously identified as residues important for binding serotonin and other 
competitive antagonists. 
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While this study provided valuable information regarding the binding affinities of 
the primary ginger compounds with the 5-HT3 receptor as well as several other 
competitive antagonists, there exist some limitations from a theoretical viewpoint which 
may impact on the results obtained. For example, the 3.5Å resolution of the X-ray 
structure used in the analysis is relatively low making it difficult for the crystallographer 
to unambiguously assign atomic coordinates. This level correlates to a resolution where 
the backbone atom positions and those of the bulky side chains are mostly visible. A 
higher resolution of around 1.2 Å would have provided more accurate positioning. which 
means the impact of this limitation was somewhat reduced by conducting energy 
minimisations of the receptor to reduce local areas of strain. Additionally, Hassain et al.19 
speculated that the crystal structure that was captured is in the closed conformation, 
meaning that the ligands could act differently within the selected binding sites if the 
crystal structure was in a different conformation.   
Molecular docking relies on classical molecular mechanics to estimate binding 
energies. Compared to techniques which incorporate quantum mechanics to explore the 
energetics of molecular interactions, classical mechanics is not as accurate however 
computations for large atomic systems using quantum mechanics is not feasible at the 
current time. Molecular docking techniques which incorporate flexibility in the target 
residues lining the ligand binding site offer a more realistic approach to estimating the 
binding affinities of protein-ligand interactions. Our analysis used a more rigid approach 
to the docking operation and could limit the degree to which the conformational space 
could be explored by the ligands. To date, no 5-HT3 crystal structures exists with a ligand 
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bound to either the serotonin binding or the allosteric site 5-HT3 receptor; however, if 
published in the future, this will be an area of further investigation. 
 The concentration of major active constituents within commercial 
ginger products using reverse phase-high performance liquid 
chromatography  
In this study, the concentration of principle bioactive compounds within 20 
commercial ginger products were quantified. To achieve this, a protocol was developed 
using reverse phase HPLC analysis, which is a widely-used and validated method that 
delivers a high level of precision. It is also superior to other methods such as gas 
chromatography–mass spectrometry, which, due to the increase in temperature, can result 
in a degradation of compounds and therefore affect the results of the analysis.20  
This study also expanded on the current literature by including the following 
additions to the study protocol. First, we have expanded on previous studies by including 
an additional compound, [10]-shogaol, in the analysis. [10]-shogaol has not been 
extensively studied; however, in vitro research suggests that it possesses anti-
inflammatory properties and might aid wound healing21,22 This compound has been rarely 
quantified in commercial products so by including it in this analysis, this study provided 
information regarding the concentration of this compound in a large variety of previously 
unanalysed commercial ginger products.  
The range of products analysed was also expanded, which aids current 
understanding of the typical concentration of compounds within different types of ginger 
products. The range of products used in this study is of particular benefit to Australian 
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practitioners and consumers, as all products are readily available in Australian stores. 
Furthermore, as part of the study protocol, the yield of the two extraction procedures used 
in this study was validated using a mix of ginger standards of a predetermined quantity. 
This process improves the accuracy of the analysis and is a significant strength as this 
procedure was not undertaken consistently in previous studies.  
While this study was able to determine the concentration of several of these 
principle compounds, numerous additional compounds could not be analysed due to the 
lack of commercial standards for these compounds. In addition, the samples used in this 
study were purchased locally (as opposed to purchasing directly from the manufacturer). 
The concentration of compounds could therefore have been influenced by factors such as 
storage conditions, which might make them unrepresentative of the initial products. 
However, this does provide valuable insight into the concentration of these compounds 
at time of purchase to the consumer, which reflects the “real world” concentration of 
compounds in these products as received by consumers.  
 The effect of a standardized ginger extract on chemotherapy-
induced nausea and vomiting related quality of life in patients 
undergoing moderately and highly emetogenic chemotherapy: a 
randomized controlled trial. 
The clinical trial undertaken as part of this PhD thesis addressed several key 
limitations in the current research literature (see Chapters 2 and 3). It also investigated 
previously unexplored outcomes such as nutrition status and cancer-related fatigue (see 
Chapters 8 and 9).  
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The Academy of Nutrition and Dietetics published an Evidence Analysis Manual 
designed to guide the systematic appraisal of the literature.23 Using the Quality Criteria 
Checklist provided as part of this manual, studies are assigned a positive, neutral or 
negative quality rating based on the studies inclusion of measures that aim to reduce bias 
and confounding factors. Using this checklist (Appendix G), the trial presented in 
Chapters 8 and 9 meets the required criteria to the point where it can be classified as a 
‘positive’ quality study, incorporating several features that represent robust, gold standard 
study design and methodology. These include double blinding of investigators and 
patients to the allocation procedure, the inclusion of a placebo study arm and randomised 
allocation of participants to the intervention of placebo group. In addition, using the 
NHMRC National Health and Medical Research Council (NHMRC) Hierarchy of 
Evidence Guidelines (IV-I, with I being the strongest level of evidence), this trial provides 
level II evidence.  
This study further included robust study design features that are specific to the 
investigation of interventions to treat CINV. Parallel and cross-over styles of RCT study 
design are two viable study designs that were employed in previous clinical trials that 
investigated ginger supplementation. Both have advantages and disadvantages; however, 
when conducting research relating to the study of anti-emetic interventions, there are 
unique considerations that warrant special consideration. Cross-over trials offer many 
advantages, including the ability to avoid inter-patient variability, and are of particular 
interest to studies with limited resources or time constraints because they reduce the  
sample size needed for  parallel study designs.24 However, the advantages of a cross-over 
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trial do not outweigh their risks in anti-emetic studies for several reasons. First, there is 
considerable variation in CINV experiences between cycles and therefore, by following 
this study design, there is an increased risk of within-patient variability, a variation that 
could negate the reduction in inter-patient differences.25 Additionally, due to the impact 
that anti-emetic control during the initial cycle of chemotherapy has on CINV control 
during subsequent cycles, the cross-over design is problematic as the initial intervention 
will significantly influence the results of the subsequent intervention when the study is 
crossed over.26 Ethical considerations also come into play if anti-emetic medications are 
changed when the initial intervention is effective. A parallel study design is clearly 
preferable when studying anti-emetic interventions and was the approach used in this 
study.  
Another strength of this study was that it was prospective and pragmatic, studying 
the range of patients encountered in clinical practice. This enhances the applicability of 
the results to a significant proportion of the cancer population. Randomised controlled 
trials in homogenous populations, while considered a gold standard study method, have 
at times been criticized for their reduced external validity, which is caused by the 
constraints of the study design (e.g. narrow inclusion/exclusion criteria) leading to results 
with limited generalisability.27 This study followed patients over three chemotherapy 
cycles in order to obtain a more accurate assessment of their experience with CINV over 
the course of their chemotherapy (which tends to worsen with time) instead of capturing 
outcomes in one isolated cycle, as was done in most previous studies.8 Patients were also 
enrolled on the basis of the emetogenicity of their chemotherapy regimen, reflecting the 
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wide range of regimens encountered in clinical practice, rather than confining the sample 
to specific regimens (e.g. cisplatin-based regimens only28,29) or specific cancer types (e.g. 
breast cancer patients only30). 
This study is also the first to investigate the effect of ginger supplementation on 
fatigue using a validated questionnaire. Cancer-related fatigue is a highly prevalent and 
burdensome symptom for cancer patients.31 Reasons for the observed improvement in 
fatigue in this study are currently unclear. A possible explanation is that nausea and 
vomiting can result in fatigue due to low food intake as well as affecting quality of life. 
However, the significant association between the ginger intervention and reduced fatigue 
at cycle 3, despite low levels of nausea, suggests that there could be an additional 
mechanism of action. The effect of ginger on cognition, mood, or fatigue was not 
rigorously assessed in previous studies and should be further explored in future studies.   
An additional strength of this study was the analysis of the intervention and 
placebo capsules at the commencement and completion of the clinical trial using HPLC 
analysis in order to determine the potency of the intervention over the trial period. This 
is a significant strength because ginger, as with all herbal formulations, contains a large 
variety of bioactive compounds that can exert various effects on the human body. By 
ensuring the formulation contained a therapeutic dose of the active compounds 
throughout the trial period, it can be concluded that sufficient concentrations of the 
bioactive compounds were present at all times and that there was no significant 
degradation of the intervention over time.  
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The following potential limitations of the study are also acknowledged. The 
attrition rate is a primary limitation of this clinical trial. This could be attributed to the 
harsh nature of chemotherapy as well as the potentially burdensome study design of the 
clinical trial. Due to the number of withdrawals in cycles 2 and 3, it is likely that this 
resulted in under-powering of the study and subsequent inability to detect significant 
differences in CINV-related measures at these specified time points. Future studies 
should include inflation factors in their sample size calculations to mitigate attrition and 
implement strategies to reduce dropouts. In addition, a questionnaire was developed for 
this study to assess the presence of prognostic factors that are understood to influence the 
risk of CINV. Unfortunately, due to the low completion rate of this questionnaire, these 
prognostic factors could not be analysed. However, prognostic factors including 
chemotherapy emetogenicity, gender, and age were recorded during the initial participant 
interview and so were able to be included in the analysis. Based on the observations of 
this trial, the following strategies could be implemented to prevent attrition in future 
studies in this area: 
 The perceived burden of the study might be reduced by condensing the study 
questionnaire booklet. This could be achieved by reducing the number of 
investigated outcomes or by selecting alternative validated questionnaires that 
contain fewer items. For example, the Multinational Association of Supportive 
Care in Cancer (MASCC) Anti-emesis Tool is a validated questionnaire that 
assesses acute and delayed CINV by asking four questions at two separate time 
points (24 hours after chemotherapy and 4 days post-chemotherapy).32  
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 Similarly, the replacement of the study booklet with mobile apps could reduce 
the burden further as patients would no longer need to mail the booklet, it could 
appear more visually appealing, and some apps provide reminders that could 
help patients with adherence to the study protocol. The MASCC Anti-emesis 
Tool is available as an app that allows the patient to send their questionnaire 
responses to the investigators in real time. However, the digital literacy of 
potential participants would need to be assessed before enrolment to avoid 
participant confusion and improper use. 
 More regular contact with participants could improve adherence. In our study, 
patients were contacted at the start of each chemotherapy cycle and five days 
post-chemotherapy via telephone. Providing text reminders or additional phone 
calls could help provide support to the participants.  
 Due to the funding constraints of this study, we were unable to offer incentives 
(e.g. money, vouchers) to participants for their participation. Completion rates 
could be improved by providing tangible incentives.  
 The attitudes, beliefs and behaviours of healthcare professionals in 
regards to dietary supplements. 
The results of this survey study provided a comprehensive assessment of the 
perceptions of healthcare professionals with respect to key issues related to dietary 
supplements. In total, 370 healthcare professionals responded, which is similar to, or 
larger than, previous studies in this area.33,34 Methods used to contact a large sample of 
dietitians resulted in a strong response. Although significant efforts were made to increase 
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the number of respondents from other professions (e.g. pharmacists), these strategies 
were not successful. Consequently, relative to dietitians, only a small number of other 
healthcare professionals were recruited. The high proportion of dietitian respondents 
(78%), particularly Australian dietitians, is a significant contribution to the literature due 
to the lack of any previous studies in this population. However, this is also a limitation as 
it reduces the ability of the results to be extrapolated to the general healthcare community. 
Future studies should consider additional avenues of disseminating to various healthcare 
professionals in order to improve the generalisability of results. 
This study specifically focused on dietary supplements rather than the more 
general term, “complementary and alternative medicines”. This term, which embraces a 
variety of treatment modalities, was used in several previous studies.35 However, the term 
“dietary supplement” also embraces several different preparations (e.g. herbal, vitamin, 
mineral and amino acid components) and could have been responsible for the high level 
of neutral responses on some questions. For example, when asked if respondents thought 
dietary supplements are safe, 60% responded as neutral. However, the primary aim of this 
survey was to determine how healthcare professionals view dietary supplements as whole 
and so the undecided responses to some questions provide meaningful information 
towards this aim. 
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 Overall implications for clinical practice and 
future research directions 
Adjuvant ginger supplementation is a low-cost, widely available intervention that 
healthcare professionals could utilise in order to provide a significant benefit to cancer 
patients undergoing chemotherapy without significant side effects. Due to the growing 
clinical interest and treatment potential of ginger supplementation, this thesis aimed to 
improve the current understanding of the efficacy, safety, and feasibility of ginger 
supplementation as part of clinical practice. In this chapter, the implications of the 
research conducted in this thesis are discussed, along with recommendations for clinical 
practice and future research. 
 Assessment of the current body of evidence 
In Chapters 2 and 3, the use of ginger supplementation was reported to be a 
promising intervention for CINV but one with insufficiently high-level evidence to 
demonstrate a clear effect. At the time of the initial systematic literature review, the 
evidence for the use of ginger as an adjuvant treatment for CINV was graded as ‘C’ 
according to the NHMRC evidence-based guidelines,36 indicating that the evidence 
provided some support for the use adjuvant ginger supplementation in treating CINV but 
that clinical judgment was required due to existing limitations. Due to the continued 
research in this area, it is appropriate to reassess the evidence grade presented in our initial 
systematic review.  
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In order to create an evidence-based recommendation, the NHMRC guidelines 
recommend that the literature is assessed according to five separate criteria: the strength 
of the evidence, consistency, clinical impact, generalizability and applicability to the 
Australian context. The evidence-base for adjuvant ginger supplementation will now be 
discussed using these criteria.  
Strength of the evidence: This criterion includes the number of studies, level of 
evidence and risk of bias in the included studies). Eight clinical trials are published in this 
area, in addition to the clinical trial presented in this thesis. However, many of these 
studies include some or all of the limitations cited in our original literature review 
(Chapters 2 and 3) and not all are double-blind, parallel (as opposed to crossover) studies. 
Consistency of results: While the limitations described in Chapter 2 are still 
present in many of these studies, most studies have consistently reported adjuvant ginger 
supplementation to reduce measures of CINV. When combined with the studies included 
in our initial review, from a total of 9 studies (including the trial conducted as part of this 
thesis) 6 reported ginger supplements to be associated with significant improvements in 
CINV and 3 found no effect.8,37,38  
Clinical impact: Although the clinical significance of ginger supplementation in 
our trial was minor, the majority of previous studies (all of which recruited patients with 
previous experience of CINV) have generally reported moderate reductions in measures 
of CINV.  
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Generalizability: The study design and pragmatic cohort used in most studies 
reflect common cancer populations, antiemetic medications and chemotherapy regimens. 
Because of this, the results of the majority of studies in this area are generalizable to the 
general cancer population with few caveats.  
Applicability to the Australian context: The applicability of these studies to the 
Australian context is difficult to elucidate. As discussed in Chapter 9, the average severity 
of CINV and CINV-related QoL in our study was low. A potential explanation is that 
while the prevalence of CINV remains high, due to uptake of evidence-based anti-emetic 
guidelines in combination with the introduction of anti-emetics such as aprepitant, the 
average severity of CINV is low at the recruiting hospital used in this trial. If the severity 
of CINV identified in our trial is similar in other major Australian hospitals then this 
suggests that the addition of ginger supplementation to current antiemetic therapy is not 
necessarily useful in the Australian context. It could be more useful in cancer populations 
that do not have reliable access to current generation anti-emetics such as in developing 
countries. Indeed, the control of CINV in Australia is reported to be high, with one study 
reporting Australia to have the lowest prevalence of vomiting in patients receiving MEC 
when compared to five other Oceanic countries.2  
336 
Table 13-1 NHMRC Body of evidence matrix 
 
Using the NHMRC Body of evidence matrix (Table 13-1) to guide this 
recommendation, it is evident that there is mostly consistent evidence from multiple level 
II studies that contain moderate risks of bias to indicate that adjuvant ginger 
supplementation is associated with moderate reductions in CINV in populations that are 
probably similar to that of the Australian cancer population and that are probably 
applicable to the Australian healthcare context with some caveats. Hence, although there 
is continued research in this area, due to the mixed results and extant limitations, the 
recommendations from our previous review are still appropriate and therefore, there is C 
level evidence, indicating that the “Body of evidence can be trusted to guide practice in 
most situations” (Figure 13-1).  
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Figure 13-1 Definition of NHMRC grades recommendations 
 
However, further studies are required to address additional clinically-relevant 
issues including the optimal dosing regimen and drug-nutrient interactions. Until these 
issues are addressed, the use of adjuvant ginger supplementation requires clinical 
judgment by the healthcare professional. Using the existing literature for reference, the 
patient should be informed of the optimal type, amount and frequency of dosage. 
Specifically, the current evidence suggests that the optimal dosing regimen is 0.5-1g of a 
standardized extract that is divided into four capsules per day and consumed 
approximately every 4 hours (e.g. 250mg with each meal) commencing on the day of 
chemotherapy and continuing for the following 5 days. In addition, the monitoring of 
adverse events (e.g. thrombocytopenia) and the management of drug-nutrient interactions 
(e.g. patients on anticoagulant therapy) needs to be observed.  
 Safety implications associated with ginger supplementation 
Commonly prescribed medications are associated with a wide-range of known 
side-effects; however, this does not preclude their use in the clinical setting. There are 
well-explored safety profiles with approved medications. In addition, health care 
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professionals are well-trained in the appropriate use of these medications. In order to 
integrate dietary supplements into clinical practice, these interventions require a safety 
profile that is elucidated to the same extent as standard medications.  
As demonstrated by the results of the systematic literature review on the potential 
anti-platelet effect of ginger (Chapter 5) as well as the results from the survey study, 
which found that concern regarding drug-nutrient interactions was the primary concern 
of healthcare professionals, it is evident that further research is required in order to 
investigate the safety profile of ginger supplementation in the clinical setting. While 
adverse events were monitored during our clinical trial, the safety profile of ginger should 
be further explored in clinical trials in order to inform healthcare professionals who are 
interested in the therapeutic use of ginger. The clinical trial undertaken as part of this 
thesis regularly assessed side-effects associated with the intervention through multiple 
methods, including a pre- and post- cycle safety assessment questionnaire during 
treatment, patient interview and perusal of patients’ medical chart for documented 
adverse events. Future studies should expand on this by including the assessment of 
objective measures such as blood chemistry. In particular, the platelet count and measures 
of blood coagulation such as INR as well as close monitoring for physical indications of 
abnormal bleeding (e.g bruising) should be investigated to determine the effect of ginger 
on platelet aggregation during chemotherapy. If strategies such as these are implemented, 
the amount of data regarding the safety of dietary supplements will be improved.  
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Furthermore, the results of the HPLC study (Chapter 10) indicate that it is feasible 
for patients to achieve an intake of the principle active compounds of ginger by 
consuming certain commercially available products that is comparable to the majority of 
dietary supplements analysed in this study. These results will be of value to healthcare 
practitioners, particularly nurses, who regularly recommend ginger products to patients 
who experience nausea and vomiting, as well as to patients who could be seeking ginger 
for its potential effect against nausea. However, this also suggests that certain food 
products that contain large quantities of ginger could be able to exert a comparable effect 
on platelet aggregation when compared to dietary supplements. This also highlights the 
need for future clinical trials to monitor participant intake of ginger products as this could 
significantly affect the amount of total active compounds consumed by participants and 
therefore, confound results.  
 Dissemination of evidence-based recommendations  
One of the aims of the research program presented in this thesis was to investigate 
the feasibility of ginger supplementation as an adjuvant treatment for chemotherapy-
induced nausea and vomiting. An additional step that is required before dietary 
supplements are recommended for clinical practice is the dissemination of data regarding 
the safety and efficacy of dietary supplements such as ginger to healthcare professionals. 
The respondents of the included survey (Chapter 7) reported a significant lack of training 
(58% respondents indicated that they were not well-trained) and a strong interest in 
further training in dietary supplements (80%). The results of this study can inform current 
training approaches.  
340 
Many educational resources are available to assist healthcare professionals with 
dietary supplementation. These include short courses delivered by the Australasian 
College of Nutritional and Environmental Medicine, and many Australian universities 
offer postgraduate courses in complementary medicine including RMIT University 
(Master of Wellness), University of Tasmania (Graduate Certificate in Evidence-based 
Complementary Medicine), and the University of New England (Master of Health 
Science). However, the results of our survey suggest that such resources are underutilized. 
One possible explanation for this is that while many of these university courses include 
training in dietary supplements, they also include training in other complementary 
therapies that might not be relevant to all healthcare professionals. In addition, these are 
separate courses that a healthcare professional would need to complete in addition to their 
professional degree, entailing additional time and financial commitments. An alternative 
to this is the introduction of evidence-based training into existing university curricula for 
required professional degrees. A large majority (80%) of respondents from our study said 
that they think universities should provide training in this area as part of their professions 
curricula, which demonstrates a clear demand for this type of tertiary training. By 
integrating dietary supplement-related education into existing curricula, it would reduce 
the potential time and financial burden of additional course work and would also ensure 
that all graduates of professional degrees receive a consistent education. The problem 
remains, however, of how to do so in the context of already crowded curricula, the content 
of which is primarily driven by legislative and accreditation requirements.   
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Dietitians are in a key position to help educate patients and the general public 
about dietary supplements. Surveyed dietitians were highly interested in this area (68%). 
This interest can also be seen from the strong membership rates (>300 members) of the 
Dietitian’s Association of Australia (DAA) Integrative Medicine interest group. 
However, respondent dietitians felt that they had not previously received adequate 
training in this area (55%). In the DAA National Competency Standards for Entry Level 
Dietitians, there are currently no standards that specifically address dietary supplements. 
Due to the strong interest in further training expressed by the practising dietitians in this 
survey, the addition of competency standards that directly relate to the education, 
research, and prescription of dietary supplements requires consideration. 
Curriculum requirements for US dietetics education state that “graduates will 
have knowledge of complementary and alternative nutrition and herbal therapies” and 
that “graduates will have knowledge of dietary supplements”.39 Furthermore, a taskforce 
initiated by the Academy of Nutrition and Dietetics developed a set of competencies 
related specifically to dietary supplements (Figure 13-1) and while integration of these 
competencies into university curricula was inconsistent, many US universities now offer 
training in this area as part of the require dietetic degrees.40,41 Hence, a possible example 
for how Australian dietetics could progress dietary supplement-related training is by 
mirroring the initiatives introduced in the USA. 
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Figure 13-2 Dietary supplement-related competencies 
 
 Additional future directions 
 Investigation of ginger supplementation within unexplored cancer populations 
To date, trials that have investigated the use of ginger supplementation for CINV 
primarily focused on patients undergoing highly- and moderately- emetogenic 
chemotherapy regimens. The results of a clinical trial by Sontakke et al.42 demonstrated 
that ginger supplementation was able to reduce CINV to the same extent as the antiemetic 
metoclopramide. While metoclopramide is no longer recommended as a first line therapy 
in highly- and moderately- emetogenic chemotherapy regimens, it is still used during low 
emetogenic chemotherapy regimens or as a PRN rescue anti-emetic. Due to the low-cost 
and safety profile of ginger, future clinical trials should investigate whether ginger 
supplementation could be an effective alternative to metoclopramide when used during 
low emetogenic chemotherapy regimens or as a rescue anti-emetic.  
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 Rigorous assessment of blinding 
While a post-hoc analysis was conducted as part of the clinical trial presented in 
this thesis to determine the efficacy of blinding measures, due to the distinct taste and 
aroma of ginger, it would be useful to assess the efficacy of the blinding procedure before 
the commencement of future clinical trials. This could be performed by randomly 
administering either the intervention or placebo to a small subset of cancer patients or 
healthy participants for a timeframe that resembles the timeframe of the intended study 
and recording the ability of participants to correctly guess their assigned group. 
 Further research regarding dosing regimens and preparations 
In the clinical trial included in thesis, it was postulated that a daily dosing regimen 
of four capsules per day would provide superior protection when compared to the once 
or twice daily regimen that was used in previous studies. While we were able to find 
significant differences between the intervention and placebo when using this regimen, 
our trial design did not allow us to compare the efficacy to other dosing regimens. In 
future studies, it is recommended that the effect of different dosages is further explored. 
Due to the potential burden of the dosing regimen used in this study, it would also be of 
interest to explore the efficacy of slow-release capsule formulations, as this would 
potentially provide same consistent plasma concentration of ginger while reducing the 
required effort of the patient.  
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 Investigation of the pharmacokinetics, absorption, and bioavailability of 
different ginger products 
There is limited data on the absorption and excretion of ginger compounds in 
humans.43,44 Further studies in this area would be of use to clinical trials as information 
from these studies could be used to inform optimal dosing regimens. In particular, as the 
mechanism of action of ginger is likely to be in the gut, future studies are needed to assess 
the pharmacokinetics of ginger compounds within the gastrointestinal tract. Furthermore, 
as demonstrated by the multiple ginger products analysed in Chapter 7, there are a number 
of different ginger food products and supplement preparations. Currently, the limited 
pharmacokinetic data available pertains to dietary supplements. It would be of interest to 
clinicians and patients to also determine the pharmacokinetics of active ginger 
compounds within different food products. 
 Investigation of the effect of ginger on intercycle nausea and vomiting 
Currently, there is limited investigation related to the prevalence and management 
of intercycle CINV, nausea and vomiting that occurs 14-16 days after a chemotherapy 
cycle.45 However, current evidence suggests that this can occur in up to 27% of patients.45 
Therefore, future studies could examine the effect of these symptoms on QoL as well as 
the effect of anti-emetic interventions such as ginger supplementation on the management 
of these symptoms,  
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 In silico investigation of principle ginger compounds within additional sites 
within the 5-HT3 receptor 
Site-directed mutagenesis studies have to date identified a number of key residues 
important for binding serotonin or other competitive agonists/antagonists as well as other 
potential binding sites for allosteric modulation within the 5-HT3 receptor. From this 
information we selected two sites of interest for comparison. Though the evidence to date 
suggests that the transmembrane channel could be a likely site for allosteric modulation 
it is more likely that ligands acting there are more lipophilic in nature than the ginger 
ligands. However, there may well be other potential sites that and future in silico studies 
could focus on other previously unexplored regions of the receptor.  An important aspect 
to the action of these receptors is the stoichiometry of the subunits and its impact ligand-
induced alterations in activity. Although this study focused on the homomeric A+A- 
receptor future work could compare the results obtained here with that of a heteromeric 
receptor, A+B- or B+A-, for example. While awaiting further crystal structures to become 
available, these heteromeric models could be created by homology modelling techniques.  
 Further investigation into the effect of ginger on fatigue  
Fatigue is the most common side-effect reported by cancer patients, with up to 
three quarters of patients undergoing chemotherapy or radiotherapy reporting significant 
fatigue.46 Several interventions have been investigated for their effect on fatigue, 
including dietary supplements such as carnitine. Ginger, however, has not been 
previously investigated as an intervention for fatigue but due to the results of the clinical 
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trial included in this thesis, further trials are recommended to confirm these results and if 
replicated, to investigate the potential mechanism by which it exerts this effect. 
 Expanding HPLC analyses to multiple batches 
One of the limitations of the HPLC analysis included in this thesis (Chapter 10), is that 
only one sample of each product was analysed. Due to the influence of heat, moisture, 
length of storage, and origin of ginger on the analysed compounds, future studies should 
compare the concentration of compounds in multiple batches of the analysed product in 
order to determine a more representative quantification of the compounds within a 
particular product. 
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 Conclusion  
Adjuvant ginger supplementation for the treatment of nausea is an example of a 
widely-used dietary supplement with promising evidence to support its use. In a series of 
reviews and studies, the research program presented in this thesis investigated adjuvant 
ginger supplementation for the treatment of CINV, the level of active compounds within 
various commercial ginger products, and explored the mechanisms by which ginger could 
interact with key pathways involved in CINV. The results of the main study in this thesis, 
the randomized controlled trial addressed multiple previous limitations in the literature 
and in doing so, demonstrated ginger supplementation to be significantly associated with 
improved CINV-related QoL and cancer-related fatigue. However, no significant 
reduction in the prevalence and severity of CINV were reported. The results of the HPLC 
analysis demonstrated that dietary supplements as well as certain ginger-based 
confectionary and beverages contained sufficient quantities of active compounds to be 
potentially protective against nausea. In addition, the survey results presented in this 
thesis indicate that there a number of barriers to the effective use of dietary supplements 
such as ginger extract by healthcare professionals. In particular, concerns regarding drug-
nutrient interactions and insufficient training were primary barriers identified.  
Ginger supplementation is a low-cost, widely-available, well-tolerated and 
potentially effective adjuvant treatment for CINV. While this thesis provides evidence 
for the use of adjuvant ginger supplementation for CINV-related QoL, future studies are 
needed to elucidate the efficacy in reducing the prevalence of CINV and should focus on 
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the safety and optimal dosage of ginger supplementation in patients undergoing 
chemotherapy treatment. Furthermore, the dissemination of evidence-based information 
and the further integration of education regarding dietary supplements into tertiary 
training is recommended to inform healthcare professionals and clinical practice. If larger 
studies address these recommendations, the use of adjuvant ginger supplementation will 
be a viable adjuvant treatment that healthcare professionals could utilise in order to 
improve CINV-related outcomes in clinical practice.   
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Appendices A. GRID Analysis and Structural Similarity Map  
1) GRID RESULTS  
a) Serotonin Site 
Probe Description LEAU MOVE Most Neg pt 
Kcal/mol 
NZ X Y Z Nearest 
residue 
OH2 Water 2 0 -20 106 170.587 184.903 266.820 Ser150 
C1= Aromatic CH 0 0 -5.6799 84 163.153  182.237 259.487 Trp63 
C3 Methyl C 0 0 -6.0628 84 163.153 182.237 259.487 Trp63 
O1 Alkyl hydroxyl 1 0 -15.6125 23 165.487 172.903 239.153 Leu12 
OH Phenol hydroxyl 1 0 -12.9040 28 168.153  170.903 240.820 Asp162 
O Carbonyl O 1 0 -10.2049 23  165.820 172.903 239.153 Val27 
DRY Hydrophobic 0 0 -2.9457 115 171.820 192.903 269.820 Leu137 
BOTH Amphipathic 0 0 -1.4328 80 164.820  176.903 258.153 Trp156 
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b) Allosteric Site 
Probe Description LEAU MOVE Most Neg pt 
Kcal/mol 
NZ X Y Z Nearest 
residue 
OH2 Water 2 0 -19.7242 49 170.393 184.930 266.750 GLU B 
102 
C1= Aromatic CH 0 0 -5.7054 27 163.060 182.263 259.417 ASN B 
101 
C3 Methyl C 0 0 -6.1074 27 163.060 182.263 259.417 ASN B 
101 
O1 Alkyl hydroxyl 1 0 -15.7207 5 172.393 176.263 252.083 ALA B 
208 
OH Phenol hydroxyl 1 0 -11.9311 15 176.060 200.930 264.750 ILE B  48 
O Carbonyl O 1 0 -10.0362 15 176.060 200.930 264.750 ILE B  48 
356 
DRY Hydrophobic 0 0 -3.5633 20 172.060 192.930 269.750 LEU B  58   
BOTH Amphipathic 0 0 -1.1253 24 179.060 187.930 273.750 ARG B  65 
357 
 
(2) Colour key to Structural Similarity Map for Serotonin Site 
Colour key to Structural Similarity Map for Allosteric Site 
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Appendices B. Fasta Sequencing of Murine and Human 5-HT3 Receptor 
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Appendices C. CONSORT Diagram 
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CONSORT 2010 checklist of information to include when reporting a randomised 
trial* 
 
Section/Topic 
Ite
m 
No Checklist item 
Reported 
on page 
No 
Title and abstract 
 1a Identification as a randomised trial in the title Title page 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT 
for abstracts) 
282 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 284 
2b Specific objectives or hypotheses 285 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 285 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 286 
4b Settings and locations where the data were collected 285 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and 
when they were actually administered 
287 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and 
when they were assessed 
288 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 292 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 287 
8b Type of randomisation; details of any restriction (such as blocking and block size) 287 
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 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered 
containers), describing any steps taken to conceal the sequence until interventions were assigned 
287 
 
Implementation 
10 Who generated the random allocation sequence, who enrolled participants, and who assigned 
participants to interventions 
287 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care 
providers, those assessing outcomes) and how 
287 
11b If relevant, description of the similarity of interventions N/A 
Statistical 
methods 
12a Statistical methods used to compare groups for primary and secondary outcomes 292 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 292 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended 
treatment, and were analysed for the primary outcome 
300 
13b For each group, losses and exclusions after randomisation, together with reasons 300 
Recruitment 14a Dates defining the periods of recruitment and follow-up 286 
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 293 
Numbers 
analysed 
16 For each group, number of participants (denominator) included in each analysis and whether the 
analysis was by original assigned groups 
292 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size 
and its precision (such as 95% confidence interval) 
294 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 294 
Ancillary 
analyses 
18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, 
distinguishing pre-specified from exploratory 
N/A 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 299 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of 
analyses 
300 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 300 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other 
relevant evidence 
300 
363 
Other information  
Registration 23 Registration number and name of trial registry 285 
Protocol 24 Where the full trial protocol can be accessed, if available 285 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 306 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on 
all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-
pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references 
relevant to this checklist, see www.consort-statement.org. 
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365 
366 
Appendices E. Patient Information and Withdrawal Form 
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Appendices F. Survey Questions Plan 
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Demographic 
Age 
 <30 
 31-40 
 41-50 
 51-60 
 >61 
What is your profession? 
 Dietitian 
 Doctor 
 Surgeon 
 Allied Health Professional 
 Nurse 
 Psychiatrist 
 Psychologist 
 Other 
How many years have you worked as in your profession?0-2 
 2-5 
 5-10 
 10-15 
 15-25 
 >25 
What is your highest level of education? 
 Diploma 
 Bachelor 
 Masters 
 PhD 
Job area (greatest time spent in your current position) 
379 
 Acute care  
 Community 
 Private practise 
 Industry  
 Other ______________________________ 
Approximately how much of your workload is spent consulting with cancer patients? 
 81-100% 
 50-80% 
 <50% 
Do you sell supplements as part of your clinical practise? 
Do you consider this a conflict of interest? 
Do you feel you have any other potential conflicts of interest that may bias your response 
to this survey? For example, profit gain from advertising specific supplements. 
Attitudes regarding dietary supplements 
Please describe how much you agree or disagree with the following statements regarding 
dietary supplements. 
Strongly agree, agree, neutral, disagree, strongly disagree. 
 I am knowledgeable about dietary supplements. 
 I am interested in dietary supplements. 
 People in your profession are knowledgeable about dietary supplements 
 I was well trained in dietary supplements. 
 This area is important to improving health outcomes. 
 Dietary supplements are effective. 
 <response to Q3> should be knowledgeable about dietary supplements. 
 <response to Q3>  should be considered an authority on dietary 
supplements. 
 There is a high demand for dietary supplements. 
 I am often asked about dietary supplements by patients or clients. 
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 I feel confident in answering questions regarding dietary supplements. 
 I am interested in further training on dietary supplements. 
 Dietary supplements are safe. 
 <response to Q3> should play a greater role in the prescription of dietary 
supplements. 
 <response to Q3> should play a greater role in the education regarding 
the use of dietary supplements. 
 <response to Q3> should play a greater role in research regarding the use 
of dietary supplements. 
 I think universities should offer more training in these areas as part of 
their curriculum. 
 I am able to access trustworthy information regarding dietary 
supplements. 
 I regularly recommend dietary supplements to clients/patients.  
How often do you personally take one or more dietary supplement? 
 Daily/most days/occasionally/never 
Support for position 
Please answer how strongly the following groups of people would agree or disagree with 
your position on these therapies. 
 Doctors 
 Dietitians 
 Your professions governing body (i.e DAA for Australian 
dietitians)General public 
 Pharmacists 
 Nurses 
 Naturopaths  
For the general public, who do you believe are the primary sources of information 
regarding dietary supplements? (Tick as many as you feel suitable) 
 Doctors 
 Pharmacists 
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 Naturopaths 
 Dietitians 
 Nurses 
 Friends and family 
 Television/radio 
 Internet  
 Other 
 
For the general public, who should be the primary sources of information regarding 
dietary supplements? (Tick as many as you feel suitable) 
 Doctors 
 Pharmacists 
 Naturopaths 
 Dietitians 
 Nurses 
 Friends and family 
 Television/radio 
 Internet  
 Other 
Where do you get your information regarding dietary supplements? (Tick as many as you 
feel suitable)  
 Conferences 
 Workshops  
 Colleagues 
 Friends and family 
 Evidence databases (e.g PEN library) 
 DAA guidelines or other official guidelines 
 Television/radio 
 Internet 
 Books 
 Academic journals 
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What is the minimum level of evidence that you require before you would feel confident 
utilising or recommending specific dietary supplements in your workplace? Please select 
only one response. 
 Cell culture and lab research 
 Animal studies 
 Case studies 
 Observational and epidemiological studies 
 Non-blinded, open label human trials 
 Randomised control trials  
 Meta-analysis 
 Published guidelines  
 Other 
If you selected other, could you please elaborate on this? 
<Answer box> 
 
In relation to your answer to the previous question, approximately how many of these 
studies/guidelines would need to be published before you utilise specific dietary 
supplements? 
 One 
 Two to four 
 Five or more 
What area do you think dietary supplements are most effective for? Please tick as many 
as you feel necessary.  
 Sports performance 
 Acute-care (e.g. cancer cachexia, post-operative recovery) 
 Cancer prevention 
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 Cancer treatment 
 Symptom management (e.g. nausea, fatigue) 
 Prevention of other chronic diseases (e.g cholesterol management) 
 Management and treatment of other chronic diseases (e.g. CVD, T2DM) 
 Weight loss 
 Digestive disorders (e.g. IBS, Chrons disease) 
 Mental and cognitive issues (e.g. stress) 
 Sleep disorders 
 Other 
 Dietary supplements are not effective for any area 
 
If you selected other, could you please elaborate on this? 
<Answer box> 
What do you feel are the major barriers to you recommending the use of dietary 
supplements to your patients/clients? Please tick as many as you feel necessary.  
 A lack of training in this area 
 A lack of confidence in this area 
 Concerns regarding potential interactions with other treatments 
 Concerns regarding potential negative effects of dietary supplements 
 Concerns about the regulation of dietary supplements  
 Perceived lack of efficacy of dietary supplements 
 It may conflict with the advice of the patients/clients medical team  
 Lack of authority to recommend dietary supplements to patients/clients 
 A lack of interest in this area 
 Concerns regarding financial burden on patient 
 Perceived Lack of quality dietary supplements on the market 
 No barriers, I recommend the use of dietary supplements. 
 Other 
If you selected other, could you please elaborate on this? 
<Answer box> 
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Do you have any suggestions to address these barriers? 
What do you feel are the major enablers to you recommending the use of dietary 
supplements to your patients/clients? Please tick as many as you feel necessary. 
 I have sufficient training in this area 
 There are sufficient regulations regarding dietary supplements  
 There is sufficient research to show the efficacy of dietary supplements 
 There is sufficient research to show the safety of dietary supplements 
 The physicians and medical team of patient/client are supportive of the 
use of dietary supplements 
 I have sufficient autonomy to recommend dietary supplements to 
patients/clients 
 Dietary supplements are cost-effective.  
 There are high-quality supplements available on the market. 
 No enablers, I do not currently recommend the use of dietary 
supplements. 
 Other 
Which area would you like to learn more about? Please tick as many as you feel suitable. 
 Specific dietary supplements 
o If so, could you please specify? Please list as many supplements 
as you feel necessary. 
 The usage of dietary supplements for specific diseases (e.g. cancer) or 
goals (e.g. sports performance) 
 Drug-supplement interactions 
 Regulatory issues regarding dietary supplements 
 Reliable sources of information regarding dietary supplements 
 Adverse effects of dietary supplements 
 Other 
o Could you please specify? 
Do you wish to say anything else that was not covered in the previous questions? 
Conclusion  
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You have completed our survey, we sincerely thank you for your input!  
If you have any questions regarding this project, please the principal investigator, Liz 
Isenring (lisenrin@bond.edu.au). 
Should you have any complaints concerning the manner in which this research is being 
conducted please make contact with: 
Bond University Human Research Ethics Committee, c/o Bond University Office of 
Research Services.  
Bond University, Gold Coast, 4229 
Tel: +61 7 5595 4194 Fax: +61 7 5595 1120 Email: buhrec@bond.edu.au 
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Quality Assessment Criteria of Included Clinical Trial 
  Rating Explanation 
Quality Rating (+,0,-) Positive +   
Year 2015   
Relevance Questions     
1 Would implementing the studied intervention or 
procedure (if found successful) result in improved 
outcomes for the patients/clients/population group? 
(NA for some Epi studies) 
Yes CINV is a serious clinical issue that affects a large 
proportion of the cancer population. Treatments to 
improve this control will significantly improve patient 
outcomes. Ginger supplementation is a widely-
available, low-cost, and easy to administer potential 
intervention. 
2 Did the authors study an outcome (dependent 
variable) or topic that the 
patients/clients/population group would care about? 
Yes Interest in CAM therapies is high amongst cancer 
patients. Nausea and vomiting are highly distressing to 
patients undergoing treatment. 
3 Is the focus of the intervention or procedure 
(independent variable) or topic of study a common 
issue of concern to dietetics practice? 
Yes Vomiting and in particular, nausea, are highly prevalent 
in this population, affecting up 60% of patients 
undergoing chemotherapy. 
4 Is the intervention or procedure feasible? (NA for 
some epidemiological studies) 
Yes Ginger is a well-tolerated, widely-available 
intervention. Many previous studies have been 
conducted successfully. 
Validity Questions     
1 Was the research question clearly stated? Yes   
1.1 Was the specific intervention(s) or procedure 
(independent variable(s)) identified? 
Yes 1.2g standardized ginger extract (4x300mg). 
1.2 Was the outcome(s) (dependent variable(s)) 
clearly indicated? 
Yes Primary outcome: Chemotherapy-induced nausea-
related quality of life 
Secondary outcomes: see protocol chapter (chapter 8) 
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1.3 Were the target population and setting 
specified? 
Yes Chemotherapy-naïve patients commencing moderately 
or highly emetogenic chemotherapy regimens.  
Recruited from Princess Alexandra Hospital, 
Queensland, Australia 
2. Was the selection of study subjects/patients 
free from bias? 
Yes   
2.1 Were inclusion/exclusion criteria specified 
(e.g., risk, point in disease progression, diagnostic 
or prognosis criteria), and with sufficient detail and 
without omitting criteria critical to the study? 
Yes Patients were recruited if they were chemotherapy-
naïve, were due to receive a moderately or highly 
emetogenic chemotherapy regimen, were at least 18 
years old, had a baseline Karnofsky score >60, had no 
known concurrent neoplasms or illness that induces 
nausea independent of chemotherapy, and did not self-
prescribe therapies or complementary products used for 
nausea. 
 
Patients were excluded if they met any of the following 
criteria: scheduled to receive radiotherapy during the 
study period, pregnant or lactating, concurrent use of 
other ginger-containing supplements and ingestion of 
large quantities of ginger, history of adverse reactions 
to ginger, and thrombocytopenia.  
2.2 Were criteria applied equally to all study 
groups? 
Yes As stated in manuscript 
2.3 Were health, demographics, and other 
characteristics of subjects described? 
Yes As shown in Figure 1 of manuscript 
2.4 Were the subjects/patients a representative 
sample of the relevant population? 
Yes Gender, age, chemotherapy regimen were represented 
in equal proportions and is representative of the general 
cancer population 
3 Were study groups comparable? Yes Y 
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3.1 Was the method of assigning subjects/patients 
to groups described and unbiased? (Method of 
randomization identified if RCT) 
Yes Patients were randomised using a computer generated 
randomisation sequence 
3.2 Were distribution of disease status, prognostic 
factors, and other factors (e.g., demographics) 
similar across study groups at baseline? 
Yes As shown in Figure 1 of manuscript 
3.3 Were concurrent controls used? (Concurrent 
preferred over historical controls.) 
Yes A parallel trial design was used for this study 
3.4 If cohort study or cross-sectional study, were 
groups comparable on important confounding 
factors and/or were pre-existing differences 
accounted for by using appropriate adjustments in 
statistical analysis? 
N/A   
3.5 If case control study, were potential 
confounding factors comparable for cases and 
controls? (If case series or trial with subjects 
serving as own control, this criterion is not 
applicable. Criterion may not be applicable in some 
cross-sectional studies.) 
N/A   
3.6 If diagnostic test, was there an independent 
blind comparison with an appropriate reference 
standard (e.g., “gold standard”)? 
N/A   
4 Was method of handling withdrawals 
described? 
Yes   
4.1 Were follow up methods described and the 
same for all groups? 
Yes All patients were followed up at the end of each 
chemotherapy cycle as well as at the commencement of 
cycle 2 and 3. This was consistent across all patients 
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4.2 Was the number, characteristics of withdrawals 
(i.e., dropouts, lost to follow up, attrition rate) 
and/or response rate (cross-sectional studies) 
described for each group? (Follow up goal for a 
strong study is 80%.) 
Yes This was included in the study flow diagram, table X 
and discussed in the discussion section of the 
manuscript 
4.3 Were all enrolled subjects/patients (in the 
original sample) accounted for? 
Yes All dropouts were documented with given reason 
4.4 Were reasons for withdrawals similar across 
groups? 
N Reasons for dropout were varied and no consistent 
pattern between groups was apparent 
Dropouts were slightly higher in the placebo group 
4.5 If diagnostic test, was decision to perform 
reference test not dependent on results of test under 
study? 
N/A   
5 Was blinding used to prevent introduction of 
bias? 
Yes Y 
5.1 In intervention study, were subjects, 
clinicians/practitioners, and investigators blinded to 
treatment group, as appropriate? 
Yes All patients were blinded as well as all research staff 
involved in the recruitment process 
5.2 Were data collectors blinded for outcomes 
assessment? (If outcome is measured using an 
objective test, such as a lab value, this criterion is 
assumed to be met.) 
N Outcome was self-reported. Due to the nature of the 
outcomes, blinding of the outcome is not possible. 
5.3 In cohort study or cross-sectional study, were 
measurements of outcomes and risk factors 
blinded? 
N/A   
5.4 In case control study, was case definition 
explicit and case ascertainment not influenced by 
exposure status? 
N/A   
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5.5 In diagnostic study, were test results blinded to 
patient history and other test results? 
N/A   
6 Were intervention/therapeutic 
regimens/exposure factor or procedure and any 
comparison(s) described in detail? Were 
intervening factors described? 
Yes   
6.1 In RCT or other intervention trial, were 
protocols described for all regimens studied? 
Yes All details are included in methods section as well as 
the trial protocol paper. 
6.2 In observational study, were interventions, 
study settings, and clinicians/provider described? 
N/A   
6.3 Was the intensity and duration of the 
intervention or exposure factor sufficient to 
produce a meaningful effect? 
Yes Patients were followed during the time period (first 5 
days of chemotherapy) where CINV is likely to occur. 
Dosage of intervention is in line with preliminary 
clinical and pre-clinical evidence. 
6.4 Was the amount of exposure and, if relevant, 
subject/patient compliance measured? 
Yes Patients were asked to record their compliance. Patients 
were also interviewed at the end of each cycle to assess 
compliance and blinding 
6.5 Were co-interventions (e.g., ancillary 
treatments, other therapies) described? 
Yes Anti-emetic use and chemotherapy regimen was 
recorded 
6.6 Were extra or unplanned treatments described? N/A   
6.7 Was the information for 6.4, 6.5, and 6.6 
assessed the same way for all groups? 
Yes   
6.8 In diagnostic study, were details of test 
administration and replication sufficient? 
N/A   
7. Were outcomes clearly defined and the 
measurements valid and reliable? 
Yes   
7.1 Were primary and secondary endpoints 
described and relevant to the question? 
Yes   
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7.2 Were nutrition measures appropriate to 
question and outcomes of concern? 
Yes PG-SGA is a validated questionnaire to assess nutrition 
status. This was administered by an accredited 
practising dietitian.  
7.3 Was the period of follow-up long enough for 
important outcome(s) to occur? 
Yes   
7.4 Were the observations and measurements based 
on standard, valid, and reliable data collection 
instruments/tests/procedures? 
Yes All questionnaires were validated and have been widely 
used in the cancer setting 
7.5 Was the measurement of effect at an 
appropriate level of precision? 
Yes   
7.6 Were other factors accounted for (measured) 
that could affect outcomes? 
Yes Influence of multiple prognostic factors (e.g. age, 
emetogenicity, anticipatory CINV) were assessed 
7.7 Were the measurements conducted consistently 
across groups? 
Yes   
8. Was the statistical analysis appropriate for 
the study design and type of outcome 
indicators? 
Yes   
8.1 Were statistical analyses adequately described 
the results reported appropriately? 
Yes   
8.2 Were correct statistical tests used and 
assumptions of test not violated? 
Yes   
8.3 Were statistics reported with levels of 
significance and/or confidence intervals? 
Yes   
8.4 Was “intent to treat” analysis of outcomes done 
(and as appropriate, was there an analysis of 
outcomes for those maximally exposed or a dose-
response analysis)? 
Yes   
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8.5 Were adequate adjustments made for effects of 
confounding factors that might have affected the 
outcomes (e.g., multivariate analyses)? 
Yes   
8.6 Was clinical significance as well as statistical 
significance reported? 
Yes   
8.7 If negative findings, was a power calculation 
reported to address type 2 error? 
Yes   
9. Are conclusions supported by results with 
biases and limitations taken into consideration? 
Yes   
9.1 Is there a discussion of findings? Yes   
9.2 Are biases and study limitations identified and 
discussed? 
Yes   
10. Is bias due to study’s funding or sponsorship 
unlikely? 
Yes   
10.1 Were sources of funding and investigators’ 
affiliations described? 
Yes   
10.2 Was there no apparent conflict of interest? Yes   
 
